Jun 15, 2015 - movement disorders conferences and meetings in underserved areas. Applications, which ...... 310 Big data
WWW.MDSCONGRESS2015.ORG
19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
JUNE 14-18
2015
MDS-0415-094
WASHINGTON DC • MUNICH • ORLANDO • VIENNA • NEW YORK • BARCELONA • MIAMI • ROME • NEW ORLEANS • KYOTO • ISTANBUL
FINAL PROGRAM
SAN DIEGO, CA, USA SCAN TO LEARN MORE ON OUR WEBSITE!
• CHICAGO • PARIS • BUENOS AIRES • TORONTO • DUBLIN • SYDNEY • STOCKHOLM • SAN DIEGO •
WASHINGTON DC • MUNICH • ORLANDO • VIENNA • NEW YORK • BARCELONA • MIAMI • ROME • NEW ORLEANS • KYOTO • ISTANBUL
• CHICAGO • PARIS • BUENOS AIRES • TORONTO • DUBLIN • SYDNEY • STOCKHOLM • SAN DIEGO •
20th International Congress of Parkinson’s Disease and Movement Disorders JUNE 19-23, 2016 • BERLIN, GERMANY
Save the Date
www.mdscongress2016.org IMPORTANT DATES
October 1, 2015 Abstract Submission Opens December 1, 2015 Registration Opens January 7, 2016 Abstract Submission Closes April 15, 2016 Early Registration Deadline May 18, 2016 Final Pre-Registration Deadline
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Table of Contents ABOUT MDS............................................................................................. 3
MANCHESTER GRAND HYATT FLOOR PLAN............................................. 14
MDS MEMBERSHIP INFORMATION........................................................... 5
ABSTRACT INFORMATION AND SCHEDULES............................................ 15
MDS EDUCATION INFORMATION............................................................... 6
MAP OF DOWNTOWN SAN DIEGO........................................................... 20
CONTINUING MEDICAL EDUCATION (CME) INFORMATION......................... 9
AWARDS INFORMATION......................................................................... 21
INTERNATIONAL CONGRESS INFORMATION A-Z...................................... 10 Abstracts (See page 15 for daily schedules)..................................................10 Badges.........................................................................................................10 Camera Policy...............................................................................................10 Certificate of Attendance..............................................................................10 Coffee Breaks................................................................................................11 Congress Information Desk...........................................................................11 Continuing Medical Education (CME) ...........................................................11 Currency.......................................................................................................11 Evaluations...................................................................................................11 Events...........................................................................................................11 Exhibit Hall...................................................................................................11 Floor Plans of the Manchester Grand Hyatt .................................................11 Guided Poster Tours......................................................................................11 Internet .......................................................................................................11 MDS Booth...................................................................................................12 Official Language.........................................................................................12 Press Information ........................................................................................12 Registration Desk.........................................................................................12 Scientific Sessions........................................................................................12 Special Accessibility Needs...........................................................................12 Speaker Ready Room ...................................................................................12 Ticketed Sessions .........................................................................................12 Venue...........................................................................................................12 Weather.......................................................................................................12
MDS 19TH INTERNATIONAL CONGRESS SESSION DEFINITIONS................ 27 SCHEDULE-AT-A-GLANCE...................................................................... 28 Sunday, June 14, 2015 .................................................................................29 Monday, June 15, 2015.................................................................................31 Tuesday, June 16, 2015.................................................................................36 Wednesday, June 17, 2015...........................................................................41 Thursday, June 18, 2015...............................................................................46 FACULTY LISTING................................................................................... 50 GUIDED POSTER TOUR ABSTRACTS (BY TITLE, AUTHOR)......................... 54 ABSTRACTS (BY TOPIC, TITLE, AUTHOR)................................................. 62 LATE-BREAKING ABSTRACTS.................................................................119 MDS STUDY GROUP ABSTRACTS............................................................120 CORPORATE THERAPEUTIC SYMPOSIA...................................................126 EXHIBITOR INFORMATION.....................................................................132 Exhibit and Poster Hall Floor Plan...............................................................133 Exhibitor Directory.....................................................................................134 EDUCATION GRANT SUPPORTERS..........................................................144 ACKNOWLEDGEMENTS..........................................................................145 CERTIFICATE OF ATTENDANCE...............................................................147
1
Dear Colleagues, We would like to formally welcome you to San Diego, CA, USA, where blue skies line over 70 miles of picturesque coastline and beautiful weather and friendly locals create a welcoming vibe all its own. The International Parkinson and Movement Disorder Society is excited to be hosting the 19th International Congress of Parkinson’s Disease and Movement Disorders in San Diego, June 14-18, 2015. Bordered by the Pacific Ocean to the west, the Laguna Mountains to the east and Mexico to the south, the diverse neighborhoods of San Diego are spread out over 4,200 square miles, offering endless opportunities for exploration and activities. Enjoy a variety of cuisine and culture in San Diego, a vibrant metropolitan city with a laid-back, small town feel. We are pleased to have you join us to share knowledge with each other and to actively participate in advancing the field of Movement Disorders all while enjoying one of the fastest growing cities in the United States. We are pleased to welcome you to San Diego for the 19th International Congress and are glad you are taking part in this exceptional Scientific Program. We promise an unforgettable experience. With kind regards,
Matthew Stern President, International Parkinson and Movement Disorder Society, 2013-2015
2
Victor Fung Chair, Congress Scientific Program Committee, 2013 - 2015
Irene Litvan Co-Chair, Congress Scientific Program Committee, 2015
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
About MDS
Ataxia Chorea Dystonia Gait disorders Huntington’s disease Myoclonus and startle Parkinson’s disease and parkinsonism Restless legs syndrome Stiff person syndrome Tardive dyskinesia Tics and Tourette syndrome Tremor and essential tremor In recent years, there has been tremendous growth in new diagnostic information, pharmacological and neurosurgical treatments for Movement Disorders, as well as a greater understanding of impaired motor control function. MDS offers you and your patients an essential link to this knowledge. In 1985, The Movement Disorder Society was founded on the initiative of Professors Stanley Fahn and C. David Marsden, whose leadership and vision guided the expansion of clinical expertise and research in this field. This not-for-profit organization merged in 1992 with the International Medical Society for Motor Disturbances. Publication of the journal Movement Disorders began in 1986, and the first International Congress was held in 1990.
PURPOSE, MISSION AND GOALS
About MDS
The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control. The spectrum of clinical disorders represented by the Society includes, but is not limited to:
Purpose: The objective and mission of the Society shall be to advance the neurological sciences pertaining to Movement Disorders; to improve the diagnosis and treatment of patients; to operate exclusively for scientific, scholarly and educational purposes; to encourage research; to provide forums, such as medical journals, scientific symposia and International Congresses, for sharing ideas and for advancing the related clinical and scientific disciplines; to encourage interest and participation in the activities of the Society among healthcare and allied professionals and scientists; and to collaborate with other related professional and lay organizations. Mission and Goals: To disseminate knowledge about Movement Disorders by: •
Providing educational programs for clinicians, scientists and the general public designed to advance scientific and clinical knowledge about Movement Disorders
•
Sponsoring International Congresses and Symposia on Movement Disorders
•
Collaborating with other international organizations and lay groups
•
Publishing journals, video and other collateral materials committed to high scientific standards and peer review
To promote research into causes, prevention and treatment of Movement Disorders by: •
Using the Society’s influence and resources to enhance support for research
•
Facilitating the dissemination of information about research
•
Encouraging the training of basic and clinical scientists in Movement Disorders and related disorders
In 2013, The Movement Disorder Society officially changed its name to For the purposes of favorably affecting the care of patients with Movement the International Parkinson and Movement Disorder Society, in order to recognize the growing importance of Parkinson’s disease care and research Disorders, the Society will provide expertise, advice and guidance to: within the field of Movement Disorders. • Regulatory agencies to assist them in the approval process of safe and effective therapeutic interventions •
The public (media) and patient support groups by informing them of new research and therapeutic advances
•
Governments to assist them in the development of policies that affect support of research and patient care
•
Educational efforts to assist in developing standards of training in the specialty 3
About MDS
About MDS MDS OFFICERS (2013-2015)
President Matthew Stern, USA
President-Elect Oscar Gershanik, Argentina
MDS INTERNATIONAL EXECUTIVE COMMITTEE
Paolo Barone, Italy Bastiaan Bloem, Netherlands Murat Emre, Turkey Susan Fox, Canada Victor Fung, Australia Etienne Hirsch, France Beom Jeon, Korea Michael Okun, USA Anthony Schapira, United Kingdom Mark Stacy, USA
INTERNATIONAL CONGRESS OVERSIGHT COMMITTEE
Chair: Philip Thompson, Australia Günther Deuschl, Germany Victor Fung, Australia Oscar Gershanik, Argentina Christopher Goetz, USA Anthony Lang, Canada Irene Litvan, USA Matthew Stern, USA
CONGRESS SCIENTIFIC PROGRAM COMMITTEE
Chair: Victor Fung, Australia Co-Chair: Irene Litvan, USA Tim Anderson, New Zealand Daniela Berg, Germany Erwan Bezard, France K. Ray Chaudhuri, United Kingdom Carlo Colosimo, Italy Marina de Koning-Tijssen, Netherlands 4
Secretary Francisco Cardoso, Brazil
Secretary-Elect Treasurer Claudia Trenkwalder, Christopher Goetz, Germany USA
Günther Deuschl, Germany Joaquim Ferreira, Portugal Oscar Gershanik, Argentina Glenda Halliday, Australia Hyder Jinnah, USA Paul Krack, France Olle Lindvall, Sweden Timothy Lynch, Ireland José Obeso, Spain Per Odin, Sweden Lynn Rochester, United Kingdom Robert Rodnitzky, USA Raymond Rosales, Philippines Klaus Seppi, Austria Matthew Stern, USA Antonio Strafella, Canada D. James Surmeier, USA Ryosuke Takahashi, Japan Eng-King Tan, Singapore Philip Thompson, Australia Claudia Trenkwalder, Germany
CONGRESS LOCAL ORGANIZING COMMITTEE
Chair:Irene Litvan David Barba Jennifer Friedman Stephanie Lessig Stuart Lipton Fatta Nahab Howard Poizner Dee Silver Mark Tuszynski
Treasurer-Elect David John Burn, United Kingdom
Past-President Günther Deuschl, Germany
PAST-PRESIDENTS
2011-2013 Günther Deuschl, Germany 2009-2011 Philip Thompson, Australia 2007-2009 Anthony Lang, Canada 2005-2006 Andrew Lees, United Kingdom 2003-2004 C. Warren Olanow, USA 2001-2002 Werner Poewe, Austria 1999-2000 Mark Hallett, USA 1997-1998 Eduardo Tolosa, Spain 1995-1996 Joseph Jankovic, USA 1991-1994 C. David Marsden, United Kingdom 1988-1991 Stanley Fahn, USA
INTERNATIONAL MEDICAL SOCIETY FOR MOTOR DISTURBANCES PAST-PRESIDENTS
1993-1994 C. Warren Olanow, USA 1991-1992 Bastian Conrad, Germany 1989-1990 Mark Hallett, USA 1987-1988 Mario Manfredi, Italy 1985-1986 C. David Marsden, United Kingdom
MDS INTERNATIONAL SECRETARIAT
International Parkinson and Movement Disorder Society 555 East Wells Street, Suite 1100 Milwaukee, WI 53202-3823 USA Tel: +1 414-276-2145 Fax: +1 414-276-3349 E-mail: [emailprotected] Website: www.movementdisorders.org
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
MDS Membership Information MDS ASSOCIATE MEMBERSHIP PROGRAM*
• • •
Eligible delegates will be contacted by e-mail one month following the International Congress. The International Secretariat will provide special instructions to apply online for the Associate Membership option.
Non-members attending the International Congress have the opportunity to receive membership with the International Parkinson and Movement Disorder Society (MDS) absolutely free for one year’s time! Eligible MDS aims to facilitate communication between Researchers, Clinicians, and delegates will receive one year of membership including immediate access other Health Professionals in working towards common goals of: to online member benefits upon acceptance to the Society. Disseminating updated knowledge Promoting research; and Improving quality of life, independence, and care for individuals affected by movement disorders.
We welcome you to join 5,000 (+) of your colleagues already working together in the MDS Community.
Interested individuals are encouraged to apply online within 30 days of receiving the invitation via e-mail. *Participants paying the Non-member registration fee are eligible to apply. Contact us or visit our website to learn more: International Parkinson and Movement Disorder Society www.movementdisorders.org
Clinician Student Researcher
Health Professional Fellow
Resident
MEMBERSHIP BENEFIT HIGHLIGHTS
Annual subscription to Society Journals: Movement Disorders Available in Print and Online Movement Disorders-Clinical Practice Available Online
MDS International Secretariat 555 East Wells Street, Suite 1100 Milwaukee, WI 53202 USA Tel: + 1 414-276-2145 Fax: + 1 414-276-3349 E-mail: [emailprotected]
JOIN US IN 2015!
Quarterly Newsletter entitled: Moving Along Available in Print and Online Members Only Access to the Society’s online resources: Membership Directory, CME Activities, Streaming Content, Webcasts, and an in-depth Video Library Member Discounts for Registration at MDS Activities Voting Rights in Society Leadership elections Visit www.movementdisorders.org/MDS/membership.htm for full details on benefits available to members.
We expect this to be an exciting year for MDS and look forward to bringing you news, updates and other initiatives in the field through the Society’s journals, newsletter, and the MDS website.
5
About MDS
Free 12-Month Trial Membership!
JOIN OUR MEMBERSHIP COMMUNITY
The International Parkinson and Movement Disorder Society (MDS) warmly welcomes all individuals practicing, researching, or studying in the field of Movement Disorders to become members of the Society, its activities, and to contribute to the development of the specialty and field.
About MDS
MDS Education Information To better fulfill its global mission of advancing the neurological sciences as they relate to the field of Movement Disorders, MDS is continually expanding its educational portfolio. This growing portfolio offers an increasing variety of high caliber continuing medical education and continuing professional development opportunities in Movement Disorders. For more information about the opportunities listed in this section, please visit www.movementdisorders.or/MDS/Education.htm or e-mail [emailprotected].
OUTREACH EDUCATION PROGRAMS
The following outreach education programs are intended to support movement disorders conferences and meetings in underserved areas. Applications, which include a proposed program, a budget and an online form, are submitted through the MDS website. Corresponding MDS Regional Sections and the MDS Education Committee review outreach education applications throughout the year. Developing World Education Program Through the Developing World Education Program (DWEP), funds are administered in a flexible support program tailored to the needs of each region. The funds can be used to sponsor faculty travel and accommodation, logistics costs or other course expenses which are approved at the time of application. Ambassador Program The Ambassador Program supports the travel of one or two international experts, who are MDS Members, to an underserved area for the purposes of education and scientific exchange. Sponsored speakers should deliver a keynote lecture during the meeting. Visiting Professor Program The Visiting Professor Program supports the travel of one or two international experts, who are MDS Members, to an underserved area for the purposes of education and scientific exchange. During the visit, invited experts should conduct teaching seminars in local hospitals or institutions, participate in grand rounds and/or provide input to further the understanding of movement disorders in the host country. Parkinson and Movement Disorders Curriculum The Parkinson and Movement Disorders Curriculum provides an overview of movement disorders and a clinical approach to the evaluation and management of common movement disorders. This curriculum is specially developed for trainees, internists, general neurologists and other clinicians interested in acquiring a basic understanding of movement disorders.
6
ONLINE EDUCATION Device-Aided Medical Therapies for Parkinson’s Disease Device-Aided Medical Therapies in Parkinson’s Disease is a new online course series designed by a panel of worldwide specialists around the main practical issues involved in therapeutic treatments of Parkinson’s disease. This course series, provided as 10 separate modules, addresses issues such as identifying patients who may or may not benefit from the treatment, understanding the titration and the monitoring of clinical response, recognizing the main complications and managing them, and comparing these treatments with conventional oral dopaminergic therapies, as well as against each other. Each module will take approximately one hour to complete. MDS is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. MDS designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™ for each module. Physicians should only claim credit commensurate with the extent of their participation in the activity. Coffee Break CME The Coffee Break CME program provides education critical to providing the best care possible. Scientific content is presented in a modular format where each module is focused on a single topic. Each module can be completed in a short period of time and provides the clinician with updated information relevant to their practice. Both standard approaches and new advances are highlighted. MDS is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. MDS designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™ for each module. Physicians should only claim credit commensurate with the extent of their participation in the activity. Journal CME Visit the Educational Resources page on the MDS website to view a list of Movement Disorders journal articles available for CME credit. MDS is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. MDS designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™ for each module. Physicians should only claim credit commensurate with the extent of their participation in the activity. MDS Video Library This Members Only library consists of video supplements from the Movement Disorders journal since 1986. You may search the Video Library by keyword, author, volume and issue or a combination of these fields.
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
MDS Education Information
• • • • •
8th Annual European Section Summer School for Young Neurologists; Prague, Czech Republic; September 4-6, 2015 Deep Brain Stimulation for Movement Disorders; Grenoble, France; September 10-11, 2015 Multidisciplinary Allied Health Professionals Team Training; São Paulo, Brazil; September 10-12, 2015 Bridges and Boundaries in Movement Disorders: The Role of Neuroimaging; Pisa, Italy; November 12-13, 2015 2nd Middle East Camp for Parkinson’s, Movement Disorders and Neuromodulation: From Neurodegeneration to Neuroregeneration; Dubai, UAE; November 19-21, 2015
RATING SCALES AND TRAINING VIDEOS Rating Scales MDS provides rating scales and related resources published in the Movement Disorders journal to physicians, researchers and health professionals interested in Parkinson’s disease and other movement disorders. By making these scales available, MDS works to improve the diagnosis of movement disorders and patient care, as well as increase the validity and reliability of research studies. You can access the rating scales below online by visiting: www.movementdisorders.org/MDS/Education/Rating-Scales.htm. Links to the MDS-UPDRS and UDysRS training programs and rating scales use permission forms are also available through the rating scales link. Licensing fees are free for individual use, but fees may apply for government, nonprofit or industry-funded research. The following rating scales are currently available: Global Assessment Scale for Wilson’s Disease Global Dystonia Scale Non-Motor Symptoms Scale (NMSS) + (Includes NMSQ) Quality of Life Essential Tremor Questionnaire Rating Scale for Psychogenic Movement Disorders Rush Dyskinesia Rating Scale * Rush Videobased Tic Rating Scale UFMG Sydenham’s Chorea Rating Scale (USCRS) Unified Dyskinesia Rating Scale (UDysRS) + * Unified Dystonia Rating Scale (UDRS) Unified Multiple System Atrophy Rating Scale (UMSARS) Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) + *
Asterisk (*) indicates scale was developed by MDS; Plus symbol (+) indicates translations of the scale are available. Training Videos MDS publishes several audiovisuals, which are available for sale from the MDS International Secretariat. All materials are available in DVD format. Special reduced rates are available to MDS Members. For more information or to place an order, visit www.movementdisorders.org/MDS/Education/ Latest-E-Learning/MDS-E-Store.htm. The titles that are currently available for purchase include: Instructional Video for Motor Fluctuation Diaries in Parkinson’s Disease Authored by C.G. Goetz, M. Grobman, L. Blasucci, and G.T. Stebbins, this instructional video demonstrates the 3 states of Parkinson’s disease, off, on, and on with dyskinesia, with the intent to assist patients in completion of their motor fluctuation diaries. This video is 15 minutes. Toronto-Western Spasmodic Torticollis Rating Scale TWSTRS Training Video Authored by C. Comella, S. Bressman, C.G. Goetz, and A. Lang, this instructional video demonstrates the 10 categories in the TWSTRS scale with verbal and visual examples of scoring in each category. This video is approximately 1 hour and 25 minutes. Unified Dyskinesia Rating Scale Teaching Program (UDysRS) Authored by C.G. Goetz, John G. Nutt and G.T. Stebbins. This teaching program provides guidelines and rating examples of the Unified Dyskinesia Rating Scale, a new scale used for evaluating Parkinson’s disease. This video is approximately 52 minutes. Utility of an Objective Dyskinesia Rating Scale for Parkinson’s Disease: (Rush Dyskinesia Rating Scale) Authored by Goetz, et al. Movement Disorders Volume 9, Video Supplement. 2. This video provides guidelines and rating examples of the Rush Dyskinesia Rating Scale, a scale widely used for evaluating dyskinesias in Parkinson’s disease. This video is approximately 17 minutes. Unified Parkinson’s Disease Rating Scale Training Video (1995) Authored by C. G. Goetz, G.T. Stebbins, T. Chmura, S. Fahn, H. Klawans, and C. D. Marsden, this video demonstrates the different categories of the motor section of the UPDRS, with verbal and visual examples of scoring in each category. This video is approximately 1 hour. Standardized Training Tools for the UPDRS Activities of Daily Living Scale (UPDRS Part II) (2003) Authored by C.G. Goetz, P.A. Lewitt, and M. Weidenman. Movement Disorders Volume 18, Video Supplement. 2. This video provides suggestions on the application and interview techniques for Part II of 7
About MDS
LIVE COURSES
Through the MDS Regional Sections, MDS offers a robust list of live course learning opportunities. Below is a sample of upcoming courses offered through MDS. Please note that dates and locations are subject to change. For the most up-to-date list of live courses, please visit www.movementdisorders.org/MDS/Education.htm.
About MDS
MDS Education Information the UPDRS with patient examples and guidelines for raters. This video is approximately 1 hour and 15 minutes. The International Parkinson and Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Training Video (2010) The International Parkinson and Movement Disorder Society (MDS)sponsored new version of the UPDRS is founded on the critique that was formulated by the Task Force for Rating Scales in Parkinson’s disease (Mov Disord 2003;18:738-750). The MDS-UPDRS has four parts: Part I (nonmotor experiences of daily living), Part II (motor experiences of daily living), Part III (motor examination) and Part IV (motor complications). This video is approximately 2 hours and 5 minutes.
MDS REGIONAL SECTIONS European Section The International Parkinson and Movement Disorder Society-European Section (MDS-ES) serves MDS Members who live in Europe as well as select countries in Northern Africa. The MDS-ES Executive Committee is chaired by Prof. Olivier Rascol of Toulouse University Hospital in Toulouse, France. The MDS-ES Education Committee is chaired by Prof. Angelo Antonini of the Institute of Neurology, IRCCS San Camillo in Venice, Italy. During the past year, MDS-ES educational activities have been held in Italy, Spain, Hungary, Portugal, Greece, Germany, Slovenia, Italy, Austria, Israel, Russia, Udmurtia, Moldova, Bulgaria, South Africa and Morocco. The official MDSES website includes a wealth of programming and Section information, including section leadership and mission and details about MDS Regional Development initiatives. One can also find information on fellowships, links to scholarly papers and keynote publications and a calendar of events. For more information about the MDS-ES, please visit www.movementdisorders.org/MDS/Regional-Sections/European-Section. htm. Asian and Oceanian Section The International Parkinson and Movement Disorder Society-Asian and Oceanian Section (MDS-AOS) serves MDS members from the majority of the Asian continent, as well as Australia, New Zealand and Oceania. The MDS-AOS Executive Committee is chaired by Dr. Louis Tan of the National Neuroscience Institute in Singapore. The MDS-AOS Education Committee is co-chaired by Prof. Madhuri Behari of the All India Institute of Medical Sciences in New Delhi, India and Prof. Shen-Yang Lim of the University of Malaya in Kuala Lumpur, Malaysia. The Asian and Oceanian Section was formed in 2006 at the 10th International Congress of Parkinson’s Disease and Movement Disorders in Kyoto, Japan. Since its foundation, MDS-AOS 8
has developed educational programs in India, Sri Lanka, China, Malaysia, the Philippines, Vietnam, Myanmar, Taiwan, Korea, Thailand and the United Arab Emirates among other locations. The official MDS-AOS website includes programming and Section information, including details about AOS Regional Partners, leadership, the MDS-AOS Visiting Trainee Grant and a calendar of events. In 2016, the MDS-AOS is holding the 5th Asian and Oceanian Parkinson’s Disease and Movement Disorders Congress (AOPMC) in Manila, Philippines March 11-13, 2016. Please visit www.movementdisorders.org/aopmc2016 for more information. For further information on MDS-AOS or its educational opportunities, please visit www.movementdisorders.org/MDS/Regional-Sections/Asian Oceanian-Section.htm. Pan American Section The International Parkinson and Movement Disorder Society-Pan American Section (MDS-PAS) is composed of MDS Members who live in the countries of the Western Hemisphere. The MDS-PAS Executive Committee is chaired by Dr. Jorge Juncos of Emory University in Atlanta, GA, USA. The MDSPAS Education Committee is chaired by Dr. Irene Litvan of the University of California San Diego in San Diego, CA, USA. The MDS-PAS supports educational programming throughout the entire region and has recently held courses in the United States, Argentina, and Brazil. The official MDSPAS website includes a variety of programming and section information including details about the Regional Needs Assessment Survey, MDS-PAS Visiting Trainee Grant and MDS-PAS calendar of events. For additional information on the MDS-PAS or its educational programming, please visit www.movementdisorders.org/MDS/RegionalSections/Pan-America-Section.htm.
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Continuing Medical Education (CME) Information PURPOSE
The purpose of the 19th International Congress of Parkinson’s Disease and Movement Disorders is to offer a forum for clinical and basic discussion on a variety of movement disorder topics, including presentations of current research and available treatments.
LEARNING OBJECTIVES
1. Describe the pathophysiology and neurobiology of Parkinson’s disease and other movement disorders; 2. Discuss the diagnostic approaches and tools available for Parkinson’s disease and other movement disorders; 3. Discuss the pharmacological and non-pharmacological treatment options available for Parkinson’s disease and other movement disorders.
TARGET AUDIENCE
The target audience of the 19th International Congress of Parkinson’s Disease and Movement Disorders includes clinicians, researchers, postdoctoral fellows, medical residents, medical students and other healthcare professionals with an interest in the current research and approaches for the diagnosis and treatment of movement disorders.
ACCREDITATION STATEMENT
The International Parkinson and Movement Disorder Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION
The International Parkinson and Movement Disorder Society designates this educational activity for a maximum of 35 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
FACULTY FINANCIAL DISCLOSURE INFORMATION
It is the policy of the International Parkinson and Movement Disorder Society (MDS) to ensure balance, independence, objectivity and scientific rigor in all sponsored educational activities. All faculty participating in any MDS sponsored activities are required to disclose to the activity audience any real or apparent conflict(s) of interest that may have a direct bearing
Faculty financial disclosure information will be provided to participants in San Diego.
CLAIMING CME CREDIT
To claim CME credit for participation in the 19th International Congress of Parkinson’s Disease and Movement Disorders, participants must complete and submit an online CME Request Form. Instructions for claiming credit: After June 16, 2015, please visit: www.mdscongress2015.org/registration/ cme. 1. Log in after reading the instructions on the page. You will need your International Congress Registration ID which is located on your name badge, registration confirmation or e-mail [emailprotected]. 2. Follow the on-screen instructions to claim CME credit for the sessions you attended. 3. You may print your certificate from your home or office, or save it as a PDF for your records. The UEMS-EACCME® and the AMA recognize each other’s CME credits since 2000. In 2002 the UEMS-EACCME® and the AMA signed an agreement of mutual recognition of CME credits between Europe and the USA whereby European physicians attending an event in the USA have their credits recognized in Europe and American physicians attending an event in Europe have their credits recognized in the USA. If you have any questions or need help claiming credit contact the MDS International Secretariat at [emailprotected].
9
Congress Information
Through state-of-the-art lectures, hot topic reviews, controversy debates, teaching courses, skills workshops and video sessions, participants will be better able to:
on the subject matter of the continuing medical education (CME) activity. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It remains for the audience to determine whether the speaker’s outside interest may reflect a possible bias in either the exposition or the conclusions presented.
International Congress Information A-Z
All registered Congress delegates will also receive the published abstracts on a USB, available for pickup in the registration area during regular Congress hours. For further information regarding abstracts, poster presentation schedules and abstract publication, please see pages 15–18.
LATE-BREAKING ABSTRACTS AND MDS STUDY GROUP ABSTRACTS
All accepted Late-Breaking Abstract and MDS Study Group posters are displayed in the Harbor Foyer, 2nd Level, Monday – Thursday throughout the duration of the International Congress. These poster presentations will take place on Wednesday, June 16 from 12:00 – 13:30. An online
publication supplement of the Late-Breaking Abstracts and MDS Study Group Abstracts is available as of June 14, 2015 on the 2015 International Congress website, www.mdscongress2015.org. For further information regarding Late-Breaking and MDS Study Group Abstracts, poster presentation schedules and publication, please see page 15.
BADGES
All International Congress attendees will receive a name badge with their registration materials. Badges should be worn at all times as they are used to gain access into all International Congress sessions and activities. Badge colors will be identified as follows: Blue = Delegate Purple = Press
Yellow = Exhibitor Black = Staff
CAMERA POLICY
Cameras are not permitted in any 19th International Congress educational sessions or in the poster areas.
CERTIFICATE OF ATTENDANCE
A certificate of attendance is available in the back of the 2015 Final Program.
Connect to the Movement Disorder Community Through the MDS Website MDS Website Resources: • Journals • Online CME • Video Library • EBM Reviews • Regional Section Updates • Rating Scales • MDS-UPDRS and UDysRS Online Training • and much more!
Visit the MDS website today at www.movementdisorders.org 10
MDS-0315-489
Congress Information
ABSTRACTS
All accepted abstracts (including Late-Breaking and MDS Study Group Abstracts) are presented as a poster at the 2015 International Congress. All regular accepted abstracts are published as a supplement to the MDS Journal online edition. Additionally, select abstracts are presented in a Guided Poster Tour. All published abstracts are available on the MDS abstracts website, where you can download a PDF of accepted abstracts or search by author, keyword or abstract title. Please visit www.mdscongress2015.org for further publication information.
JUNE 14-18
2015
19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
SAN DIEGO, CA, USA
International Congress Information A-Z COFFEE BREAKS
Coffee and tea will be available at the following times/locations: Sunday, June 14, 10:00 – 11:00 Monday, June 15, 10:00 – 10:30 Tuesday, June 16, 10:00 – 11:00 Wednesday, June 17, 10:00 – 10:30 Thursday, June 18, 9:30 – 10:00
Seaport Foyer, 2nd Level Grand Hall, Lobby Level Grand Hall, Lobby Level Grand Hall, Lobby Level Grand Hall, Lobby Level
Location: Palm Foyer, 2nd Level (in the Registration area)
CONTINUING MEDICAL EDUCATION (CME)
Please refer to page 9 for Continuing Medical Education information.
CURRENCY
The official currency of the 19th International Congress is US Dollars; no other currency will be accepted.
EVALUATIONS
Please take time to complete the evaluation form provided at each session you attend. Your input and comments are essential in planning future educational programs for MDS. Upon completion, evaluations may be returned to the session room attendants, or to the MDS Booth (located in the Grand Hall, Lobby Level).
EVENTS Welcome Ceremony Sunday, June 14 Location: Seaport Ballroom A–E, 2nd Level, Seaport Tower 19:30 – 21:30 All International Congress attendees are warmly invited to attend the International Congress Welcome Ceremony at the Manchester Grand Hyatt. This event is open to all registered delegates. MDS Video Challenge Pre-Event Gathering Wednesday, June 17 Location: Harbor and Seaport Foyers, 2nd Level 19:00 – 20:00 MDS Video Challenge Wednesday, June 17 Location: Seaport Ballroom A-E, 2nd Level, Seaport Tower 20:00 – 22:00 Please join Masters of Ceremony Anthony Lang and Kapil Sethi as they host a world-renowned panel of Movement Disorders experts in guiding
The 2015 Panel of Experts are:
Congress Information
CONGRESS INFORMATION DESK
participants through unique Movement Disorder cases. The cases will be presented by representatives from Movement Disorder Centers around the world and discussed by the Panel of Experts. Awards will be given for the most interesting and challenging cases. Country pride will add an enjoyable spirit of competition to this event. The goal of this session is for attendees to learn from a series of unusual and interesting patients and see how senior experts approach these types of challenging cases. Susan Fox, Canada Shen-Yang Lim, Malaysia Tim Lynch, Ireland Susanne Schneider, Germany Maria Stamelou, Greece This event is open to all registered delegates.
EXHIBIT HALL
Location: Grand Hall, Lobby Level For more information, please refer to pages 132-140. Monday, June 15: Tuesday, June 16: Wednesday, June 17: Thursday, June 18:
9:00 – 18:00 9:00 – 18:00 9:00 – 18:00 9:00 – 16:00
FLOOR PLANS OF THE MANCHESTER GRAND HYATT
Please refer to page 14.
GUIDED POSTER TOURS
Guided Poster Tours will give small groups of delegates an opportunity to hear discussion by abstract authors on a select group of abstracts in several sub-categories. They will take place in various session rooms, and will be led by members of the MDS faculty and leadership. There will be 16 total Guided Poster Tours with four simultaneous tours per day from Monday, June 15 through Thursday, June 18. Each tour will feature abstracts on a specific topic. Please refer to pages 15–18 for further Guided Poster Tour information and schedules.
INTERNET
Complimentary Wi-Fi will be available throughout the Manchester Grand Hyatt for all attendees. To access: 1. View available Wireless Networks 2. Connect to MDS Wi-Fi Network 3. Enter Password: sandiego 11
International Congress Information A-Z MDS BOOTH
•
Location: Grand Hall, Lobby Level The MDS Booth hours are as follows:
Congress Information
Monday, June 15: Tuesday, June 16: Wednesday, June 17: Thursday, June 18:
9:00 – 18:00 9:00 – 18:00 9:00 – 18:00 9:00 – 16:00
OFFICIAL LANGUAGE
The official language of the International Congress is English.
PRESS INFORMATION
Members of the working media receive waived registration for the 19th International Congress. Journalists and writers should report to the Congress Information Desk on the 2nd Level with their credentials to register for the International Congress. All press must wear their name badge for admittance into MDS sessions. Please visit www.mdscongress2015.org/Congress-2015/Press.htm for further information and requirements.
REGISTRATION DESK
Location: Palm Foyer, 2nd Level Name badges, scientific session tickets, abstract USB’s, Final Programs and International Congress bags can be collected at the International Congress Registration Desk. Registration Desk hours are as follows: Saturday, June 13: Sunday, June 14: Monday, June 15: Tuesday, June 16: Wednesday, June 17: Thursday, June 18:
16:00 – 20:00 7:00 – 20:00 7:00 – 18:00 7:00 – 18:00 7:00 – 18:00 7:00 – 16:00
SCIENTIFIC SESSIONS
The 2015 Scientific Program will incorporate Therapeutic Plenary Sessions, Plenary and Parallel Sessions, Teaching Courses, Video Sessions, Skills Workshops, Guided Poster Tours and Blue Ribbon Highlights. Sessions will focus on the latest developments in: • •
12
Multi-system proteinopathies Movement Disorder topics, including, but not limited to, ataxia, chorea, dystonia, myoclonus, Parkinson’s disease, restless legs syndrome, spasticity, stereotypies, tics and tremors
•
Basic Science issues, including, but not limited to, genetics, neuroimaging, neuropharmacology, surgical therapy and transplantation Other less common clinical conditions
SPECIAL ACCESSIBILITY NEEDS
To ensure any special needs can be properly met, requests should have been addressed in advance with the MDS International Secretariat. Delegates requiring special arrangements in order to fully participate in the International Congress should provide a written description of such needs to the MDS Information Desk upon arrival.
SPEAKER READY ROOM
Location: Balboa A-B, 2nd Level, Seaport Tower All speakers and Guided Poster Tour presenters must check in at the Speaker Ready Room with their presentation materials the day prior to their scheduled presentation. Equipment is available to allow faculty and presenters to review their presentations. Audio/Visual personnel will be available for assistance. The Speaker Ready Room hours are as follows: Saturday, June 13: Sunday, June 14: Monday, June 15: Tuesday, June 16: Wednesday, June 17: Thursday, June 18:
16:00 – 20:00 7:00 – 18:00 7:00 – 18:00 7:00 – 18:00 7:00 – 18:00 7:00 – 16:00
TICKETED SESSIONS
Tickets are required for admission into all Parallel Sessions, Teaching Courses, Video Sessions, and Skills Workshops. There is no additional fee for tickets to these sessions. Please check the Registration Desk for ticket availability. Therapeutic Plenary Sessions, Plenary Sessions and poster sessions do not require a ticket to attend.
VENUE
The Manchester Grand Hyatt One Market Place San Diego, CA 92101 USA
WEATHER
The average daytime temperature in San Diego in June is approximately 67° F (19° C).
e t a se a D e s i n’s D the
o s n e i k v r Sa Oceanian Pa rs Congress ES
IN de d r P n o P I a s i L I n D H t ia 5th As Movemen • MANILA, P 16 and 0 2 , 3 1 – 1 1 h Marc
www.movementdisorders.org/AOPMC2016
MDS-0115-444
Important Dates: Abstract Submission Opens: July 1, 2015 Registration and Housing Opens: September 25, 2015 Abstract Submission Closes: September 30, 2015
Congress Information
Manchester Grand Hyatt Floor Plan
FOURTH LEVEL:
Posters Science and Technology Pavilion
THIRD LEVEL:
Faculty/Leadership Lounge
14
SECOND LEVEL:
Registration Speaker Ready Room Plenary Sessions Breakout Sessions Late-Breaking and Study Group Posters
LOBBY LEVEL:
Guided Poster Tours Regional Assemblies MDS Business Meeting Welcome Ceremony MDS Video Challenge Corporate Therapeutic Symposia
Exhibits Posters
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstract Information and Schedules ABSTRACT PUBLICATION
All regular accepted abstracts are published as a supplement to the MDS Journal and are available utilizing a searchable feature on the Congress website, www.mdscongress2015.org/Congress-2015/Abstracts, as of June 14, 2015. Please also visit www.movementdisorders.org to access The Movement Disorders Journal, where you can download a PDF of accepted abstracts.
Late-Breaking Abstracts and MDS Study Group Abstracts are published as an online supplement on the 2015 International Congress website, www.mdscongress2015.org/Congress-2015/Abstracts. These abstracts are available for download as of June 14, 2015.
GUIDED POSTER TOURS
Guided Poster Tours give groups of delegates an opportunity to hear discussion on a select group of abstracts in several sub-categories. Attendance is limited, and admission will be granted on a first-come, firstserved basis. Guided Poster Tours do not require a ticket to attend. A list of Guided Poster Tour abstracts and authors can be found on pages 54 – 61. Abstracts selected for a Guided Poster Tour presentation are published in a supplement to the MDS Journal, and can be found on the searchable abstract website.
MDS STUDY GROUP ABSTRACTS
All accepted MDS Study Group Abstract posters are displayed in the Harbor Foyer, 2nd Level, Harbor Tower, Monday – Thursday throughout the duration of the Congress. MDS Study Group Abstract poster presentations will take place Wednesday, June 17 from 12:00 – 13:30 in the Harbor Foyer, 2nd Level, Harbor Tower.
POSTER SESSIONS
Poster sessions give each delegate an opportunity to view their colleagues’ posters on the most current research in the field of Movement Disorders. Authors will be present for 1.5 hours each day to explain their work and answer questions. All accepted abstracts are presented as a poster at the 2015 International Congress. Poster sessions are held Monday – Thursday during the Congress. Posters are available for viewing in the Grand Hall, Lobby Level, and the Coronado Ballroom, 4th Level, Harbor Tower, from 9:00 – 18:00, Monday through Wednesday, and 9:00 – 16:00 on Thursday. Poster session topics and schedules vary by date; please see the complete listing of scheduled poster presentation dates, times and locations on pages 16 – 18.
15
Congress Information
All registered Congress delegates will also receive the published abstracts on a USB, available for pickup in the registration area during regular Congress hours.
LATE-BREAKING ABSTRACTS
All accepted Late-Breaking Abstract posters are displayed in the Harbor Foyer, 2nd Level, Harbor Tower, Monday – Thursday throughout the duration of the Congress. Late-Breaking Abstract poster presentations will take place Wednesday, June 17 from 12:00 – 13:30 in the Harbor Foyer, 2nd Level, Harbor Tower.
Abstract Information POSTER SESSION SCHEDULE (LISTED BY ABSTRACT NUMBER)
Congress Information
All poster sessions will take place at the Congress venue; the Manchester Grand Hyatt, in the specific room locations as listed below. Monday, June 15 • Presentation Time: 12:30 - 14:00 Abstract Numbers: Category Name: 1-66 Parkinson’s disease: Neuroimaging and neurophysiology 67-136 Parkinson’s disease: Pathophysiology 137-167 Parkinson’s disease: Psychiatric manifestations 168-350 Parkinson’s disease: Clinical trials, pharmacology and treatment 351-364 Choreas (non-Huntington’s disease) 365-374 Myoclonus Tuesday, June 16 • Presentation Time: 12:30 - 14:00 Abstract Numbers: Category Name: 375-489 Parkinson’s disease: Non-motor symptoms 490-514 Neurophysiology 515-524 Therapy in movement disorders: Neurotoxin 525-531 Pediatric movement disorders 532-535 History 536-633 Surgical Therapy: Parkinson’s disease 634-667 Surgical Therapy: Other movement disorders 668-740 Other (non-category specific) Wednesday, June 17 • Presentation Time: 12:00 - 13:30 Abstract Numbers: Category Name: 741-754 Drug-induced movement disorders 755-770 Neuropharmacology 771-846 Parkinsonism (secondary and parkinsonism-plus) 845-903 Parkinson’s disease: Cognition 904-907 Pathophysiology (other movement disorders) 908-957 Ataxia 958-965 Education in movement disorders 966-1016 Neuroimaging 1017-1066 Parkinson’s disease: Genetics 1067-1089 Rating scales 1090-1111 Therapy in movement disorders: Medical Late-Breaking and MDS Study Group Abstracts Thursday, June 18 • Presentation Time: 12:00 - 13:30 Abstract Numbers: Category Name: 1112-1148 Epidemiology 1149-1182 Genetics 1183-1218 Phenomenology and clinical assessment of movement disorders 1219-1237 Rare genetic and metabolic diseases 1238-1253 Restless legs syndrome and other sleep disorders 1254-1263 Tics/Stereotypies 1264-1266 Therapy in movement disorders: Gene and cell-based therapies 1267-1278 Cognitive disorders 1279-1362 Dystonia 1363-1395 Huntington’s disease 1396-1426 Quality of life/caregiver burden in movement disorders 1427-1439 Spasticity 1440-1473 Tremor 16
Location: Grand Hall (Lobby Level) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Location: Grand Hall (Lobby Level) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Location: Grand Hall (Lobby Level) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Harbor Foyer (2nd Level, Harbor Tower) Location: Grand Hall (Lobby Level) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower)
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstract Information POSTER SESSION SCHEDULE (LISTED ALPHABETICALLY BY ABSTRACT CATEGORY) Category Name 908-957 351-364 1267-1278 741-754 1279-1362 958-965 1112-1148 1149-1182 532-535 1363-1395 365-374 966-1016 755-770 490-514 668-740 771-846 168-350
Wednesday, June 17 Monday, June 15 Thursday, June 18 Wednesday, June 17 Thursday, June 18 Wednesday, June 17 Thursday, June 18 Thursday, June 18 Tuesday, June 16 Thursday, June 18 Monday, June 15 Wednesday, June 17 Wednesday, June 17 Tuesday, June 16 Tuesday, June 16 Wednesday, June 17 Monday, June 15
Presentation Time: 12:00 - 13:30 12:30 - 14:00 12:00 - 13:30 12:00 - 13:30 12:00 - 13:30 12:00 - 13:30 12:00 - 13:30 12:00 - 13:30 12:30 - 14:00 12:00 - 13:30 12:30 - 14:00 12:00 - 13:30 12:00 - 13:30 12:30 - 14:00 12:30 - 14:00 12:00 - 13:30 12:30 - 14:00
Location Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Grand Hall (Lobby Level) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Coronado Ballroom (4th Level, Harbor Tower) Grand Hall (Lobby Level) Coronado Ballroom (4th Level, Harbor Tower)
845-903 Wednesday, June 17 12:00 - 13:30 Grand Hall (Lobby Level) 1017-1066 Wednesday, June 17 12:00 - 13:30 Coronado Ballroom (4th Level, Harbor Tower) 1-66 Monday, June 15 12:30 - 14:00 Grand Hall (Lobby Level) 375-489 67-136 137-167 904-907 525-531 1183-1218
Tuesday, June 16 Monday, June 15 Monday, June 15 Wednesday, June 17 Tuesday, June 16 Thursday, June 18
12:30 - 14:00 12:30 - 14:00 12:30 - 14:00 12:00 - 13:30 12:30 - 14:00 12:00 - 13:30
Grand Hall (Lobby Level) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Grand Hall (Lobby Level)
1396-1426 Thursday, June 18
12:00 - 13:30 Coronado Ballroom (4th Level, Harbor Tower)
1219-1237 1067-1089 1238-1253 1427-1439 634-667 536-633 1264-1266
Thursday, June 18 Wednesday, June 17 Thursday, June 18 Thursday, June 18 Tuesday, June 16 Tuesday, June 16 Thursday, June 18
12:00 - 13:30 12:00 - 13:30 12:00 - 13:30 12:00 - 13:30 12:30 - 14:00 12:30 - 14:00 12:00 - 13:30
Grand Hall (Lobby Level) Coronado Ballroom (4th Level, Harbor Tower) Grand Hall (Lobby Level) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Coronado Ballroom (4th Level, Harbor Tower) Grand Hall (Lobby Level)
1090-1111 515-524 1254-1263 1440-1473
Wednesday, June 17 Tuesday, June 16 Thursday, June 18 Thursday, June 18
12:00 - 13:30 12:30 - 14:00 12:00 - 13:30 12:00 - 13:30
Coronado Ballroom (4th Level, Harbor Tower) Grand Hall (Lobby Level) Grand Hall (Lobby Level) Coronado Ballroom (4th Level, Harbor Tower) 17
Congress Information
Ataxia Choreas (non-Huntington's disease) Cognitive disorders Drug-induced movement disorders Dystonia Education in movement disorders Epidemiology Genetics History Huntington's disease Myoclonus Neuroimaging Neuropharmacology Neurophysiology Other (non-category specific) Parkinsonism (secondary and parkinsonism-plus) Parkinson's disease: Clinical trials, pharmacology and treatment Parkinson's disease: Cognition Parkinson's disease: Genetics Parkinson's disease: Neuroimaging and neurophysiology Parkinson's disease: Non-motor symptoms Parkinson's disease: Pathophysiology Parkinson's disease: Psychiatric manifestations Pathophysiology (other movement disorders) Pediatric movement disorders Phenomenology and clinical assessment of movement disorders Quality of life/caregiver burden in movement disorders Rare genetic and metabolic diseases Rating scales Restless legs syndrome and other sleep disorders Spasticity Surgical Therapy: Other movement disorders Surgical Therapy: Parkinson's disease Therapy in movement disorders: Gene and cellbased therapies Therapy in movement disorders: Medical Therapy in movement disorders: Neurotoxin Tics/Stereotypies Tremor
Presentation Date:
Abstract Schedules GUIDED POSTER TOUR SCHEDULE
* No Guided Poster Tours on Sunday
Guided Poster Tours give groups of delegates an opportunity to hear discussion on a select group of abstracts in several sub-categories. Attendance is limited, and admission will be granted on a first-come, first-served basis. Guided Poster Tours do not require a ticket to attend.
Congress Information
A list of Guided Poster Tour abstracts and authors can be found on page 54 – 61. Abstracts selected for a Guided Poster Tour presentation are published in a supplement to the MDS Journal, and can be found on the searchable abstract website. MONDAY, JUNE 15 • 12:30 - 14:00 GPT 1 Parkinson's disease: Seaport F, 2nd Level, Seaport Tower Phenomenology GPT 2 Sleep disorders and RLS Harbor A, 2nd Level, Harbor Tower GPT 3 Tremor Harbor B-C, 2nd Level, Harbor Tower GPT 4 Parkinson's disease: Non- Harbor G, 2nd Level, Harbor Tower motor features TUESDAY, JUNE 16 • 12:30 - 14:00 GPT 5 Lewy body dementia and Seaport F, 2nd Level, Seaport Tower Dementias GPT 6 Huntington’s disease and Harbor A, 2nd Level, Harbor Tower other choreiform disorders GPT 7 Rating scales Harbor B-C, 2nd Level, Harbor Tower GPT 8 Genetics Harbor G, 2nd Level, Harbor Tower
WEDNESDAY, JUNE 17 • 12:00 - 13:30 GPT 9 Parkinson's disease: Seaport F, 2nd Level, Seaport Tower Clinical trials GPT 10 Dystonia Harbor A, 2nd Level, Harbor Tower GPT 11 Surgical therapy of Harbor B-C, 2nd Level, Harbor Tower Movement Disorders GPT 12 Basic Science Harbor G, 2nd Level, Harbor Tower THURSDAY, JUNE 18 • 12:00 - 13:30 GPT 13 Atypical Parkinsonism Seaport F, 2nd Level, Seaport Tower GPT 14 Surgical therapy of Harbor A, 2nd Level, Harbor Tower Parkinson's disease GPT 15 Parkinson's disease: Harbor B-C, 2nd Level, Harbor Tower Cognitive and behavioral aspects GPT 16 Parkinson's disease: Harbor G, 2nd Level, Harbor Tower Neuropharmacology
2015 MDS Education Calendar
MDS-ES Summer School for Young Neurologists September 4-6, 2015 Prague, Czech Republic
2nd Middle East Camp for Parkinson’s, Movement Disorders and Neuromodulation November 19-21, 2015 Dubai, UAE
18
Deep Brain Stimulation for Movement Disorders September 10-11, 2015 Grenoble, France
MDS-PAS School for Young Neurologists November 26-28, 2015 Mexico City, Mexico
Allied Health Team Training for Parkinson’s Disease September 10-12, 2015 São Paulo, Brazil
Bridges and Boundaries in Movement Disorders: The Role of Neuroimaging November 12-13, 2015 Pisa, Italy
Dates and Locations are subject to change. For a complete up-to-date list of courses, visit
www.movementdisorders.org/ MDS/education.htm
Congress Information
Map of Downtown San Diego
20
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Awards Information HONORARY MEMBERSHIP AWARDS
The Honorary Membership Awards recognize individuals who have made extraordinary contributions to the field of Movement Disorders or otherwise to the Society.
The enigma of action tremor in the elderly Stanley Fahn Lecturer – Günther Deuschl, MD
Sunday, June 14, as part of the Welcome Ceremony 19:30 – 21:30
C. Warren Olanow, MD, FRCPC New York, NY, USA
Anne Young, MD, PhD Boston, MA, USA
PRESIDENT’S DISTINGUISHED SERVICE AWARD
The President’s Distinguished Service Award is given in recognition of long and distinguished service to the International Parkinson and Movement Disorder Society. Sunday, June 14, as part of the Welcome Ceremony 19:30 – 21:30
STANLEY FAHN LECTURE
Monday, June 15 as part of Plenary Session 2101: Presidential Lectures 8:00 – 8:30 The Stanley Fahn Award Lecture was created to recognize an outstanding scholar and role-model clinician in the field of Movement Disorders. The selected lecturer must show evidence of exceptional contributions which have resulted in better understanding of the cause, diagnosis, or treatment of Movement Disorders, and have translated into meaningful improvements in the standard of clinical practice. The selected lecturer must demonstrate evidence of consistent dedication to Movement Disorders education and research.
Prof. Deuschl received many high ranking awards and honors like Max Nonne and H. Berger awards. He is currently a visiting Professor at the Shanghai Jiao Tong University and is an honorary member of several neurological Societies. He was the Editor of Movement Disorders from 2004-2010 and is an Editorial Board member of several international journals. He has served as the president of the German Society of Neurology (2006-2008), as the President of the International Parkinson and Movement Disorder Society (2011-2013) and is currently president of the European Academy of Neurology. He is glad to have many fellows and friends in the movement disorder community around the world.
21
Congress Information
Günther Deuschl received his MD at the University of Munich and started his training with Albrecht Struppler at the Department of Neurology in Munich and subsequently worked in Freiburg with C.H. Lücking and E. Schenk where he was promoted to assistant professor in 1988 and associate professor in 1993. In 1991 he spent a sabbatical at the National Institutes of Health, Bethesda/USA with Mark Hallett. In 1995 he was elected as full Professor of Neurology at the Christian-Albrechts-University in Kiel, Germany, and chairman of the Department of Neurology and is still in this position. He has built a visible deep brain surgery program in Kiel. Together with his team he focused on the pathophysiology and clinical studies for deep brain stimulation for Parkinson’s disease and dystonia. He created a national research group for deep brain stimulation which has contributed to the development of the field. His other main interest has been the study of tremor particularly clinical analysis, epidemiology, genetics, computational analysis, pathophysiology and neurophysiology of tremors. He led the writing group for the MDS consensus statement on tremor. Further scientific interests are dystonia, amnestic syndromes and clinical neurophysiology. Publications see: www.researcherid.com/ rid/A-7986-201.
Awards Information C. DAVID MARSDEN LECTURE
Congress Information
Monday, June 15 as part of Plenary Session 2101: Presidential Lectures 9:30 – 10:00 The C. David Marsden Lecture was created to recognize an outstanding scholar and inspiring neuroscientist in the field of Movement Disorders. The selected lecturer must show evidence of exceptional contributions which have resulted in better understanding of the neurobiology of Movement Disorders, and have translated into tangible improvements in clinical therapy and/or providing insight into normal brain function in the control of movement. The selected lecturer must demonstrate evidence of consistent dedication to Movement Disorder education and research. Basil Ganglia and Pathophysiology: Puzzles, paradoxes and clues C. David Marsden Lecturer – José Obeso, MD, PhD
Medicine, and particularly in neurology/neuroscience journals like, Annals of Neurology, Brain, Trends in Neuroscience. etc. His current H-index is 68. He has also contributed to teaching and academics with over one hundred book chapters including one recently in the Harrison’s Textbook of Medicine (with Drs. Olanow and Schapira), editorial pieces and several hundred communications and lectures at scientific meetings. Prof. Obeso has also served on the editorial boards of prestigious journals, including Annals of Neurology, and Movement Disorders and has reviewed routinely for Lancet, Lancet Neurology, Journal of Neuroscience, Brain, Neurobiology of Disease, etc. and served on the scientific grants review committees of the Parkinson’s Disease Foundation, Michael J. Fox Foundation, Anne Obretch Parkinson Foundation or Dystonia Foundation. He is an honorary member and Invited Professor of several organizations and institutions such as the Colombian Neurological Association, French Neurological Society, Bolivian Neurological Association and Professor of the Universidad de La Habana (Cuba).
JUNIOR AWARDS
Three Junior Awards recipients have been selected based on their significant contribution to research in the field of Movement Disorders. José A. Obeso graduated from the University of Navarra in 1976 and specialized in neurology and neurophysiology in San Sebastian and Pamplona, Spain. From 1980 to 1982 he worked as a researcher in movement disorders under the supervision of Professor C. David Marsden in London. These two years made a decisive impact in his career. Prof. Obeso is currently director of the CINAC at the Hospital Puerta del Sur in Mostoles, Madrid, Spain and full Professor of Neurology in the CEU-San Pablo University in Madrid. He has directed a highly productive clinical and experimental group for many years, with significant contributions in areas such as dystonia and myoclonus, continuous dopaminergic for Parkinson’s disease, pathophysiology of the basal ganglia and surgical treatment of Parkinson’s disease. Prof. Obeso and his team have concentrated on defining compensatory mechanism in early phase of PD and in determining the most relevant therapeutic challenges in PD. Currently he is focused on defining the origin of cell vulnerability in Parkinson’s disease and the need to stop the neurodegeneration process rather than concentrating on restoring striatal dopamine levels only. He is the Chief Editor of the Movement Disorders Journal, the leading publication in the field of Parkinson’s disease and movement disorders. Prof. Obeso has published more than 325 peer-reviewed papers on movement disorders and the pathophysiology of the basal ganglia, the mechanisms of surgery and more recently in a new more progressive model of inducing dopamine depletion in the rat and monkey. He has a high number of relevant publications in top general journals of medicine like The Lancet and New England Journal of Medicine, Lancet Neurology, Nature 22
Monday, June 15 8:30 – 9:30 2101: Plenary Session: Presidential Lectureships Chairs: Matthew Stern, Oscar Gershanik Md. Mashiar Rahman, PhD Jeonju-si, Jeollabuk-Do, Korea The mitochondrial serine protease HtrA2 degrades diseaseassociated prion protein Md. Mashiar Rahman, PhD1, Shahina Akhter, PhD2 and Seong-Tshool Hong, PhD2. 1Department of Genetic Engineering and Biotechnology, Jessore University of Science & Technology, Jessore, Khulna, Bangladesh, 7408 and 2 Department of Medicine, Chonbuk National University, Jeonju, Jeollabukdo, Republic of Korea, 561756. Objective: The goal of this study was to elucidate the neuroprotective role of HtrA2 in prion disease (PrD) Background: The clearance of disease-associated prion protein in brain is the most challenging and important task in current biomedical research. Until now, there are no evidences available for intraneuronal PrP detoxification. Bacterial HtrA/DegP is part of a large family of related serine proteases, members of which are found in most organisms, including humans and Drosophila. One of the four human serine proteases, HtrA2 has extensive homology with bacterial heat-shock protein DegP, which protects bacterial cells from stress-induced toxicity due to misfolded proteins.
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Awards Information
Results: The ectopic expression of mPrP showed accumulation of mPrP in the brain of Drosophila with a much more punctuate pattern of immunoreactivity particularly at older ages with prominent intracellular inclusion, reduced lifespan, locomotor dysfunction and rough eyes phenotype, which indicates a toxic dominant mechanism of mPrP for the etiopathogenesis of PrD. The ectopic expression of HtrA2 alone markedly improved the locomotion and longevity of the fly. However, upon coexpression; HtrA2 completely degraded accumulated mPrP in the fly brain resulted the rescue of the mPrP-induced phenotype of premature loss of climbing ability, longevity and developmental defects in the Drosophila eye. In vitro enzymatic assay also showed that HtrA2 has the capability to degrade disease-associated prion protein from PrD Drosophila brain.
“mismatch detector”. Although task-based fMRI studies have previously demonstrated hypoactivity of the right TPJ in FMD patients, this region has not been examined in the resting state. Methods: Resting state multi-echo BOLD fMRI and MP-RAGE images were obtained in 35 patients with clinically definite FMD and 35 ageand sex-matched healthy controls using a 3T Skyra Siemens scanner. Pre-processing was performed using the AFNI tool meica.py. Group-wise comparison between FMD patients and healthy controls was performed using AFNI GroupInstaCorr with the right TPJ as seed region-of-interest. Age, sex, BDI depression scores and childhood trauma scores were included as potential covariates. Results: As compared to controls, FMD patients demonstrated decreased functional connectivity (pG MTTS2 (mt-tRNASer(AGY)) variant in a patient with dystonia and choreoathetoid movements R.J.B.Ellis, M.Bonello, N.A.Fletcher, S.A.Hardy, R.W.Taylor (Liverpool, United Kingdom) 356 ADCY5 mutations can cause benign hereditary chorea R.Erro, N.E.Mencacci, J.Hersheson, S.Wiethoff, B.Balint, C.Ganos, M.Stamelou, N.P.Quinn, H.Houlden, N.W.Wood, K.P.Bhatia (London, United Kingdom) 357 Acute onset hemichorea-hemiballism after treatment with recanalization of middle cerebral artery H.Kim, J.H.Jin, H.G.Roh, H.Y.Kim (Seoul, Korea) 358 Network localization of hemichorea S.Laganiere, A.Boes, L.Shih, M.Fox (Boston, MA, USA) 359 Choreoballism arising from the involvement of the putamen: A report of 18 cases and a systemic literature review D.Lee, H.G.Woo, T.B.Ahn (Seoul, Korea) 360 Management of aceroplasminemia with a combination of venesection, fresh frozen plasma and desferrioxamine M.Narasimhan, S.Ramanathan, C.Turner, L.Ramon (Sydney, Australia) 361 Optical coherence tomography in Huntington disease V.Parisi, E.Gatto, S.Ochoa, D.Scocco, E.Fernandez Rey (Buenos Aires, Argentina) 362 Clinical characteristics and genetic testing of a Huntingtin mutation negative cohort K.J.Peall, H.R.Morris, M.Wardle (Cardiff, United Kingdom)
Abstracts by Topic
363 Pyramidal involvement in Huntington’s disease. Preliminary report A.Sanguinetti, E.M.Gatto, M.Cesarini, J.Etcheverry, V.Parisi, G.Persi, L.Bevacqua, P.Lopez, A.Bertotti (Buenos Aires, Argentina) 364 Non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder, chorea and dementia associated with antibodies to IgLON5: Case report M.M.Simabukuro, L.Sabater, T.Adoni, R.G.Cury, M.S.Haddad, C.H.Moreira, L.Oliveira, R.C.Alves, L.A.Soster, R.A.Nogueira, C.Graig, R.Nitrini (São Paulo, Brazil)
MYOCLONUS
365 Ortostatic myoclonus: Clinical and electrophysiological features of four patients H.Apaydin, B.Zeydan, A.Gunduz, G.Kiziltan, S.Ertan, M.Kiziltan (Istanbul, Turkey) 366 Cortical myoclonus in neurocritical care unit in patients with acute stroke and stroke like syndrome patients N.Chaudhary, J.M.K.Murthy, S.Jaiswal, M.Reddy (Hyderabad, India)
76
367 Electrophysiological findings in Rasmussen’s encephalitis A.Gunduz, M.E.Kiziltan, T.Coskun, S.Delil, N.Yeni, Ç.Özkara (Istanbul, Turkey) 368 Isolated lingual myoclonus as a presentation of celiac disease D.C.Khandelwal, C.M.Sharma, B.Kumawat (Jaipur, India) 369 Psychiatric features may be clinical spectrum of myoclonus dystonia syndrome regardless of SGCE gene mutation J.Y.Kim, W.W.Lee, H.J.Kim, B.S.Jeon (Seoul, Korea) 370 Limbic encephalitis associated with anti–voltage-gated potassium channel complex antibodies mimicking Creutzfeldt-Jakob disease M.J.Liu, G.Chang (Phoenix, AZ, USA) 371 An interesting case of post-infectious myoclonus secondary to infection with cytomegalovirus S.Padidam, D.E.Kremens (Philadelphia, PA, USA) 372 The efficacy of piracetam for management of cortical myoclonus: A meta-analysis of randomized control clinical trials A.R.Sanchez, R.C.M.L.Alemany (Pasig City, Philippines) 373 The prevalence of affected muscles and the associations between the numbers of affected muscles and age of onset and duration of disease in hemifacial spasm K.Ukantapornpong, P.Chairangsaris (Bangkok, Thailand) 374 The added value of neurophysiologic investigations in posthypoxic myoclonus J.C.van Zijl, M.Beudel, B.M.de Jong, J.van der Naalt, H.J.van der Hoeven, F.Lange, W.M.van den Bergh, J.W.J.Elting, M.A.J.Tijssen (Groningen, Netherlands)
PARKINSON’S DISEASE: NON-MOTOR SYMPTOMS
375 Safety and efficacy of transdermal rotigotine for the treatment of fatigue and quality of life (QOL) in patients with Parkinson’s disease K.Abe, S.Kitamura, I.Yokoa, J.Ogura, M.Fjita, H.Yoshikawa (Nishinomiya, Japan) 376 Constipation preceding Parkinson’s disease – Systematic review and meta-analysis K.L.Adams-Carr, A.Schrag, S.Shribman, J.P.Bestwick, A.Lees, A.J.Noyce (London, United Kingdom) 377 Levodopa attenuates fatigue in reserpine-treated mice – An animal model of Parkinson’s disease A.S.Aguiar, Jr., D.L.Scheffer, R.D.S.Prediger, A.S.Latini (Florianópolis, Brazil) 378 Aspiration pneumonia in a hospitalized Parkinson’s disease cohort L.Almeida, D.Martinez-Ramirez, K.W.Hageland, J.C.Giuni, C.Little, J.P.Chapman, B.Ahmed, E.Monari, M.Troche, M.S.Okun (Gainesville, FL, USA) 379 Delineating non-motor symptoms in early Parkinson’s disease and first-degree relatives F.Baig, M.Lawton, M.Rolinski, C.Ruffmann, K.Nithi, S.G.Evetts, H.R.Fernandes, Y.Ben-Shlomo, M.T.M.Hu (Oxford, United Kingdom)
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 380 Safinamide significantly reduces pain treatments when given as add-on therapy to levodopa in patients with Parkinson’s disease and fluctuations P.Barone, C.Cattaneo, E.Bonizzoni, R.La Ferla, M.Sardina (Baronissi (Salerno), Italy) 381 Impulse control disorder and rapid eye movement sleep behavior disorder in Parkinson’s disease S.Bayard, Y.Dauvilliers, H.Yu, M.Croisier Langenier, A.Rossignol, M.Charif, C.Geny, V.Cochen De Cock (Montpellier, France) 382 Association of side of onset of motor symptoms to prevalence of various domains of non-motor symptoms (NMS) in Parkinson’s disease (PD) R.S.Boddepalli, T.S.Khan (Weston, FL, USA) 383 Unmasking the face of Parkinson’s disease: Immediate and 3 month followup from a randomized double-blind shamcontrolled behavioral intervention D.Bowers, C.Sapienza, R.Rodriguez, H.Fernandez, M.S.Okun (Gainesville, FL, USA) 384 Rotigotine objectively improves sleep in Parkinson’s disease: A pilot study with actigraphic recording G.Calandra-Buonaura, P.Guaraldi, A.Doria, S.Nassetti, V.Favoni, S.Cevoli, F.Provini, P.Cortelli (Bologna, Italy) 385 Sleep and sleepiness symptoms as predictors of cognitive decline in early Parkinson’s disease: Results from the PPMI study L.M.Chahine, B.Tran, S.Xie, S.Christi, D.Abi, C.Linder, R.Purri, T.Simuni, G.Murray, W.Daniel (Philadelphia, PA, USA) 386 Fatigue in Parkinson’s disease: The evidence of regional cerebral glucose metabolism abnormalities S.S.Cho, K.Aminian, S.Houle, A.E.Lang, M.Criaud, A.P.Strafella (Toronto, ON, Canada) 387 Olfaction and neuropsychiatric symptoms in early Parkinson’s disease J.K.Choi, J.Y.Hong, M.K.Sunwoo, J.H.Ham, J.J.Lee, P.H.Lee, Y.H.Sohn (Wonju, Korea) 388 Comparative patient satisfaction and efficacy of a Parkinson’s disease enrichment program (PEP) T.K.Choudhury, M.K.York, C.Harris, K.Crist, B.Treece, T.Satterwhite (Houston, TX, USA) 389 Does the pattern of striatal dopamine depletion contribute non-motor symptoms in Parkinson’s disease? S.J.Chung, J.J.Lee, J.H.Ham, P.H.Lee, Y.H.Sohn (Seoul, Korea)
391 Excessive daytime sleepiness in Parkinson’s disease: Subjective and objective measures V.Cochen De Cock, S.Bayard, I.Jaussent, M.Charif, B.Carlander, C.Geni, Y.Dauviliers (Montpellier, France)
393 Subthalamic stimulation lead coordinates correlate with non-motor effects in Parkinson’s disease H.Dafsari, J.N.Petry-Schmelzer, T.Dembek, A.Rizos, A.Antonini, P.MartinezMartin, K.R.Chaudhuri, V.Visser-Vandewalle, L.Timmermann, On Behalf of EUROPAR and the IPMDS Non Motor PD Study Group (Cologne, Germany) 394 Dopamine dysregulation syndrome in patients with Parkinson’s disease in a rural based movement disorders clinic in Western India S.D.Desai (Anand, India) 395 Compulsive tobacco use in patients with Parkinson’s disease on dopamine agonist /levodopa therapy: Is it also an impulse control disorder? S.D.Desai (Anand, India) 396 The non motor network in early Parkinson’s disease: Is there first network tightening followed by network loosening? N.J.Diederich, N.Sauvageot, V.Pieri, G.Hipp, M.Vaillant (Luxembourg-City, Luxembourg) 397 Does movement impairments cause anxiety in Parkinson’s disease? A chicken or egg question K.A.Ehgoetz Martens, C.G.Ellard, Q.J.Almeida (Waterloo, ON, Canada) 398 Intensive rehabilitation enhances lymphocytes BDNF-TrkB signaling in patients with Parkinson’s disease C.Fontanesi, S.Kvint, G.Frazzitta, G.Pezzoli, A.Di Rocco, A.Quartarone, H.Y.Wang, M.F.Ghilardi (New York, NY, USA) 399 Olfaction and nonmotor symptoms (NMS) in subjects with scans without evidence of dopaminergic deficit (SWEDDs) M.E.Fullard, D.Weintraub, J.E.Duda, J.F.Morley (Philadelphia, PA, USA) 400 Relationship between olfaction, motor and nonmotor symptoms and dopamine transporter binding in de novo PD M.E.Fullard, D.Weintraub, J.E.Duda, J.F.Morley (Philadelphia, PA, USA) 401 Prevalence and severity of non motor symptoms (NMS) of Parkinson’s disease (PD) in the elderly – An Australian perspective S.Gangadharan, A.Withanage, C.P.Padmakumar, M.Rees, A.Johnson (Newcastle, Australia) 402 The assessment of visuospatial functions in Parkinson’s disease patients without dementia M.Gultekin, A.Ekinci, M.Mirza (Kayseri, Turkey) 403 The assessment of apathy symptoms in Parkinson’s disease patients without dementia M.Gultekin, A.Ekinci, M.Mirza (Kayseri, Turkey)
Abstracts by Topic
390 Supine sleep and obstructive sleep apnea syndrome in Parkinson’s disease V.Cochen De Cock, N.Benard-Serre, V.Driss, M.Charif, B.Carlander, D.Cugy, S.Bayard (Montpellier, France)
392 Pharmacological treatment for apathy in Parkinson’s disease: A systematic review C.A.Cooper, N.Dahodwala (Philadelphia, PA, USA)
404 Assessing postural stability in early stages of Parkinson’s disease H.D.Hambardzumyan, H.M.Manvelyan (Yerevan, Armenia) 405 Non-motor symptoms in Parkinson’s disease: A correlation with depression and quality of life H.D.Hambardzumyan, H.M.Manvelyan (Yerevan, Armenia)
77
Abstracts by Topic 406 Characterize sleep related disorders in subtypes of Parkinson’s disease S.Hanif, M.S.Bashir, T.M.Muhammad, J.A.Bajwa (Riyadh, Saudi Arabia)
420 Prevalence of non-motor fluctuations in Parkinson’s disease R.Llorens-Arenas, M.Rodriguez-Violante, A.Cervantes-Arriaga, D.Piña-Fuentes, M.I.Lopez-Belmonte, P.Escobar-Martinez (Mexico City, Mexico)
407 Use of the SpeechVive device improves communication in people with Parkinson’s disease J.E.Huber, S.Snyder, C.E.Rountrey, C.L.Ludlow (West Lafayette, IN, USA)
421 Fatigue and cardiac sympathetic denervation in Parkinson’s disease C.C.Luca, D.Spengler, F.Nahab, A.Serafini, M.Georgiou, C.Singer (Miami, FL, USA)
408 Zero non-motor symptoms in a martial arts expert L.J.Jaffe (San Diego, CA, USA)
422 Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson’s disease patients with chronic pain G.Madeo, T.Schirinzi, M.Pierantozzi, A.Stefani, S.Natoli, A.Pisani (Rome, Italy)
409 Impulse control disorders and compulsive behaviors in Parkinson’s disease and control subjects S.Jesus, C.Cortes, I.Huertas-Fernandez, M.T.Caceres-Redondo, F.Carrillo, M.Bernal-Escudero, L.Vargas-Gonzalez, M.Carballo, P.Mir (Seville, Spain) 410 An 8-year follow-up on the effect of subthalamic deep brain stimulation on pain in Parkinson’s disease Y.J.Jung, H.J.Kim, B.S.Jeon, H.Park, W.W.Lee, S.H.Paek (Seoul, Korea) 411 Evaluation of cardiovascular autonomic dysfunction in Parkinson’s disease by cardiovascular autonomic indexes Y.J.Kang, T.K.Lee, J.H.Park, K.B.Sung (Bucheon-si, Korea) 412 Increased energy expenditure may be reversed by dopaminergic medications in patients with Parkinson’s disease K.Kashihara, A.Hongo, H.Kagayama, K.Hasegawa (Okayama, Japan) 413 Prevalence, severity and treatment rate of major non-motor Parkinson’s disease symptoms according to social media platform PatientsLikeMe A.Killoran (Morgantown, WV, USA) 414 Sleep assessment in Parkinson’s disease – The use of Parkinson’s KinetiGraph L.Klingelhoefer, M.Horne, A.Rizos, A.Sauerbier, S.McGregor, D.Trivedi, L.Perkins, K.Ray Chaudhuri (Dresden, Germany) 415 The Biodex system: Sensitive for fall detection in Parkinsonism E.Lapointe, E.Lafleur Prudhomme, M.Panisset (Sherbrooke, QC, Canada) 416 REM sleep disorders in early onset Parkinsonism: Non-motor symptoms and the functional predictors perspective in advanced age L.A.Leandro, H.G.Teive (Curitiba, Brazil)
Abstracts by Topic
417 Swallowing, voice and freezing of gait in patients with Parkinson’s disease – Correlation between each other and contribution to quality of life S.Y.Lee, S.M.Cheon, J.W.Kim (Busan, Korea) 418 The role of catastrophizing and non-motor symptoms in quality of life of Parkinson’s disease patients S.F.Lerman, G.Bronner, N.Warman-Alaluf, O.S.Cohen, G.Yahalom, S.Hassin-Baer (Tel Hashomer, Israel) 419 Clinical analysis of the non-motor symptoms of Parkinson’s patients with diabetes Y.Liu, C.Liu, J.Zhang, M.Wang, S.Chen, C.Zhao (Jinan, China)
78
423 Odour identification testing is a quick and accurate diagnostic tool for Parkinson’s disease P.Mahlknecht, K.Seppi, B.Pinter, E.Reiter, C.Müller, A.Djamshidian, M.Nocker, G.K.Wenning, F.Krismer, J.Willeit, S.Kiechl, W.Poewe, G.Göbel (Innsbruck, Austria) 424 Clinical features and varieties of non motor fluctuations in Parkinson’s disease N.Mansurova, A.Prokhorova (Tashkent, Uzbekistan) 425 Changes in retinal morphology and visual field in early Parkinson’s disease C.J.Mao, L.Ling Li, X.Y.Ji, J.Jing Wei, J.Jing Chen, S.Sha-Sha Guo, Y.Yi Chen, S.J.Li, C.F.Liu (Suzhou, China) 426 The clinical analysis of sleep disorders in patients with Parkinson’s disease and the study of them by polysomnogram Z.Mao, S.Ji, Q.Yang, H.Ye, Z.Xue (Wuhan, China) 427 The contribution of the insula in Parkinson’s disease: A quantitative meta-analysis study M.Marion, L.Christopher, P.Boulinguez, B.Ballanger, A.E.Lang, S.S.Cho, A.P.Strafella (Toronto, ON, Canada) 428 Heart rate variability by passive leg raising test in patients with Parkinson’s disease and multiple system atrophy in early stages V.A.Martínez Villota, J.D.Triana, W.William Fernández Escobar (Pasto, Colombia) 429 Combining antipsychotics and antidepressants increase falls in Parkinson’s disease D.Martinez-Ramirez, J.C.Giugni, L.Almeida, B.Ahmed, V.Rundle-Gonzalez, A.R.Bona, E.Monari, C.J.Hass, M.S.Okun (Gainesville, FL, USA) 430 Fatigue is associated with performance on a demanding finger motor task in Parkinson’s disease D.Martino, T.Tamburini, P.Zis, E.Pelosin, A.Sauerbier, G.Abbruzzese, K.RayChaudhuri, L.Avanzino (London, United Kingdom) 431 Elevated salivary DJ-1 in Parkinson’s disease is associated with altered salivary secretion J.M.Masters, A.J.Noyce, G.Giovannoni, T.T.Warner, G.B.Proctor (Herts, United Kingdom) 432 The effect of sleep and wakefulness disorders on cognitive function in Parkinson’s disease R.J.Matmurodov, O.E.U.Turgunkhujaev, K.M.Khalimova, U.S.Ergashev (Tashkent, Uzbekistan)
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 433 Quality of life in PD correlates with arising from chair, gait and postural stability A.Mentreddi, N.Patel, I.Bernstein, K.Pravin, S.M.McClintock, C.M.Cullum, M.M.Husain, R.B.Dewey (Dallas, TX, USA) 434 Inner retinal layer thickness of the fovea depends on dopaminergic medications in Parkinson’s disease S.Miri, S.Glazman, Y.Ding, S.Slotnick, E.M.Shrier, A.Joh, I.Bodis-Wollner (Brooklyn, NY, USA) 435 The effect of istradefylline for anhedonia in Parkinson’s disease H.Nagayama, M.Mishina, K.Kimura (Bunkyo-Ku, Japan) 436 Pattern of non motor symptoms (NMS) among subtypes of Parkinson’s disease in Arab ancestry S.Nahrir, M.N.AlMotiri, Z.G.AlJohani, G.A.Alhifthi, T.M.Alayan, J.A.Bajwa (Riyadh, Saudi Arabia) 437 Parkinson’s disease duration: Non motor symptoms: Arab ancestry “The new dimension” S.Nahrir, Z.G.AlJohani, G.A.Alhifthi, M.N.AlMotiri, T.M.Alayan, J.A.Bajwa (Riyadh, Saudi Arabia) 438 Early onset Parkinson’s disease vs. late onset Parkinson’s disease – Is there any difference in non motor symptoms among Arab ancestry? S.Nahrir, G.A.Alhifthi, M.N.AlMotiri, Z.G.AlJohani, T.M.Alayan, J.A.Bajwa (Riyadh, Saudi Arabia)
446 Emaciation and life prognosis in Parkinson’s disease K.Park, T.Oeda, A.Umemura, M.Kohsaka, S.Tomita, H.Sugiyama, H.Sawada (Kyoto, Japan) 447 E-DUO Study: Use of levodopa-carbidopa intestinal gel in Spanish advanced Parkinson’s disease patients. Non-motor symptoms and clinical global impression subanalyses J.C.Parra, D.Santos, M.J.Catalán, I.Regidor (Madrid, Spain) 448 An observational study of pattern of admission in Parkinson’s disease B.S.Paul, G.Paul, G.Singh, S.Kaushal, U.Verma (Ludhiana, India) 449 Real time imaging of stomach motility in patients with REMsleep behavior disorder and de novo Parkinson’s disease E.K.Paule, T.Hasemann, A.Hermsen, E.Sittig-Wiegand, D.Vadasz, K.Eggert, S.Knake, W.H.Oertel (Mainz, Germany) 450 Effect of acute non-oral dopaminergic (apomorphine and levodopa) treatment on non-motor symptoms in Parkinson’s disease L.Perkins, M.Politis, F.Niccolini, A.Sauerbier, R.Inniss, A.Martin, D.Trivedi, K.RayChaudhuri (London, United Kingdom) 451 Dysarthria in Parkinson’s disease: Lusophony vs. francophony comparison (FraLusoPark) S.Pinto, I.Guimarães, R.Rothe-Neves, J.Sadat, R.Cardoso, A.T.Britto, F.Viallet, J.Ferreira, F.Cardoso (Aix-en-Provence, France)
439 Does impaired peripheral vasoconstrictor response predict orthostatic hypotension in Parkinson’s disease? T.Nakamura, M.Suzuki, A.Okada, J.Suzuki, M.Hirayama, G.Sobue (Nagoya City, Japan)
452 REM sleep behavior disorder and neuropathology in Parkinson’s disease R.B.Postuma, C.H.Adler, J.G.Hentz, H.A.Shill, E.Driver-Dunckley, M.N.Sabbagh, S.A.Jacobson, C.M.Belden, L.I.Sue, B.N.Dugger, G.Serrano, T.G.Beach (Montreal, QC, Canada)
440 Olfactory dysfunction in Parkinson’s disease could be associated with central cholinergic system E.Oh, J.G.Lim, J.Park, J.Youn, J.S.Kim, W.Jang (Daejeon, Korea)
453 Non-motor symptom burden in Parkinson’s disease: A longitudinal study K.M.Prakash, N.V.Nadkarni, W.K.Lye, L.M.Chew, M.H.Yong, E.K.Tan (Singapore)
441 Opicapone and non-motor symptoms in Parkinson’s disease: Results from a double-blind, randomized, placebo-controlled study and open-label extension C.Oliveira, A.Lees, J.Ferreira, N.Lopes, R.Costa, R.Pinto, T.Nunes, J.F.Rocha, P.Soares-da-Silva (S.Mamede do Coronado, Portugal)
454 Prevalence of wearing off symptoms among Parkinson’s disease patients at a tertiary hospital P.A.A.Quitasol, C.L.Go (Manila, Philippines)
442 Heart rate variability during sleep stages to assess autonomic function in patients with Parkinson’s disease: A preliminary polysomnographic study D.B.Oropeza-Canto, M.Velázquez-Vaquero, R.Flores-Morales, A.Espinosa-Cerón (Puebla, Mexico)
444 Course of cognitive and neuropsychiatric features in patients with Parkinson’s disease H.K.Park, J.E.Kim (Goyang, Korea)
456 Role of premotor symptoms on non-motor symptoms burden and quality of life M.Rodriguez-Violante, A.Cervantes-Arriaga, I.Estrada-Bellmann, R.Leal-Ortega, R.Millán-Cepeda, H.Morales-Briceño, G.Neri-Nani, R.Llorens-Arenas, H.CalderonFajardo, C.Zuñiga-Ramirez, A.Jorge de Sarachaga (Mexico City, Mexico) 457 Motor and non-motor features of Parkinson’s disease in idiopathic REM sleep behaviour disorder M.Rolinski, M.Lawton, S.Evetts, F.Baig, C.Ruffmann, C.E.Mackay, T.Quinnell, Z.Zaiwalla, Y.Ben-Shlomo, M.T.M.Hu (Oxford, United Kingdom)
445 Orthostatic dizziness in Parkinson’s disease is attributed to impaired cerebral autoregulation: A trancranial doppler study J.Park, W.Jang, J.S.Kim, J.Youn, E.Oh (Busan, Korea)
79
Abstracts by Topic
443 Prevalence of non-motor symptoms in Parkinson’s disease versus age-matched healthy controls: A systematic review with meta-analysis G.Pagano, E.E.Tan, M.Tagliati (Campobasso, Italy)
455 Impaired contrast sensitivity is associated with more severe cognitive impairment and nigrostriatal denervation in Parkinson’s disease A.J.Ridder, M.L.T.M.Muller, V.Kotagal, K.A.Frey, R.L.Albin, N.I.Bohnen (Ann Arbor, MI, USA)
Abstracts by Topic 458 Symptom severity and pain intensity may be risks for post STN DBS impulsivity in Parkinson’s disease A.Rothstein, B.Avery, A.Boyanpally, J.Hesse, R.Coghill, A.Laxton, S.Tatter, M.Siddiqui, I.Haq (Winston Salem, NC, USA) 459 Comparing speech function in persons with Parkinson’s disease in clinical and home environments C.E.Rountrey, N.M.Borras, C.L.Ludlow (Harrisonburg, VA, USA) 460 Parkinson’s disease: Markers of lower body mass index (BMI) J.J.E.Rovers, S.S.Wu, B.R.Bloem, M.S.Okun, B.Post (Nijmegen, Netherlands) 461 An evaluation of non-motor symptoms in Parkinson’s disease patients using 2 rating scales A.Sánchez-Jordán, D.Padilla-Carmona, U.Rodríguez-Ortiz, M.C.Boll (Mexico City, Mexico) 462 Orthostatic hypotension increases the risk of falls in idiopathic Parkinson’s disease patients M.Sarchioto, M.Zibetti, S.Maule, V.Milazzo, E.Montanaro, A.Romagnolo, S.Angrisano, F.De Matteis, C.A.Artusi, A.Bernardini, L.Lopiano (Turin, Italy) 463 REM density in patients with early or late stage Parkinson’s disease. A polysomnography-based case-control study L.A.Schroeder, O.Rufra, N.Sauvageot, F.Fays, V.Pieri, N.J.Diederich (Howald, Luxembourg) 464 Skin biopsy is useful for diagnostic tool of Lewy body disease R.Sengoku, H.Sumikura, Y.Saito, Y.Nishina, S.Miyagawa, T.Komatsu, M.Ikemura, Y.Saito, K.Kanemaru, S.Murayama (Tokyo, Japan) 465 Characterizing apathy and possible neural correlates in Parkinson’s disease J.H.Shin, J.Y.Lee, A.Kim, S.A.Shin, Y.K.Kim (Seoul, Korea) 466 Mood fluctuations in Parkinson’s disease: Toward a better understanding C.Siri, N.Meucci, A.Colombo, E.Reali, B.Pozzi, G.Sacilotto, M.Zini, G.Pezzoli (Milan, Italy) 467 Different cardiovascular modulation in Parkinson’s disease patients with tremor dominant subtype compared to those with akinetic rigid dominant subtype P.Solla, C.Cadeddu, A.Cannas, D.Fonti, G.Orofino, M.Deidda, L.Cugusi, M.Meloni, G.Mercuro, F.Marrosu (Cagliari, Italy)
Abstracts by Topic
468 Apathy in movement disorders: A cross-sectional study M.Sousa, J.Ribeiro, I.Marques, F.Cunha, N.Canário, F.Moreira, A.Freire, C.Januário (Coimbra, Portugal) 469 Olfactory performance and resting state functional connectivity in non-demented drug naïve patients with Parkinson’s disease M.K.Sunwoo, J.Cha, J.H.Ham, S.K.Song, J.Y.Hong, J.M.Lee, Y.H.Sohn, P.H.Lee (Seongnam, Korea) 470 Sleep disturbances in Parkinson’s disease and related disorders: Using Parkinson’s disease sleep scale-2 K.Suzuki, A.Numao, Y.Watanabe, H.Fujita, M.Miyamoto, T.Miyamoto, S.Suzuki, H.Sakuta, T.Kadowaki, K.Hirata (Mibu, Japan) 471 The impact of diabetes mellitus on non-motor symptoms in patients with Parkinson’s disease E.E.Tan, G.Pagano, M.Tagliati (Los Angeles, CA, USA)
80
472 Parkinson’s sleep disorder A.N.Taravari, F.R.Mexhiti (Skopje, Macedonia) 473 Hyposmia as a predictor of non-motor features in patients with de novo Parkinson’s disease B.L.Tran, L.M.Chahine, J.Rick, M.Christi, D.Abigail, L.Carly, P.Rachael (Philadelphia, PA, USA) 474 Transcranial magnetic stimulation increases overall cognition in patients with Parkinson’s disease J.Trung, A.Hanganu, S.Jobert, B.Mejisa-Constain, A.L.Lafontaine, M.A.Bruneau, O.Monchi (Montreal, QC, Canada) 475 Effect of saccadic movement impairment cognition in Parkinson’s disease O.E.U.Turgunkhujaev, R.J.Matmurodov (Tashkent, Uzbekistan) 476 Effect of single levodopa/carbidopa intake on heart rate variability in Parkinson’s disease A.F.Vasilenko, M.V.Shestakova (Chelyabinsk, Russia) 477 A comprehensive approach to Parkinson’s disease C.P.Vaughan, A.E.Vandenberg, F.C.Goldstein, L.M.Trotti, A.P.Hermida, M.L.Weeks, S.A.Factor (Atlanta, GA, USA) 478 Increased odds of bladder and bowel symptoms in early Parkinson’s disease compared to healthy controls C.P.Vaughan, J.L.Juncos, A.D.Markland, K.L.Burgio, P.S.Goode, T.M.Johnson II (Atlanta, GA, USA) 479 Patients with REM behavior disorder demonstrate degraded contrast sensitivity visual acuity while patients with restless legs syndrome do not P.H.Vogt, E.M.Keasler, M.J.Khayata, W.H.Whitfield, J.M.Sanchez, G.Barr, D.Huang, C.Maitland (Tallahassee, FL, USA) 480 Frequency and predictors of fatigue in Parkinson’s disease in a population-based cohort E.Warrlich, E.J.Vollstedt, S.Tunc, C.Bibergeil, C.Kritzinger, J.Graf, V.Tadic, C.Klein, M.Kasten (Lübeck, Germany) 481 Olfactory function in Parkinson’s disease and related disorders Y.Watanabe, K.Suzuki, A.Numao, M.Miyamoto, T.Miyamoto, H.Fujita, T.Kadowaki, K.Hashimoto, K.Hirata (Mibu, Japan) 482 Antipsychotic use in Parkinson’s disease is associated with increased mortality D.Weintraub, C.Chiang, H.M.Kim, J.Wilkinson, C.Marras, B.Stanislawski, E.Mamikonyan, H.C.Kales (Philadelphia, PA, USA) 483 Deep brain stimulation (DBS) in the external globus pallidus (GPe) promotes sleep in a rodent model J.Wu, M.Qiu, M.Chen, D.Nelson, J.Lu (Minneapolis, MN, USA) 484 Demographics and motor features on risk of Parkinson’s disease dementia: A meta-analysis Y.Xu, H.Shang (Chengdu, China) 485 Is palmomental reflex an important clinical marker of REM sleep behaviour disorder in patients with Parkinson’s disease? R.Yadav, R.Mahale, P.K.Pal (Bangalore, India)
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 486 Parkinson’s disease clinical study of sexual dysfunction H.Ye, Z.Mao, S.Ji, Q.Yang, Z.Xue (WuHan, China) 487 Visual exploration in Parkinson’s disease D.F.Ye, N.Vanegas-Arroyave, P.Lauro, M.Hallett, C.Lungu (Bethesda, MD, USA) 488 Chronotype and sleep quality in Parkinson’s disease R.Zangaglia, B.Minafra, M.Terzaghi, C.Pacchetti, R.Manni (Pavia, Italy) 489 Depression and nighttime-sleep problems in Parkinson’s disease K.Zhu, J.Marinus, J.J.van Hilten (Leiden, Netherlands)
NEUROPHYSIOLOGY
490 Electromyographic patterns of vocal cords during wakefulness and polysomnographic abnormalities in patients with multi-systemic atrophy E.Alfonsi, N.Pozzi, M.Terzaghi, P.Prunetti, E.Alvisi, M.Calabrese, A.Montini, M.Fresia, L.Marchetta, R.Manni, C.Pacchetti, A.Moglia (Pavia, Italy) 491 Intracranial EEG reveals differences in auditory change detection of thalamic and basal ganglia regions A.K.Beck, G.Lütjens, K.Schwabe, R.Dengler, J.K.Krauss, P.Sandmann (Hannover, Germany) 492 Prevalence of quantitaive sensory abnormalities and correlation with autonomic disturbances in patients with idiopathic Parkinson’s disease and Parkinson’s plus syndromes R.Borgohain, R.M.Kandadai, M.K.V.Ch, A.Jabeen, M.A.Kanikannan (Hyderabad, India) 493 Deep brain stimulation (DBS) rescue of gait freezing by patterned stimulation in select Parkinson’s disease (PD) patients D.L.Caputo, D.P.Schneider, R.J.DiPaola, S.F.Danish, E.L.Hargreaves (New Brunswick, NJ, USA) 494 Exercise intervention modulate corticostriatal glutamatergic neurotransmission by increased D2DR and NMDAR1 expression of striatum in PD model of rats W.Chen, X.Liu, D.Qiao, L.Hou (Beijing, China) 495 Impedance variability of the different deep brain stimulation neural targets Y.M.Fernandez, D.L.Caputo, D.P.Schneider, S.F.Danish, E.L.Hargreaves (New Brunswick, NJ, USA) 496 Effects of texting while walking (dual tasking) on objective gait parameters H.V.Gupta, T.Virmani (Little Rock, AR, USA)
498 Rubber hand illusion induced changes in sensorimotor integration in Parkinson’s disease R.Isayama, G.Jegatheeswaran, M.Vesia, B.Elahi, C.A.Gunraj, L.Cardinali, A.Farnè, R.Chen (Toronto, ON, Canada)
500 Physiological changes in Parkinson’s symptoms by slow wave potential B.B.Khodaie, A.A.A.A.Lotfinia, M.M.Ahmadi, M.M.Lotfinia (Tehran, Iran) 501 Propensity for heterosynaptic motor cortex plasticity in the de novo state predicts early motor complications of L-DOPA treatment in Parkinson’s disease A.Kishore, T.Popa, P.James, L.Yahia-Cherif, S.Pradeep, S.Krishnan, S.Meunier (Trivandrum, India) 502 Timing accuracy of voluntary rhythmic hand movement in essential tremor and Parkinson’s disease F.Luft, S.Sharifi, W.Mugge, A.C.Schouten, L.J.Bour, A.F.van Rootselaar, C.Heida (Enschede, Netherlands) 503 Intraoperative electrocorticography activity in the sensorimotor cortex differentiates generalized dystonia, segmental dystonia, and Parkinson’s disease S.Miocinovic, C.de Hemptinne, S.Qasim, J.L.Ostrem, P.A.Starr (San Francisco, CA, USA) 504 A.P.A.: How aging, Parkinson’s disease and anticipatory postural adjustments correlate A.Plate, K.Klein, A.Singh, O.Pelykh, A.Klein, J.Illmberger, K.Boetzel (Munich, Germany) 505 Developing a technique-specific nomogram for temporal discrimination threshold testing V.F.M.L.Ramos, M.Villegas, A.Esquenazi, T.Wu, M.Hallett (Bethesda, MD, USA) 506 PARK 2 gene mutation and pramipexole use during pregnancy: Report of two cases J.G.Santos, H.F.Chien, E.R.Barbosa (São Paulo, Brazil) 507 Efficacy of high-frequency repetitive transcranial magnetic stimulation on depression in Parkinson’s disease H.W.Shin, S.J.Chung, Y.H.Sohn (Seoul, Korea) 508 LTD-like effect in human motor cortex with low frequency and very short duration of paired associative stimulation P.Srivanitchapoom, J.E.Park, N.Thirugnanasambandam, P.Panyakaew, S.Pandey, T.Wu, M.Hallett (Bangkok, Thailand) 509 Orbicularis oculi muscle activity during swallowing in blepharopsm and Meig’s syndrome patients F.Tokucoglu, N.Gurgor, N.Razizadeh, S.Arici, C.Ertekin (Izmir, Turkey)
Abstracts by Topic
497 Gait cycle related modulation of electrophysiological activity in the human subthalamic nucleus of patients with Parkinson’s disease F.L.Hell, K.Boetzel, J.H.Mehrkens, S.Kammermeier, A.Plate, P.Hathway (Munich, Germany)
499 Transcranial magnetic stimulation as an early marker to differentiate between early Alzheimers disease and frontotemporal dementia and its further utility for early diagnosis and prognostication in corticobasal ganglia degeneration- A pilot study T.G.Issac, S.R.Chandra, B.C.Nagaraju, T.Issac (Bangalore, India)
510 Comparison of GPi local field potential characteristics in patients with Parkinson’s disease, craniocervical dystonia, and generalized dystonia D.D.Wang, C.de Hemptinne, S.Qasim, S.Miocinvic, J.L.Ostrem, P.A.Starr (San Francisco, CA, USA)
81
Abstracts by Topic 511 Phase reorganization of thalamic oscillatory activity contributes to the generation of the somatosensory evoked potentials in Vim thalamus in Parkinson’s disease and essential tremor patients K.Watanabe, S.Sato, M.Futaba, Y.Okamura, M.Taniguchi (Tokyo, Japan) 512 Sensorimotor integration in dopa-responsive dystonia in different dopaminergic states A.Weissbach, T.Bäumer, N.Brüggemann, V.Tadic, C.Klein, A.Münchau (Lübeck, Germany) 513 Modulation of short-latency afferent inhibition (SAI) in multisystem atrophy by low frequency (1-Hz) repetitive transcranial magnetic stimulation (rTMS) of the cerebellum F.G.Yildiz Sarikaya, E.Saka, B.Elibol, C.M.Temucin (Ankara, Turkey) 514 Temporal patterning of spike-LFP synchronization in the internal globus pallidus in Parkinson’s disease S.E.Zauber, S.Ratnadurai-Giridhara, R.M.Worth, T.Witt, L.Rubchinsky (Indianapolis, IN, USA)
THERAPY IN MOVEMENT DISORDERS: NEUROTOXIN
515 Long-term efficacy of incobotulinumA toxin in treatment of resistant dysphagia due to severe spasticity of upper oesophageal sphinter. A case report M.Basciani, F.Di Rienzo, D.Intiso (San Giovanni Rotondo, Italy) 516 Botulinum toxin treatment: Experience in a public hospital from Buenos Aires, Argentina M.J.Casen, C.Christie, S.A.Rodríguez-Quiroga, M.L.Assante, V.Díaz Aragunde, M.Mancuso, T.Arakaki, N.S.Garretto (Ciudad Autónoma de Buenos Aires, Argentina) 517 Botulinum toxin type A therapy for cervical dystonia - An update of a Cochrane systematic review and meta-analysis M.Castelão, R.Marques, G.Duarte, F.B.Rodrigues, J.J.Ferreira, P.Moore, J.Costa (Lisbon, Portugal) 518 A retrospective analysis of 73 patients switched from onabotulinumtoxinA to incobotulinumtoxinA D.R.Greeley (Spokane, WA, USA) 519 Real-world onabotulinumtoxinA treatment patterns in movement disorder patients in a prospective, observational cohort study: MOBILITY® M.Jog, M.Bhogal, G.Trentin (London, ON, Canada)
Abstracts by Topic
520 An experience of changing from onabotulinumtoxin-a to abobotulinumtoxin-a in 64 patients with focal hyperkinesias M.Kuzu, S.I.Gul, S.Tezcan, C.M.Akbostanci (Ankara, Turkey) 521 Randomized double-blind placebo-controlled cross-over study of incobotulinum toxin A for troublesome drooling in Parkinson’s disease (PD) P.Narayanaswami, A.Tarulli, E.Raynor, S.Gautam, T.Geisbush, D.Tarsy (Boston, MA, USA) 522 Botulinum toxins type A and B for cervical dystonia, blepharospasm and hemifacial spasm – An update of Cochrane movement disorders group systematic reviews F.B.Rodrigues, G.Duarte, R.Marques, M.Castelão, J.J.Ferreira, P.Moore, J.Costa (Lisbon, Portugal)
82
523 Safety and efficacy of botulinum toxin injections for lower limb spasticity management in children M.Venkatesh, D.Ghosh (Strongsville, OH, USA) 524 Clinical utility of apraclonidine in ptosis S.Wijemanne, J.Jankovic (Houston, TX, USA)
PEDIATRIC MOVEMENT DISORDERS
525 Neural and physiological changes following intensive voice therapy in children with motor speech disorders secondary to cerebral palsy C.A.Boliek, R.Bakhtiari, A.J.Reed, B.J.Major, I.Cribben, H.H.M.Gynane, A.Jaswal, D.Bremmekamp, C.M.Fox, B.Chouinard, J.Cummine (Edmonton, AB, Canada) 526 Technology-enhanced maintenance practice following intensive voice therapy (LSVT LOUD) in children with cerebral palsy and dysarthria C.M.Fox, C.A.Boliek (Denver, CO, USA) 527 Successful treatment of juvenile Parkinsonism with bilateral subthalamic deep brain stimulation in a 14-year-old girl G.Genc, S.Ertan, H.Apaydin, A.Gunduz, C.Poyraz, H.Canaz, S.Aydin (Istanbul, Turkey) 528 Is there a genetic predisposition to functional/psychogenic movement disorder? T.Hedderly, M.Woods, P.Hindley, S.Robinson (London, United Kingdom) 529 What do we know about PANS..? S.E.Munasipova, Z.A.Zalyalova (Kazan, Russia) 530 BCAP31 mutation causing congenital dystonia and central hypomyelination discovered using exome sequencing P.Vittal, D.A.Hall, E.Berry-Kravis (Chicago, IL, USA) 531 Intense imagery movements (IIM): Neuropsychological case series of a newly identified subgroup of motor stereotypies M.L.Woods, S.J.Robinson, T.J.Hedderly (London, United Kingdom)
HISTORY
532 A historical review of Wilson’s disease F.M.Branco Germiniani, B.E.Scheffer, W.O.Arruda, H.A.G.Teive (Curitiba, Brazil) 533 Catatonia: Historical perspective R.Fekete (Valhalla, NY, USA) 534 XIX-XX Century art and dystonia J.C.Martinez Castrillo, P.J.Garcia-Ruiz, J.Slawek, E.J.Sitek (Madrid, Spain) 535 Need for improved bone mineral density screening in Parkinsonism M.S.Nicoletti, B.Hanna-Pladdy, J.Rowe, K.Holmes, L.M.Shulman, S.G.Reich, R.von Coelln, M.J.Armstrong (Baltimore, MD, USA)
SURGICAL THERAPY: PARKINSON’S DISEASE
536 Predictors of functional and quality of life outcomes in Parkinson’s patients after deep brain stimulation H.Abboud, G.Genc, N.Thompson, S.Oravivattanakul, F.Alsallom, D.Floden, A.Machado, M.Gostkowski, A.Ezzeldin, H.Maarouf, O.Y.Mansour, H.H.Fernandez (Cleveland, OH, USA)
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 537 Factors associated with postoperative confusion following deep brain stimulation surgery for Parkinson’s disease H.Abboud, G.Genc, N.Thompson, S.Oravivattanakul, F.Alsallom, D.Floden, A.Machado, M.Gostkowski, A.Ezzeldin, H.Maarouf, O.Y.Mansour, H.H.Fernandez (Cleveland, OH, USA) 538 Postoperative deep brain stimulation (DBS) impedance variability in Parkinson’s disease (PD) patients implanted with Vercise system F.Alesch, R.Jain, L.Chen, T.Brücke, F.Seijo, E.Suarez San Martin, C.Haegelen, M.Verin, M.Maarouf, M.T.Barbe, S.Gill, A.Whone, M.Porta, D.Servello, L.Timmerman (Vienna, Austria) 539 Usability and technical options of rechargeable pulse generators F.Alesch, A.Amon (Vienna, Austria) 540 Effects of STN-DBS on diphasic dyskinesia patients with Parkinson’s disease A.Altinkaya, M.Fraraccio, C.Lepage, T.T.M.Pham, E.Lafleur-Prud’homme, A.F.Sadikot, N.Jodoin, M.Panisset (Montreal, QC, Canada) 541 Long-term outcomes of subthalamic deep brain stimulation in monogenic Parkinson’s disease C.C.Aquino, N.P.Visanji, I.Beaulieu-Boire, Y.Y.Poon, A.Valencia, M.Fallis, R.Munhoz, S.Kalia, M.Hodaie, A.Lozano, H.B.Ferraz, E.Rogaeva, E.Moro, A.E.Lang, A.Fasano (Toronto, ON, Canada) 542 Parkinsonism-hyperpyrexia syndrome due to deep brain stimulation withdrawal: Case report C.A.Artusi, M.Zibetti, A.Merola, A.Romagnolo, F.Dematteis, M.G.Rizzone, M.Lanotte, L.Lopiano (Turin, Italy) 543 Subthalamic nucleus deep brain stimulation (STN-DBS) reduces freezing of gait in Parkinson’s disease in the VANTAGE prospective, multi-center trial M.T.Barbe, C.Stummer, N.Van Dyck, R.Jain, L.Chen, T.Brücke, F.Seijo, E.Suarez San Martin, C.Haegelen, M.Verin, M.Amarell, S.Gill, A.Whone, M.Porta, D.Servello, F.Alesch, B.R.Bloem, L.Timmermann (Cologne, Germany) 544 Placement accuracy of deep brain stimulation electrodes implanted by frameless system - Nexframe© J.Bardon, D.Krahulik, P.Otruba, M.Nevrly, M.Vaverka, P.Kanovsky (Olomouc, Czech Republic) 545 Effects of low and high frequency STN DBS on beta oscillations and movement using synchronized neural and kinematic recordings in freely moving Parkinson’s disease subjects Z.Blumenfeld, T.E.Prieto, M.Miller Koop, A.Velisar, E.J.Quinn, M.H.Trager, C.Kilbane, J.M.Henderson, H.Bronte-Stewart (Stanford, CA, USA)
547 Benefits of subthalamic stimulation for elderly Parkinsonean patients over age 70 years S.M.Chiou, M.K.Lu, C.H.Tsai (Taichung, Taiwan)
549 Subthalamic deep brain stimulation modulates small fiberdependent sensory threshold in Parkinson’s disease R.G.Cury, R.Galhardoni, E.T.Fonoff, M.G.dos Santos Ghilardi, M.Myczkowski, M.A.Marcolin, E.R.Barbosa, M.J.Teixeira, D.Ciampi de Andrade (São Paulo, Brazil) 550 Motor cortex stimulation for gait disorders in advanced Parkinson’s disease E.U.da Silva, L.A.Nilton, Jr., J.C.E.Veiga, J.M.d.A.Silva, H.C.de Souza (São Paulo, Brazil) 551 Interest of microrecording for STN DBS T.Danaila, G.Polo, P.Mertens, E.Broussolle, S.Thobois (Bron, France) 552 Defining neural connectivity variables mediating successful clinical outcomes in deep brain stimulation for movement disorders G.A.de Erausquin, K.Vyas, E.Sanchez, L.Alba-Ferrara, D.Smith, F.Vale, T.Malapira, T.Zesiewicz (Tampa, FL, USA) 553 To test the effect of deep brain stimulation (DBS) frequencies on gait abnormalities in Parkinson’s disease (PD) A.Deep, R.Dhall, A.Lieberman, N.Krishnamurthi (Phoenix, AZ, USA) 554 Vercise DBS registry: Outcomes of a prospective, multi-center international registry for Parkinson’s disease G.Deuschl, R.Jain, S.Lin, N.Van Dyck, A.Kuhn, G.H.Schneider, C.van Riesen, H.Mehdorn, A.Schnitzler, L.Timmerman, V.Visser-Vandewalle, E.Suarez San Martin, I.Regidor, P.Eldridge, M.Cavallo, M.Sensi, J.Vesper (Kiel, Germany) 555 Effects of STN versus GPi deep brain stimulation on impulse control disorders M.G.dos Santos Ghilardi, A.M.N.Coutinho, R.G.Cury, E.R.Barbosa, M.J.Teixeira, E.Etchebehere, E.T.Fonoff (São Paulo, Brazil) 556 The effects of subthalamic nucleus deep brain stimulation on axial motor impairment, cranio-cervical dystonia, stuttering in Parkinson’s disease: Case report H.Ekmekçi, H.Kaptan (Konya, Turkey) 557 Electrode lead induced white matter changes in patients treated with deep brain stimulation R.Erasmi, O.Granert, D.Zorenkov, O.Jansen, D.Falk, G.Deuschl, K.Witt (Kiel, Germany) 558 Patient expectations and outcome after DBS: 24-month results N.Esnaashari, J.S.Hui, C.Liao, J.Liang, J.Hwu, S.Chen, M.A.Liker, D.M.Togasaki (Los Angeles, CA, USA) 559 A stimulating idea: Treating mixed essential tremor and Parkinson’s disease tremor with a novel DBS approach R.A.Falconer, S.L.Rogers, C.Kalhorn, F.Pagan (Washington, DC, USA) 560 The neuroprotective potential of subthalamic nucleus deep brain stimulation in an α-synuclein overexpression rat model of Parkinson’s disease D.L.Fischer, F.P.Manfredsson, C.J.Kemp, M.F.Duffy, N.K.Polinski, K.Steece-Collier, T.J.Collier, S.E.Gombash, D.J.Buhlinger, C.E.Sortwell (Grand Rapids, MI, USA)
83
Abstracts by Topic
546 Unilateral subthalamic nucleus deep brain stimulation for on-state freezing of gait in Parkinson’s disease P.R.Chand, R.D.Bucholz (St.Louis, MO, USA)
548 Interventional MRI (iMRI) guided DBS: Factors affecting lead placement accuracy R.R.Coleman, J.L.Ostrem, P.A.Starr, A.J.Martin, S.E.Qasim, N.Ziman, P.S.Larson (San Francisco, CA, USA)
Abstracts by Topic 561 Implementation of the 3D-atlas of the human brain for high precision robot-guided and frame-based stereotactic implantation of intracerebral deep brain electrodes H.Forutan, M.Majtanik, C.P.Buehrle, H.Treuer, A.Gierich, J.K.Mai (Duesseldorf, Germany) 562 Unilateral forel H1 stimulation for Parkinson’s disease: A possible option for axial motor symptoms F.F.Godinho, M.O.Oliveira, C.D.M.Costa, R.G.Kauark, A.T.Neves, P.R.Terzian, M.S.G.Rocha (São Paulo, Brazil) 563 Differential effects of subthalamic nucleus stimulation frequency on speech intelligibility and verbal fluency in patients with Parkinson´s disease T.Grover, D.Georgiev, R.Kaliola, L.Zrinzo, M.Hariz, T.Foltynie, M.Jahanshahi, P.Limousin, J.Candelario, E.Tripoliti (London, United Kingdom) 564 Deep brain stimulation in early stage Parkinson’s disease may reduce the relative risk of worsening of both motor symptoms and complications of therapy M.L.Hacker, J.A.Tonascia, M.Turchan, A.Currie, L.Heusinkveld, P.E.Konrad, T.L.Davis, J.S.Neimat, F.T.Phibbs, P.Hedera, L.Wang, Y.Shi, D.Charles (Nashville, TN, USA) 565 Programming strategies for tremor resistant to standard DBS settings: Constant current vs interleaving S.L.Heath, S.Miocinovic, N.B.Galifianakis (San Francisco, CA, USA) 566 Computer-guided deep brain stimulation programming using automated motion sensor-based functional mapping D.A.Heldman, C.L.Pulliam, E.Urrea Mendoza, M.Gartner, J.P.Giuffrida, E.B.Montgomery, F.J.Revilla (Cleveland, OH, USA) 567 Wearable sensors for quantifying deep brain stimulation washout effects on gait in Parkinson’s disease D.A.Heldman, E.B.Brokaw, A.J.Espay, F.J.Revilla, D.E.Riley, T.O.Mera, J.P.Giuffrida, B.L.Walter (Cleveland, OH, USA) 568 Unilateral microelectrode mapping to guide bilateral deep brain stimulation electrode implantation: A retrospective study of DBS programming outcomes T.M.Herrington, J.Simon, E.N.Eskandar (Boston, MA, USA)
Abstracts by Topic
569 Impact of advancing age on outcomes of deep brain stimulation for Parkinson’s disease P.T.Hickey, M.R.Delong, K.T.Huang, J.Gallis, B.Parente, D.A.Turner, S.P.Lad (Durham, NC, USA) 570 Interdisciplinary deep brain stimulation screening and the relationship to unintended hospitalizations and quality of life M.Higuchi, H.Morita, D.Bowers, H.Ward, L.Warren, M.DeFranco, M.S.Troche, S.Kulkarni, E.H.Monari, D.Martinez-Ramirez, K.D.Foote, Y.Tsuboi, M.S.Okun (Gainesville, FL, USA) 571 A probabilistic atlas defining an optimal deep brain stimulation site in Parkinson’s disease based on long-term clinical outcome A.Horn, R.Serrano Sandoval, T.Schmitz-Hübsch, E.Accolla, G.H.Schneider, A.A.Kühn (Berlin, Germany) 572 DBS experience at a tertiary care referral center J.Jimenez-Shahed, J.Keller, C.Hunter, J.Jankovic (Houston, TX, USA)
84
573 Optical neuromodulation of nigrostriatal pathway T.Jo, G.Oyama, K.Yoshimi, S.Sato, T.Danjo, A.Uemura, Y.Shimo, N.Hattori (Tokyo, Japan) 574 Effect of bilateral STN DBS on impulse control disorders in patients with idiopathic Parkinson’s disease- A case control study R.M.Kandadai, S.K.Jogu, A.Jabeen, A.K.Puligopu, P.Ankati, M.A.Kanikannan, R.Borgohain (Hyderabad, India) 575 Pallidal stimulation is effective for complex cranio-cervical dystonia and an unappreciated advers effect as tensor sensation H.Kaptan, H.Ekmekçi (Konya, Turkey) 576 Patient-centered outcomes of deep brain stimulation in Parkinson’s disease J.A.Karl, B.Ouyang, L.Verhagen (Chicago, IL, USA) 577 Estimating the proportion of essential tremor and Parkinson’s disease patients referred for deep brain stimulation: Five-year data from Columbia University Medical Center (2009-2014) M.Kestenbaum, E.D.Louis (New York, NY, USA) 578 The effect of subthalamic nucleus deep brain stimulation on REM sleep behavior disorder B.Kocer, S.S.Comoglu, H.Guven, A.S.Eren, S.Ferik (Ankara, Turkey) 579 Deep brain stimulation can preserve working abilities in Parkinson’s disease N.Kovács, I.Balás, S.Komoly, T.Dóczi, J.Janszky, Z.Aschermann, A.Makkos, E.Bosnyák, G.Deli (Pécs, Hungary) 580 The sequence of electrode placement affects outcomes after subthalamic nucleus deep brain stimulation for Parkinson’s disease V.Krishna, F.Sammartino, N.K.K.King, V.Bruno, C.Marras, S.Kalia, M.Hodaie, A.Lozano, A.Fasano (Toronto, ON, Canada) 581 The impact of the cause of death on neuropathological changes due to deep brain stimulation M.Kronenbuerger, K.Nolte, V.A.Coenen, J.M.Burgunder, J.Krauss, J.Weis (Baltimore, MD, USA) 582 Parkinson’s disease (PD) patient experience with deep brain stimulation (DBS) surgery using asleep interventional MRI (iMRI)-guided versus awake physiology-guided implantation techniques S.C.LaHue, J.L.Ostrem, N.B.Galifianakis, M.San Luciano, N.Ziman, S.Wang, C.Racine, P.A.Starr, P.S.Larson, M.Katz (San Francisco, CA, USA) 583 Effects of randomized subthalamic nucleus deep brain stimulation on gait in patients with Parkinson’s disease K.J.Lizarraga, J.Jagid, B.Gallo, C.Luca (Miami, FL, USA) 584 Intraoperative MRI for deep brain stimulation lead placement in Parkinson’s disease: One year motor and quality of life outcomes A.Mahajan, J.Schwalb, P.LeWitt, M.Schonberger, A.Ellenbogen, D.Taylor, J.Wall, C.Sidiropoulos (Detroit, MI, USA)
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 585 The research on deep brain stimulation to improve nonmotor symptoms of Parkinson’s disease Z.Mao, S.Ji, Q.Yang, H.Ye, Z.Xue (Wuhan, China)
598 Hemorrhage risk associated with multiple simultaneous microelectrode recording for deep brain stimulation F.T.Phibbs, A.Wang, C.Tolleson, J.L.Stroh, J.Neimat, P.Konrad (Nashville, TN, USA)
586 Short-term follow-up of bilateral subthalamic nucleus DBS in advanced PD: Gait and balance outcomes V.Marta, A.O.Iciar, C.Lidia, S.M.Arantza, D.Á.Marta, R.Ignacio (Madrid, Spain)
599 Stuttering after deep brain stimulation in Parkinson’s disease: A case series M.Picillo, G.B.Vincos, F.Sammartino, R.P.Munhoz, A.Fasano (Toronto, Canada)
587 Postoperative apathy can neutralize benefits in quality of life after subthalamic stimulation for Parkinson’s disease R.Martinez-Fernandez, P.Pelissier, J.L.Quesada, H.Klinger, E.Lhommée, E.Schmitt, V.Fraix, S.Chabardes, P.Mertens, A.Castrioto, A.Kistner, E.Broussolle, P.Pollak, S.Thobois, P.Krack (Grenoble, France)
600 Deep brain stimulation (DBS) in Parkinson’s disease (PD): Single-center experience from 2000 to 2013 N.G.Pozzi, B.Minafra, R.Zangaglia, D.Servello, C.Pscchetti (Pavia, Italy)
588 Intraoperative objective assessment and quantification of rigidity, akinesia, and tremor for optimized target-selection during DBS-implantation in Parkinson’s disease J.H.Mehrkens, J.A.Coy, B.Kai, L.Tim (Munich, Germany) 589 Neurologists’ or patients’ choice: Reasons Parkinson’s disease (PD) patients do not undergo deep brain stimulation (DBS) surgery N.F.Mercan, S.I.Gul, A.Savas, C.M.Akbostanci (Ankara, Turkey) 590 Bilateral subthalamic nucleus deep brain stimulation in elderly patients with Parkinson’s disease K.T.Mitchell, S.A.Norris, S.D.Tabbal, J.L.Dowling, K.M.Rich, J.S.Perlmutter, M.Ushe (St.Louis, MO, USA) 591 Beta-band activity changes during sleep in the subthalamic nucleus of patients with Parkinson’s disease L.Mueller, A.Auchter, M.M.Reich, F.Steigerwald, K.Reiners, I.U.Isaias, J.Volkmann (Würzburg, Germany) 592 Personality and quality of life assessments before and after deep brain stimulation surgery in patients with Parkinson’s disease M.Newlon, M.O’Connor, L.Kapust, C.Pierce, A.Silver, D.K.Simon, D.Tarsy, E.Papavassiliou, R.Alterman, L.C.Shih (Boston, MA, USA) 593 Susceptibility weighted magnetic resonance imaging for targeting of the subthalamic nucleus in Parkinson’s disease R.C.Nickl, S.Johannes, F.Steigerwald, M.M.Reich, S.Rückriegel, T.GünthnerLengsfeld, R.I.Ernestus, V.Sturm, J.Volkmann, C.Matthies (Würzburg, Germany) 594 Ipsilateral somatotopy within the subthalamic nucleus M.J.Nolt, T.Masnyk, M.T.McGraw, A.P.Monette, M.Rezak (Winfield, IL, USA)
596 The maintenance of motor function with unilateral electrode dysfunction in Parkinson’s disease after bilateral subthalamic nucleus deep brain stimulation H.Park, B.S.Jeon, H.J.Kim, W.W.Lee, C.W.Shin (Seoul, Korea) 597 Restoration of audio-spinal reflex reflects gait improvement in patients with subthalamic nucleus stimulation E.Parmentier, V.De Pasqua, G.Garraux, A.Maertens de Noordhout (Seraing, Belgium)
602 Does the use of intraoperative microelectrode recording influence the final location of lead implant in the globus pallidus interna for deep brain stimulation? S.Reddy, A.J.Fenoy, E.Furr-Stimming, W.G.Ondo, M.C.Schiess, R.Mehanna (Houston, TX, USA) 603 Unilateral STN DBS treats bilateral OFF dystonia in PD M.Rezak, A.P.Monette, M.T.McGraw, T.Masnyk, M.J.Nolt (Winfield, IL, USA) 604 Quality of life of patients with Parkinson’s disease: Development of utility values by mapping PDQ-39 to EQ-5D using data from the EARLYSTIM study C.Rinciog, S.Walleser Autiero, I.Durand Zaleski, L.Timmermann, J.L.Hueto, M.Schüpbach (Herts, United Kingdom) 605 Comparison of therapeutic and adverse effects of pallidal and subthalamic deep brain stimulation in Parkinson’s disease H.S.Ryu, J.Kim, Y.J.Kim, K.Kim, M.S.Kim, S.You, M.J.Kim, S.J.Chung (Seoul, Korea) 606 Early subthalamic neurostimulation improves quality of life of elderly patients with Parkinson’s disease H.Salimi Dafsari, P.Reker, P.Reddy, M.Silverdale, M.Pilleri, P.Martinez-Martin, A.Rizos, K.Ashkan, M.Samuel, J.Evans, V.Visser-Vandewalle, A.Antonini, K.R.Chaudhuri, L.Timmermann, On Behalf of EUROPAR and the IPMDS Non Motor PD Study Group (Cologne, Germany) 607 Gait and balance in Parkinson’s disease (PD) following bilateral subthalamic nucleus (STN) and globus pallidus interna (GPi) stimulation: 36 month follow-up of CSP#468 cohort A.I.Sarwar, K.Carlson, P.Luo, K.A.Follett, M.Stern, F.M.Weaver, D.J.Reda, E.C.Lai, For the CSP 468 Study (Houston, TX, USA) 608 MRI guided focused ultrasound VIM thalamotomy for Parkinson’s disease-First case series I.Schlesinger, A.Eran, A.Sinai, I.Erikh, M.Nassar, D.Goldsher, M.Zaaroor (Haifa, Israel) 609 Changes in subthalamic nucleus local field potentials following administration of levodopa in patients with Parkinson’s disease correlate with clinical improvement as measured by objective sensor data A.N.Sen, G.Meloni, I.Telkes, A.Abosch, N.F.Ince (Houston, TX, USA)
85
Abstracts by Topic
595 Intraoperative electrocorticography as a tool for the understanding of movement disorders: Principals and experience in 190 patients F.E.Panov, E.Levin, C.de Hemptinne, N.Swann, S.Qasim, S.Miocinovic, J.Ostrem, P.A.Starr (San Francisco, CA, USA)
601 Impact of bilateral subthalamic nuclei deep brain stimulation on gait in idiopathic Parkinson’s disease patients A.K.Puligopu, R.M.Kandadai, V.V.P.Kagita, J.Afshan, M.A.Kanikannan, R.Borgohain (Hyderabad, India)
Abstracts by Topic 610 New frontiers in focused ultrasound treatment in Parkinson’s disease: A potential paradigm for staged lesioning of the subthalamic nucleus B.B.Shah, D.S.Huss, M.B.Harrison, G.F.Wooten, S.Sperling, W.J.Elias (Charlottesville, VA, USA) 611 Motion perception during subthalamic nucleus deep brain stimulation: Current spread to vestibulothalamic tract A.G.Shaikh, K.Mewes, K.Wilson, M.R.DeLong, A.G.Machado (Cleveland, OH, USA) 612 Deep brain stimulation for Parkinson’s disease in Kazakhstan C.Shashkin, S.Akshulakov, Z.Komarov (Astana, Kazakhstan) 613 Intraoperative MRI for deep brain stimulation lead placement in Parkinson’s disease: One year motor and neuropsychological outcomes C.Sidiropoulos, P.LeWitt, A.Mahajan, M.Schonberger, A.Ellenbogen, D.Taylor, J.Wall, J.M.Schwalb (West Bloomfield, MI, USA) 614 Incidence of dyskinesia improvement following subthalamic DBS with and without medication reduction L.Solis-Cohen, D.K.Simon, D.Tarsy, E.Papavassiliou, R.Alterman, L.C.Shih (Boston, MA, USA) 615 Spinal cord stimulation improves gait performance in advanced Parkinson’s disease patients with chronic stn-dbs: Pilot study C.P.Souza, C.O.Souza, W.L.Contreras, R.G.Cury, M.G.S.Ghillard, M.J.Teixeira, E.R.Barbosa, E.T.Fonoff (Ribeirao Preto, Brazil) 616 Beta-band power: A suitable physiomarker for closed-loop deep brain stimulation in Parkinson’s disease? F.Steigerwald, G.Arnulfo, I.U.Isaias, A.Canessa, M.Reich, R.Reese, S.Johannes, C.Matthies, J.Volkmann (Würzburg, Germany) 617 Deep brain stimulation and outcome: Hints out of the smoke screen? M.H.Strothjohann (Bad Camberg, Germany) 618 Effect of STN deep brain stimulation on autonomic functions in patients with Parkinson’s disease P.Surathi, A.Lenka, K.R.Jhunjhunwala, A.Zafar, T.N.Sathyaprabha, R.Yadav, M.Nethravathi, D.Srinivas, A.Arivazhagan, P.K.Pal (Bangalore, India)
Abstracts by Topic
619 VANTAGE trial: Two year outcomes of a prospective, multicenter trial evaluating deep brain stimulation with a new multiple-source, constant-current rechargeable system (Vercise) in Parkinson’s disease L.Timmerman, R.Jain, L.Chen, T.Brücke, F.Seijo, E.Suarez San Martin, C.Haegelen, M.Verin, M.Maarouf, M.T.Barbe, S.Gill, A.Whone, M.Porta, D.Servello, F.Alesch (Cologne, Germany) 620 Cost-effectiveness of deep brain stimulation for Parkinson’s disease with a multi-source, constant-current rechargeable system: Results from the two-year follow-up of the VANTAGE trial L.Timmermann, F.Alesch, T.Brücke, F.Seijo, E.Suarez San Martin, C.Haegelen, M.Verin, M.Maarouf, M.T.Barbe, S.Gill, A.Whone, M.Porta, D.Servello, R.Jain, L.Chen, N.Mekel-Bobrov (Cologne, Germany)
86
621 Attenuation of STN beta oscillations persists immediately and 60 minutes after turning OFF chronic STN DBS M.H.Trager, E.Quinn, Z.Blumenfeld, A.Velisar, M.Koop, L.Shreve, C.Kilbane, T.Prieto, J.Henderson, H.Bronte-Stewart (Stanford, CA, USA) 622 Subthalamic deep brain stimulation can improve constipation and other bowel dysfunction in Parkinson’s disease T.Uchiyama, T.Yamamoto, Y.Watanabe, K.Hashimoto, T.Kadowaki, Y.Higuchi, T.Shingo, C.Shibata-Yamaguchi, K.Kaga, T.Yamanishi, R.Sakakibara, S.Kuwabara, K.Hirata (Tochigi, Japan) 623 A review of initial consultations for deep brain stimulation: The NYU experience R.K.Unia, A.Mogilner, M.Pourfar (New York, NY, USA) 624 Peripheral nerve grafts reduce medication requirements and reduce motor scores in Parkinson’s disease patients with deep brain stimulation therapy C.G.van Horne, G.Quintero, J.Gurwell, G.Gerhardt, J.Slevin (Lexington, KY, USA) 625 Deep brain stimulation at the sub thalamic nucleus did not cause cognitive impairment in elderly patients with idiopathic Parkinson’s disease six months after the operation I.Velentzas, H.Seferis, P.Afentouli (Marousi Athens, Greece) 626 Advanced target identification in STN-DBS with beta power of combined local field potentials and spiking activity R.Verhagen, D.G.M.Zwartjes, T.Heida, E.C.Wiegers, M.F.Contarino, R.M.A.de Bie, P.van den Munckhof, P.R.Schuurman, P.H.Veltink, L.J.Bour (Amsterdam, Netherlands) 627 STN model based on intraoperative microelectrode recordings assists in postoperative management of DBS settings and clinical research R.Verhagen, P.R.Schuurman, P.van den Munckhof, M.F.Contarino, R.M.A.de Bie, L.J.Bour (Amsterdam, Netherlands) 628 Deep brain stimulation of the subthalamic nucleus preferentially alters the translational profile of striatopallidal neurons in an animal model of Parkinson’s disease N.P.Visanji, I.K.Sarvestani, M.C.Creed, Z.S.Shoaei, J.Nobrega, C.Hamani, L.N.Hazrati (Toronto, ON, Canada) 629 Coordinated reset deep brain stimulation produces longlasting, dose-dependent improvement in motor symptoms in the Parkinsonian non-human primate J.Wang, S.Nebeck, A.Muralidharan, J.L.Vitek, K.B.Baker (Minneapolis, MN, USA) 630 Respiratory dyskinesia in a Parkinson’s patient is successfully treated with STN DBS T.Xie, R.Guan, J.Staisch, D.Casaubon, V.L.Towle, P.C.Warnke (Chicago, IL, USA) 631 The number of microelectrode passes during DBS surgery: Can it really influence surgical outcomes? X.X.Yu, H.Abboud, G.Genc, N.Thompson, S.Oravivattanakul, F.Alsallom, D.Floden, A.Machado, M.Gostkowski, H.H.Fernandez (Cleveland, OH, USA) 632 Hesitation in deciding-deep brain stimulation of Parkinson’s disease J.Y.Yun, M.R.Kim, Y.H.Lim, K.R.Kim, S.H.Paek, B.S.Jeon (Seoul, Korea)
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 633 Role of the frequency of STN stimulation on bradykinesia in Parkinsonian patients A.Zacharia, I.Sastre, D.Georgiev, M.Hariz, L.Zrinzo, T.Foltynie, M.Jahanshahi, J.Rothwell, P.Limousin (London, United Kingdom)
SURGICAL THERAPY: OTHER MOVEMENT DISORDERS
634 Long-term clinical effects of cZI compared to VIM DBS on essential tremor patients B.Ahmed, D.M.Ramirez, L.Almeida, J.C.Giugni, E.Monari, K.D.Foote, M.S.Okun (Gainesville, FL, USA) 635 Improvement in disabling action tremor associated with cerebellar multiple system atrophy by thalamic DBS: A case report P.Anprasertporn, N.Hidarilak, B.L.Guthrie, H.C.Walker (Birmingham, AL, USA) 636 Surgical treatment of post-traumatic midbrain resting-kinetic tremor with stereotactic lesions with M.E.R. of the zona incerta A.R.C.Azevedo, W.O.Contreras, P.R.Reis, R.G.Cury, F.E.F.Silva, J.Navarro, E.T.Fonoff (São Paulo, Brazil) 637 Effects of VIM-DBS on the speech motor system in ET patients: An electromagnetic articulograph study M.T.Barbe, D.Mücke, A.Hermes, J.Becker, T.A.Dembek, A.Josten, I.G.Meister, V.Visser-Vandewalle, M.Grice, L.Timmermann (Cologne, Germany) 638 Deep brain stimulation in rare movements disorders I.Beaulieu-Boire, C.C.Aquino, A.E.Lang, R.P.Munhoz, Y.Y.Poon, A.Valencia, M.Fallis, S.Kalia, M.Hodaie, E.Moro, A.M.Lozano, A.Fasano (Sherbrooke, QC, Canada) 639 Results from first year experience of dedicated pediatric DBS dystonia program at Barrow Neurological Institute at Phoenix Children’s Hospital R.D.Bhardwaj, S.Flecky, N.Remec, J.Samanta (Phoenix, AZ, USA)
645 Neuropsychological outcome of bilateral pallidal stimulation in cervical dystonia: One-year follow-up results from a prospective multicenter trial L.Dinkelbach, J.Mueller, M.Delazer, S.Elben, A.Wolters, E.Karner, W.Poewe, A.Schnitzler, J.Volkmann, M.Suedmeyer (Duesseldorf, Germany) 646 Update on deep brain stimulation for refractory Tourette syndrome: 10 patients with CM-Pf/Voi stimulation R.S.Dowd, M.H.Pourfar, A.Y.Mogilner (New York, NY, USA) 647 Impedance fluctuations in patients undergoing thalamic deep brain stimulation for essential tremor and their effect on clinical outcome J.Eskenazi, E.Tan, A.N.Mamelak, M.Tagliati (Los Angeles, CA, USA) 648 Panic disorder following implantation of deep brain stimulation (DBS) leads in the ventral intermediate nucleus of the thalamus (VIM) S.M.Fayad, U.Akbar, P.Zeilman, M.S.Okun, H.E.Ward (Gainesville, FL, USA) 649 Deep brain stimulation (DBS) interleave contact configuration with implementation of dual frequency stimulation fields improves control in essential tremor (ET) and reduces adverse effects E.M.Feinstein, D.L.Caputo, D.P.Schneider, R.J.DiPaola, S.F.Danish, E.L.Hargreaves (New Brunswick, NJ, USA) 650 Dorsal lead migration in a dystonia patient following deep brain stimulation W.Hu, A.R.Bona, D.Martinez-Ramirez, A.Wagle Shukla, K.D.Foote, M.S.Okun (Gainesville, FL, USA) 651 Functional assessment and quality of life in essential tremor following treatment with bilateral or unilateral deep brain stimulation and unilateral focused ultrasound thalamotomy D.S.Huss, R.F.Dallapiazza, B.B.Shah, M.B.Harrison, J.W.Elias (Staunton, VA, USA) 652 Deep brain stimulation for dystonia: A programming algorithm evaluated by long-term results of the German multicentre study for generalized or segmental dystonia A.D.Kirsch, A.A.Kühn, J.Müller, J.Volkmann for the Deep-Brain Stimulation for Dystonia Study Group (Würzburg, Germany)
641 The efficacy of VIM and VIM/ZI DBS in treatment of various tremors M.Bonello, J.Osman-Farah, P.R.Eldridge, B.Hammersley, L.Lowry, P.Byrne, N.A.Fletcher, S.H.Alusi (Liverpool, United Kingdom)
653 Long term effective thalamic deep brain stimulation (DBS) for neuropathic tremor in patients with hereditary motorsensory polineuropathy C.M.Lidia, A.O.Iciar, V.Marta, D.Á.Marta, R.Ignacio (Madrid, Spain)
642 Biochemical mechanisms of pallidal deep brain stimulation in X-linked dystonia Parkinsonism N.Brüggemann, A.Moser, A.Domingo, C.K.Moll, D.Rasche, C.Mohr, R.Rosales, P.Capetian, R.D.Jamora, L.V.Lee, A.Münchau, C.C.Diesta, V.Tadic, C.Klein, V.Tronnier (Luebeck, Germany)
654 Deep brain stimulation in the nucleus ventralis oralis anterior for post anoxic dystonia, case report and review of the literature? M.Mansour, Y.M.Mansour, J.Vaidyanathan (Abu Dhabi, United Arab Emirates)
643 Deep brain stimulation artifact in cervical electromyography M.V.Della Coletta, A.R.Marcião (Manaus, Brazil)
655 Therapeutic deep brain ablation via implanted DBS leads: Technique and potential complications A.Mantovani, A.R.Bona, M.S.Okun, K.D.Foote (Gainesville, FL, USA)
644 Target correlated mapping of therapeutic effects in deep brain stimulation using voxel-based estimations of neuroanatomical structures and volumes of tissue activated T.A.Dembek, M.T.Barbe, M.Åström, V.Visser-Vandewalle, L.Timmermann (Cologne, Germany)
656 Two patients with dystonia treated with internal globus pallidus deep brain stimulation (GPi-DBS) using a multiple independent source current-controlled system, a case report O.Morsi, J.Jimenez, B.Cuartero, J.Zamarro, R.Sanchez, M.Felipe, B.Segura, J.J.Martin (Murcia, Spain)
87
Abstracts by Topic
640 Delayed scalp erosion after DBS surgery: Incidence, treatment, outcomes, and prevention A.R.Bona, A.Mantovani, S.Vaziri, R.Walz, M.S.Okun, K.D.Foote (Gainesville, FL, USA)
Abstracts by Topic 657 Combined anterior and posterior lumbar rhizotomy for treatment of mixed dystonia and spasticity in children with cerebral palsy M.A.Nada, W.A.Abdel Ghany (Cairo, Egypt)
669 The effect of motor imagery on stepping characteristics and motor control of gait in persons with Parkinson’s disease P.E.Atwood, W.J.Farrington, A.C.Brandt, A.Smiley-Oyen, K.A.Lowry (Des Moines, IA, USA)
658 Reversal of acquired hepatocerebral degeneration with live donor liver transplant A.H.Qavi, S.Hammad, A.I.Rana, M.Salih, N.H.Shah, F.S.Dar, A.Ahmad (Islamabad, Pakistan)
670 Antibody spectrum in stiff person syndrome and related disorders B.Balint, I.M.Blöcker, M.Unger, W.Stöcker, C.Probst, L.Komorowski, H.M.Meinck (London, United Kingdom)
659 Does the use of intraoperative microelectrode recording influence the final location of lead implant in the ventral intermediate nucleus for deep brain stimulation? S.T.Reddy, A.J.Fenoy, E.Furr-Stimming, W.G.Ondo, M.C.Schiess, R.Mehanna (Houston, TX, USA)
671 NMDAR-antibodies in atypical corticobasal syndrome – New phenotype or (contributing) epiphenomenon? B.Balint, R.Erro, M.Stamelou, F.Brugger, E.Antelmi, A.Batla, C.Ganos, A.Vincent, K.Bhatia (London, United Kingdom)
660 Does the use of intraoperative microelectrode recording influence the final location of lead implant in the subthalamic nucleus for deep brain stimulation? S.T.Reddy, A.J.Fenoy, E.Furr-Stimming, W.G.Ondo, M.C.Schiess, R.Mehanna (Houston, TX, USA) 661 Intraoperative thresholds for capsular stimulation are predictive of the chronic therapeutic window in pallidal deep brain stimulation for dystonia R.Reese, D.Falk, H.M.Mehdorn, G.Deuschl, J.Volkmann (Würzburg, Germany) 662 Progressive ataxia under thalamic neurostimulation in essential tremor, neurostimulation effect or disease progression? M.M.Reich, J.Brumberg, F.Steigerwald, G.Marotta, T.Musacchio, D.A.Kirsch, L.Müller, K.Herrmann, A.Buck, J.Volkmann, I.U.Isaias (Wuerzburg, Germany) 663 Force platform analysis after deep brain stimulation of peduncolopontine nucleus in progressive supranuclear palsy: Report of one case C.O.Souza, R.Brant, A.L.Pardini, D.Boari, L.A.Teixeira, M.J.Teixeira, E.R.Barbosa, E.T.Fonoff (São Paulo, Brazil) 664 Coaxial deep brain stimulation of ventral thalamic nuclei and posterior subthalamic area for movement disorders H.Toda, H.Saiki, R.Okumura, S.Matsumoto, K.Iwasaki (Osaka, Japan) 665 Subthalamic stimulation for tremor A.T.Tran, G.Moguel-Cobos, R.Dhall, A.Lieberman (Phoenix, AZ, USA)
Abstracts by Topic
666 STN DBS in dystonia modulates sensorimotor integration and plasticity but not motor cortex excitability A.Wagle Shukla, J.Ostrem, D.Vaillancourt, K.Foote, J.Shuster, M.Okun (Gainesville, USA) 667 Combined deep brain stimulation in the internal globus pallidus (GPi) and pallidothalamic tract (PTT) in a patient suffering from a nigrostriatal lesion due to subarachnoid haemorrhage N.A.Wegener, S.Haegele-Link, K.Georg, P.Anita, B.Thomas, B.Ronald (St.Gallen, Switzerland)
OTHER (NON-CATEGORY SPECIFIC)
668 The Parkinson’s disease and movement disorders program at King Fahad Medical City F.Y.AlSwaiti, J.A.Bajwa, R.Mayo (Greensboro, NC, USA)
88
672 Development and evaluation of a patient decision aid, should you have botulinum toxin injections or surgery for hemifacial spasm C.T.Barrett, D.A.Grimes, V.Parker (Ottawa, ON, Canada) 673 Effect of progressive aerobic and large-amplitude training (PWR!Moves) on advanced Parkinson’s disease - A case study J.Bazan-Wigle, K.Moynahan, B.Farley (Tucson, AZ, USA) 674 Ultrastructural distribution and features of dopaminergic and cholinergic innervations of the primate subthalamic nucleus H.Belaid, L.Parolari, D.Tande, M.P.Muriel, D.Chauvet, B.Lau, C.Francois, C.Karachi (Paris, France) 675 Using a wearable sensor to evaluate activity and motor response fluctuations in patients with Parkinson’s disease (PD): Preliminary findings H.Bernad-Elazari, A.Weiss, S.Oren, Y.Cohen, A.Mirelman, N.Giladi, J.Hausdorff (Tel Aviv, Israel) 676 Optimizing CNS-delivery by lactyl stearate-coupled liposomes V.Bhargava, M.Bhargava, S.Bhargava, N.Kapoor, G.Agarwal, (Kanpur, India) 677 The figure-of-8 walk test: A clinical measure of motor skill in walking for persons with Parkinson’s disease A.C.Brandt, P.E.Atwood, W.J.Farrington, J.Van Swearingen, K.A.Lowry (Des Moines, IA, USA) 678 Auditory cues on postural control in Parkinson’s disease: A pilot study W.Buated, T.Fujinami, S.Hidaka, N.Kashyap (Nomi, Japan) 679 Walking speed and switching attention in individuals with Parkinson’s disease M.C.Caciula, M.Horvat, R.Croce (Statesboro, GA, USA) 680 Movement disorders after stroke A.Chahidi, M.Chraa, N.Kissani (Beni Mellal, Morocco) 681 Mirror movement among patients with Parkinson’s diseaseAn under-appreciated clinical sign P.Chatterjee, S.Choudhury, D.Naskar, S.Anand, B.Mondal, M.U.Kulsum, H.Kumar (Kolkata, India)
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 682 Hypoglycemia induced acute bilateral basal ganglia lesions presenting as generalized dyskinesia in a patient with diabetic uremia P.Y.Chen, S.H.Yan, S.C.Lai, C.S.Lu, T.H.Yeh (Taipei, Taiwan) 683 Cytoarchitecture of the human nitrergic neurons in basal nuclei B.L.Dos Santos, E.A.Del Bel, J.E.Pittella, V.Tumas (Ribeirão Preto, Brazil) 684 Is change in physical performance in persons with Parkinson’s disease meaningful following LSVT® BIG: A retrospective study W.J.Farrington, T.Miller, G.McGaughy, K.Mercuris, K.Lowry (Des Moines, IA, USA) 685 Clinical subtypes of Parkinson’s disease and disease progression: Data-driven comparison of new phenotypes with other cluster solutions S.M.Fereshtehnejad, S.R.Romenets, J.Anang, V.Latreille, J.F.Gagnon, R.B.Postuma (Stockholm, Sweden) 686 Continuous stimulation of the subthalamic nucleus improves skilled forelimb grasping after photothrombotic infarction in Wistar rats F.Fluri, J.Volkmann, C.Kleinschnitz (Würzburg, Germany) 687 Characterization of movement disorder phenomenology in genetically proven frontotemporal lobar degeneration: A systematic review and meta-analysis C.Gasca-Salas, B.B.Shah, M.Masellis, E.Khoo, D.Fisman, A.E.Lang, G.KleinerFisman (Toronto, ON, Canada) 688 Assessment of Parkinsonian motor symptoms using a continuously worn smartwatch: Preliminary experience E.Gazit, H.Bernad-Elazari, S.T.Moore, C.Cho, K.Kubota, L.Vincent, S.Cohen, L.Reitblat, N.Fixler, A.Mirelman, N.Giladi, J.M.Hausdorff (Tel Aviv, Israel) 689 Clinical and dynamic balance measures can predict postural instability in Parkinson’s disease patients L.T.B.Gobbi, P.H.S.Pelicioni, M.P.Pereira, J.Lahr, L.C.Morais, N.M.Rinaldi (Rio Claro, Brazil) 690 Initial treatment choice is associated with medical resource use in people aged 35 to 64 years with Parkinson’s disease E.Grubb, M.Treglia, M.Lage (Overland Park, KS, USA) 691 Smartphone-PD: Preliminary results of an mHealth application to track and quantify characteristics of Parkinson’s disease in real-time D.A.Harris, S.O.Abiola, K.M.Biglan, E.R.Dorsey, M.A.Little, S.Saria, A.Zhan (Rochester, NY, USA)
693 Ethical and legal concerns for a highly vulnerable population of 70+ cases of PD and dementia: A qualitative study in Indian context M.Kakoti, D.Misra (New Delhi, India)
695 Finally it’s time for a perspective: Barriers and facilitators in physical rehabilitation for Parkinson’s disease from the Arabian Peninsula H.Khalil, J.A.Bajwa (Irbid, Jordan) 696 The effects of 12-week exercise therapy program on the gait characteristics in people with Parkinson’s disease C.H.Kim, M.Y.Kim, B.O.Lim (Inchon, Korea) 697 Preliminary results for a national case study of virtual care visits for Parkinson’s disease R.E.Korn, M.A.Achey, R.Rodriguez, K.Rizer, I.Richard, E.R.Dorsey, H.T.Keenan (Rochester, NY, USA) 698 Validation of a smartphone application measuring bradykinesia in Parkinson’s disease W.Lee, A.Evans, D.R.Williams (Melbourne, Australia) 699 Improving of balance in patients affected by Parkinson’s disease by decreasing rigidity A.P.C.Loureiro, V.Bauer, C.d.C.Loureiro (Curitiba, Brazil) 700 Speech intelligibility perception of advanced Parkinson’s disease patients compared to early Parkinson’s disease patients and first degree relatives Y.Manor, D.Shpunt, M.Chermon, L.Fregel, A.Ezra, A.Migirov, J.Zitser, T.Gurevich (Tel Aviv, Israel) 701 Acoustic analysis of voice and speech of advanced Parkinson’s disease patients compared to early Parkinson’s disease patients and first degree relatives Y.Manor, D.Shpunt, I.Ben Asher, A.Tsvion, N.Horev, A.Ezra, A.Megirov, A.Hilel, T.Gurevich (Tel Aviv, Israel) 702 The self-perception of multiple system atrophy patients of swallowing disorders and drooling and its relation to quality of life and disease severity Y.Manor, D.Shpunt, Y.Zlotnik, A.Megirov, L.Brounshtai, T.Voler-Kohaner, T.Lupo, T.Gurevich (Tel Aviv, Israel) 703 3D sensors, a new paradigm for assessing Parkinson’s disease A.Mario, B.Jorge, M.Daniel, V.Pedro (Havana, Cuba) 704 Variability in Parkinson’s disease quality improvement measure documentation in a specialty center J.P.Martello, M.Armstrong (Baltimore, MD, USA)
Abstracts by Topic
692 Iron deposition and oxidative stress in the brain of the Zitter rat T.Kadowaki, H.Lassmann, S.Ueda, C.Schuh, K.Hirata (Mibu, Japan)
694 The Parkinsonian toxin 1-methyl-4-phenylpyridinium (MPP+), and proteins α-synuclein and glia maturation factor (GMF) activate mast cells and release proinflammatory mediators D.Kempuraj, T.Ramasamy, S.Zaheer, D.A.Santillan, M.K.Santillan, A.Zaheer (Iowa City, IA, USA)
705 Decreased FOG following multi-system behavioral intervention-A case report C.E.McLean (Hermosa Beach, CA, USA) 706 One year dynamics of spatiotemporal gait parameters and ADL performance in patients with Parkinson’s disease K.Medijainen, M.Pääsuke, P.Taba (Tartu, Estonia)
89
Abstracts by Topic 707 Intraoperative microstimulation predicts outcome of postoperative macrostimulation in STN DBS for PD R.Mehanna, A.G.Machado, F.Alsaloum, S.E.Cooper (Houston, TX, USA)
721 A pilot study of a plant-based diet intevention in Parkinson’s disease S.P.Shah, H.C.Watson, H.M.Kane, J.E.Duda (Philadelphia, PA, USA)
708 Parkinson’s disease: A regression based approach to motor symptom progression A.Mendes, A.Gonçalves, N.Vila-Chã, M.Calejo, I.Moreira, J.Fernandes, J.Damásio, A.B.Lima, S.Cavaco (Porto, Portugal)
722 The role of nutrition in Parkinson’s disease S.P.Shah, J.E.Duda (Philadelphia, PA, USA)
709 Fluorodeoxyglucose positron emission tomography (FDGPET) in prion disease K.Mente, J.O’Donnell, P.Gambetti, S.E.Jones, B.S.Appleby (Cleveland, OH, USA) 710 Mimicking progressive supranuclear palsy and causing TakoTsubo syndrome: A case report on IgLON5-encephalopathy M.T.Montojo, V.Piren, F.Benkhadra, A.Codreanu, G.Wirtz, P.Kerschen, N.J.Diederich (Mostoles, Spain) 711 e-Motion: A reliability assessment for a prototype software to complement the clinical evaluation of patients with Parkinson’s disease B.E.Muñoz, A.Navarro, Y.J.Ariza, J.D.Arango, J.L.Orozco (Cali, Colombia) 712 A powered orthosis improves the magnitude and consistency of gait initiation in Parkinson’s disease with freezing of gait M.N.Petrucci, C.D.MacKinnon, E.T.Hsiao-Wecksler (Urbana, IL, USA) 713 Withdrawn by Author 714 The mitochondrial serine protease HtrA2 degrades diseaseassociated prion protein M.M.Rahman, S.Akhter, S.T.Hong (Jessore, Bangladesh) 715 Functional (psychogenic) neurological symptoms in patients with postural tachycardia syndrome (PoTS) L.Ricciardi, A.P.Owens, G.Ferrazzano, V.Iodice, C.J.Mathias, M.J.Edwards (London, United Kingdom) 716 Unilateral decreased palpebral fissure in patients with Parkinson’s disease: A new sign to consider M.Sanchez Abraham, O.S.Gershanik, S.S.Garcia, G.Mizraji, A.Chade, G.Gomez Arevalo (Buenos Aires, Argentina)
Abstracts by Topic
717 Parkinsonism and dystonia: Predominant features in a case of ADEM H.Sarva, R.Garcia-Santibanez, W.L.Severt, M.Fabian, D.Swope, V.L.Shanker, J.C.Cabassa, J.C.Cabassa, S.B.Bressman, R.Saunders-Pullman, N.Lubarr (Brooklyn, NY, USA)
723 Psychodynamic and reality therapy for psychogenic movement disorders: report on 9 cases V.D.Sharma, R.Jones, G.Alexander, C.Testa, S.Factor (Atlanta, GA, USA) 724 Quantitative analysis of voice in Parkinson’s disease A.K.Silbergleit, P.A.Lewitt, E.L.Peterson, G.M.Gardner (West Bloomfield, USA) 725 Beat complexity and variability may optimize the effects of rythmic auditory cueing on walk in Parkinson’s disease B.Sophie, D.G.Dotov, C.D.C.Valérie, K.Torre, B.Bardy, S.Dalla Bella (Montpellier, France) 726 Effects of singing on voice and swallow in Parkinson’s disease E.L.Stegemöller (Ames, IA, USA) 727 Repetitive finger movement, Purdue pegboard and buttoning in persons with Parkinson’s disease E.L.Stegemöller, J.Uzochuckwu (Ames, IA, USA) 728 A study on subjective and objective freezing phenomena in Parkinson’s disease S.Tagashira, K.Wada, K.Tanaka, Y.Tajiri, K.Nakashima (Tottori, Japan) 729 Stressful life events precede the onset of hemifacial spasm. A retrospective study in Penang Hospital, Malaysia K.Tan, G.B.Eow, H.B.Chow, C.Cheah, Y.K.Chia, R.Kanesalingam, M.H.Rafia, R.Azman Ali, T.T.Lim (Georgetown, Malaysia) 730 Neurotological disease in intracranial tumors H.A.G.Teive, B.S.Zeigelboim, V.R.Fonseca, H.A.Carvalho, J.H.Faryniuk (Curitiba, Brazil) 731 Effectiveness of allied health therapy in the symptomatic management of progressive supranuclear palsy: A systematic review E.Tilley, S.White, M.Peters, S.A.Koblar, S.Doeltgen, J.McLoughlin (Adelaide, Australia) 732 Spinal and bulbar muscular atrophy with dementia of frontal-lobe type K.Togo, A.Umemura, T.Oeda, J.Suzuki, H.Sugiyama, H.Sawada (Kyoto, Japan)
718 Compliance with Parkinson’s disease quality measures R.B.Schneider, R.Holloway, K.Biglan, M.Burack (Rochester, NY, USA)
733 Nursing diagnoses related to motor and nonmotor symptoms in Parkinson’s disease M.H.S.Tosin, B.G.R.B.Oliveira (Rio de Janeiro, Brazil)
719 Non-tardive orofacial akathisia with dental sensory phenomenon L.M.Scorr, S.A.Factor (Atlanta, GA, USA)
734 A metabolomic study in post-mortem DBS human tissue V.Vedam-Mai, S.Sternberg, M.Williams, T.J.Garrett, M.S.Okun (Gainesville, FL, USA)
720 Psychogenic movement disorders: Are there neurocognitive differences between patients with non-epileptic seizures vs those with other hyperkinetic motor manifestations? B.M.Scott, A.M.Strutt, P.K.Lundberg-Love, A.L.Schmitt, E.R.Trifilio, D.Bowers (Gainesville, FL, USA)
735 Histopathological observations from 50 human deep brain stimulation cases V.Vedam-Mai, A.T.Yachnis, K.J.Otto, A.Gunduz, A.Wagle Shukla, C.Hess, M.S.Okun (Gainesville, FL, USA)
90
736 Non-supportive touch improves static balance in active and inactive individuals with Parkinson’s disease K.E.Welman, T.Gregory (Matieland, South Africa)
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 737 Demodex sp prevalence in Parkinson’s disease patients O.Yilmaz Kusbeci, O.Miman, M.Gedizlioglu (Izmir, Turkey) 738 Infantile systemic hyalinosis presenting as neurological hypertonic movement disorder Z.Yusuf, V.McClelland, G.Anderson, M.Irving, R.Hinds, J.McGrath, T.Hedderly (London, United Kingdom) 739 Speed influences handwriting in persons with Parkinson’s disease A.F.Zaman, E.Stegemoller (Ames, IA, USA) 740 Anti-GAD65 negative stiff-person syndrome with a favorable response to pregabalin: A case post-thymoma excision accompanying central sleep apnea G.Zhang, L.Liu, N.Xiong, J.Huang, T.Wang (Wuhan, China)
DRUG-INDUCED MOVEMENT DISORDERS
741 Distractible multifocal myoclonus following a single dose of neuroleptic R.J.Adam, F.C.F.Chang, A.Duggins, N.Mahant, V.S.C.Fung (Sydney, Australia) 742 Aripiprazole-induced movement disorders – A case-series S.Chouinard, P.Huot (Montreal, Canada) 743 Lithium induced lingual dystonia: A case report R.K.Dhamija, R.Aggarwal (New Delhi, India) 744 Levosulpiride induced movement disorder – A case series A.G.Diwan (Nashik, India) 745 Tremor and ataxia due to chronic toluene exposure: Case report F.Genç, C.Altunç, Y.B.Gömceli, A.Erdal, A.Tiltak, A.Yaman (Antalya, Turkey) 746 Can the clinical phenotype in suspected drug induced Parkinsonism reliably predict the presence of abnormal functional imaging suggesting dopaminergic deficiency? E.Jabbari, S.Molloy (London, United Kingdom) 747 Worst side effect of drugs-Parkinsonism S.Khachaturyan, A.Badalyan, G.Avagyan, H.Amirjanyan, C.Harutunyan, A.Voskanyan, H.Manvelyan (Vararshapat, Armenia) 748 Propriospinal myoclonus provoked by tramadol use H.S.Kim, Y.Kim, H.Lee (Seongnam, Korea) 749 Acute and reversible Parkinsonism with phorate A.Kumar (Patna, India)
751 Pilot study of cardio-vascular risks, insulin resistance and neurocognition in neuroleptic-induced Parkinsonism in schizophrenia: Post-hoc analysis of RCT study H.Raheb, S.Chiu, Z.Cernovsky, K.Terpstra, J.Vaughese, H.Jirui, Y.Bureau, C.John, M.Husni, R.Campbell (London, ON, Canada) 752 Clinical characteristics of tetrabenazine-induced Parkinsonism D.P.Shah, J.Jimenez-Shahed (Houston, TX, USA)
754 The effects of early versus late L-DOPA initiation in Parkinson’s disease G.Yahalom, O.S.Cohen, N.Warmann-Alaluf, C.Shabat, H.Strauss, S.Elincx-Benizri, S.Israeli-Koren, E.Stein, S.Hassin-Baer (Ramat-Gan, Israel)
NEUROPHARMACOLOGY
755 Parkinson’s disease polypharmacy: A crucial issue in the management of elderly patients S.Ataei, M.Noroozian, A.Kargar (Hamedan, Iran) 756 Dopaminergic modulation of neural progenitor cells in the hippocampal dentate gyrus in a mouse model of Parkinson’s disease W.H.Chiu, G.U.Höglinger, W.H.Oertel, V.Ries (Marburg, Germany) 757 Brain delivery of microencapsulated GDNF promotes functional and structural recovery in a primate model of Parkinson’s disease E.Garbayo, H.Lana, G.D´Addario, M.d.M.Carmona-Abellan, I.Marcilla, J.L.Lanciego, M.R.Luquin, M.J.Blanco-Prieto (Pamplona, Spain) 758 The critical role of Beclin 1 up regulation in dopamine D2 like receptor agonists-induced autophagy activation L.F.Hu, J.D.Wang, C.F.Liu (Suzhou, China) 759 L-dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson’s disease C.Isobe, C.Otsuka, T.Murata, T.Abe, Y.Terayama (Sapporo, Japan) 760 Changes in α-7 nicotinic acetylcholine receptor specific binding in the brain of dyskinetic Parkinsonian monkeys V.A.Jourdain, L.Grégoire, T.Di Paolo (Manhasset, NY, USA) 761 The adenosine A2A receptor antagonist, istradefylline enhances and prolongs the anti-Parkinsonian activity by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets T.Kanda, S.Uchida, K.Soshiroda, E.Okita, M.Kawai-Uchida, A.Mori, P.Jenner (Shizuoka, Japan) 762 Brain neurotransmitters in Parkinson’s induced rats N.Kumar, R.K.Khanna (Jaipur, India) 763 Withdrawn by Author 764 The protective effect of curcumin on tyrosine hydroxylase immunoreactivity in both substantia nigra and the ventral tegmental area, after acute aluminum intoxication W.Laabbar, A.Elgot, H.Gamrani (Marrakech, Morocco) 765 Incidence and prescribing trends of antipsychotic and antiemetic dopamine receptor blocking agents (DRBAs) in patients with Parkinson’s disease M.A.Lising, M.Lee, L.H.Poon, G.Manipon, N.B.Galifianakis (San Francisco, CA, USA) 766 Novel structural congeners of a known phosphodiesterase type-IV inhibitor against experimental Parkinson’s disease D.N.Nthenge-Ngumbau, S.Mitra, P.Verma, N.Ali, R.Singh, P.Bhattacharjee, J.Vinayagam, D.Nandi, P.Jaisankar, K.Mohanakumar (Kolkata, India)
91
Abstracts by Topic
750 Phenomenology and dopamine transporter density in a patient with amphetamine induced hyperkinetic facial movement disorders J.P.Michelis, J.R.Bedarf, F.Gaertner, S.Paus (Bonn, Germany)
753 5-Meo-DALT-induced cyclic myoclonus T.Thammongkolchai, P.Termsarasab, A.Malkhachroum, Y.Gujrati, S.J.Frucht, B.Katirji (Cleveland, OH, USA)
Abstracts by Topic 767 Neuroprotective and neurotrophic effects of apigenin and luteolin in MPTP induced Parkinsonism in mice S.P.Patil, S.Sathaye (Mumbai, India) 768 Modulation of NADPH oxidase: A plausible candidate to prevent or slow down the neurodegneration process in lipopolysaccharide induced Parkinson’s disease N.Sharma, B.Nehru (Chandigarh, India) 769 Effects and side-effects on Chinese patients with Wilson disease by unithiol (DMPS) intravenous infusion X.Wang, H.Liu (Shanghai, China) 770 Autophagy is involved in age-related sensitivity to Parkinsonian pathogenesis Y.P.Yang, H.F.Zheng, C.J.Mao, F.Wang, L.F.Hu, C.F.Liu (Suzhou, China)
PARKINSONISM (SECONDARY AND PARKINSONISM-PLUS)
771 Incidence and characteristics of serious injuries due to falls resulting from movement disorders- Japanese prospective fall study in elderly patients under home nursing care (J-FALLS) I.Aiba, Y.Saito, M.Kaneko, M.Kawai, M.Yoshioka, H.Matsuo, H.Fujimura, M.Tobita, T.Inui, K.Chida, A.Tamakoshi (Nagoya, Japan) 772 Prevalence of depression in atypical Parkinsonian disorders versus Parkinson’s disease L.Almeida, M.S.Okun, D.Bowers, H.Ward, S.Fayad, C.Jacobson, N.McFarland (Gainesville, FL, USA) 773 Prevalence of anxiety in atypical Parkinsonian patients L.Almeida, M.S.Okun, D.Bowers, H.Ward, S.Fayad, C.Jacobson, N.McFarland (Gainesville, FL, USA) 774 Usefulness of transcranial ultrasound in atypical Parkinsonism: A cross sectional study A.Alonso-Canovas, J.L.Lopez-Sendon, A.deFelipe-Mimbrera, M.C.Matute-Lozano, S.S.de laMaza-Cantero, R.Alvarez-Velasco, J.Buisan, G.Garcia-Ribas, I.AvilesOlmos, J.Masjuan, J.C.Martinez Castrillo (Madrid, Spain) 775 Progression of clinical symptoms and survival in progressive supranuclear palsy J.E.Arena, S.D.Weigand, J.L.Whitwell, S.D.Eggers, G.U.Höglinger, I.Litvan, K.A.Josephs (Rochester, USA)
Abstracts by Topic
776 Diagnosing dementia in multiple system atrophy with MDS criteria for Parkinson’s disease dementia N.Auzou, K.Dujardin, R.Biundo, A.Foubert-Samier, C.Barth, F.Tison, L.Defebvre, A.Antonini, W.G.Meissner (Bordeaux, France) 777 Perry syndrome – Characteristics of the first Portuguese family R.Barreto, M.Lopes, J.M.Roriz, M.Magalhães (Santa Maria Feira, Portugal)
780 Region-specific alterations of matrix metalloproteinase activity in multiple system atrophy F.Bassil, A.Monvoisin, M.H.Canron, A.Vital, W.G.Meissner, F.Tison, P.O.Fernagut (Bordeaux, France) 781 Young onset MSA can mimic young onset PD- clues to help the diagnosis A.Batla, M.Reich, G.Calandra Buonaura, P.Cortelli, J.Volkmann, R.P.Erro, K.P.Bhatia (London, United Kingdom) 782 Epidemiological aspects in a Tunisian cohort of Parkinsonplus syndromes M.Ben Djebara, A.Nasri, I.Kacem, L.Sellami, Y.Hizem, A.Gargouri, R.Gouider (Tunis, Tunisia) 783 Cortical excitability and sensorimotor integration correlates with cognitive profile in vascular Parkinsonism S.Benítez-Rivero, F.J.Palomar, J.F.Martín-Rodríguez, P.Álvarez de Toledo, M.J.Lama, I.Huertas-Fernández, M.T.Cáceres-Redondo, P.Porcacchia, P.Mir (Seville, Spain) 784 Diagnostic accuracy of magnetic resonance Parkinsonism index in progressive supranuclear palsy in Indian patients K.Bharambe, C.Sankhla, S.Gupta, N.Savant (Mumbai, India) 785 Palliative care in Parkinson’s disease: Patients’ perspectives I.Boersma, J.Jones, J.Carter, D.Bekelman, J.Miyasaki, J.Kutner, B.Kluger (Mount Pleasant, SC, USA) 786 Relationship between uric acid levels and progressive supranuclear palsy (PSP) D.M.Brody, I.Litvan, S.N.Rai, A.C.Cambon, D.E.Riley, D.A.Hall, B.M.Kluger, C.R.Cunningham (La Jolla, CA, USA) 787 Acute onset of shuffling gait from hypertensive hemorrhage J.Y.C.Chen, I.Keshet, J.Weinberger (San Francisco, CA, USA) 788 Gait disturbance and Parkinsonism in a patient with hereditary diffuse leukoencephalopathy with axonal spheroids and CSF1R mutation Y.F.Chen, M.Y.Lan, J.S.Liu, Y.Y.Chang (Kaohsiung, Taiwan) 789 Longitudinal follow-up and neurophysiological findings in two Chinese siblings with compound heterozygote mutations in ATP13A2 (PARK9) causing juvenile onset Parkinsonism (Kufor-Rakeb syndrome) H.L.Chiang, D.S.Y.Tsui, S.D.Kim, V.S.C.Fung (Sydney, Australia) 790 Progressive supranuclear palsy showing pure akinesia with gait freezing – Clinicopathological report of an autopsy case E.J.Choi, D.G.Lee, S.K.Khang, C.S.Lee (Seoul, Korea) 791 Parkinsonism due to neurosyphilis M.Chraa, N.Kissani (Marrakech, Morocco)
778 The effects of comorbid traumatic brain injury on motor and non-motor symptoms of Parkinson’s disease B.R.Barton, C.Stachnik (Chicago, IL, USA)
792 Corticobasal syndrome due to Creutzfeldt-Jakob disease: Report of a case C.Cosentino, Y.Nuñez, M.Velez, E.Sarapura, R.Suarez, L.Torres (Lima, Peru)
779 Abnormal insulin/IGF-1 signaling together with insulin resistance in the putamen of MSA patients F.Bassil, P.O.Fernagut, M.H.Canron, A.Vital, E.Bezard, W.G.Meissner (Bordeaux, France)
793 To study falls in Parkinson’s disease (PD) A.Deep, A.Lieberman, R.Dhall, A.Tran, M.J.Liu (Phoenix, AZ, USA)
92
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 794 Spectrum of disorders presenting as secondary Parkinsonism in a rural based medical teaching college in Western India D.S.Desai, S.D.Desai (Anand, India) 795 Sudden onset Parkinsonism following hyponatraemia correction G.Fabiani, H.A.G.Teive (Curitiba, Brazil) 796 Young onset Parkinsonism after bariatric surgery G.Fabiani, H.A.G.Teive (Curitiba, Brazil) 797 Progressive supranuclear palsy and statin use A.Fuentes, D.Standaert, C.Marras, D.Riley, D.Hall, B.Kluger, J.Juncos, S.Reich, D.Shprecher, Y.Bordelon, J.Jankovic, E.Carl, I.Litvan (La Jolla, CA, USA) 798 Usefulness of cardiac 123I-MIBG uptake, olfactory function and substantia nigra hyperechogenicity in distinguishing between Parkinson’s disease and Parkinsonian syndrome H.Fujita, K.Suzuki, A.Numao, Y.Watanabe, M.Miyamoto, T.Miyamoto, H.Takekawa, T.Kadowaki, K.Hashimoto, K.Hirata (Mibu, Japan) 799 Relationship between serum uric acid concentration and disease progression in multiple system atrophy J.Fukae, S.Yanamoto, S.Fujioka, T.Hatano, A.Mori, T.Nomi, K.Fukuhara, N.Hattori, Y.Tsuboi (Fukuoka, Japan) 800 A case of vascular Parkinsonism simultaneous with progressive supranuclear palsy (PSP) I.Gabrielyan, H.Amirjanyan, K.Harutyunyan, G.Avagyan, H.Hambardzumyan, H.Manvelyan (Yerevan, Armenia) 801 Lose-dose lithium therapy improved “off” time without worsened dyskinesias in a patient with Parkinson’s disease T.Guttuso (Buffalo, NY, USA) 802 Observing of the incidence and characteristics of Parkinson’s disease in the neurology clinic of University of Uyo Teaching Hospital, Uyo, Nigeria P.H.John, T.L.Agunbide, L.O.Agumbide, G.A.Omisore, F.O.Dike (Uyo, Nigeria) 803 Meningioma presenting as tremor dominant Parkinsonism T.Khan, S.A.McMahan (Weston, FL, USA) 804 123I-MIBG myocardial scintigraphy and neurocirculatory abnormalities in dementia with Lewy bodies J.S.Kim, H.E.Park, Y.S.Oh, I.S.Park, K.S.Lee (Seoul, Korea) 805 A neuroimaging rating scale with adjustable diagnostic validity to enhance the inter-rater reliability of hummingbird sign Y.J.Kim, Y.E.Kim, S.Y.Kang, H.Ma (Anyang, Korea)
807 Unusual manifestation of dural arteriovenous fistula presenting with Parkinsonism and impaired smooth pursuit eye movement K.H.Kim, Y.S.Park, W.T.Yoon, B.C.Suh, H.S.Moon, P.W.Chung, Y.B.Kim (Seoul, Korea)
809 Effects of isradipine in a transgenic mouse model of multiple system atrophy F.Krismer, M.Schönfeld, H.Oberacher, J.Striessnig, W.Poewe, N.Stefanova, G.K.Wenning (Innsbruck, Austria) 810 Possible neuroprotective mechanism of atorvastatin and simvastatin in experimental model of Parkinson-like symptoms A.Kumar, N.Sharma, J.Mishra (Chandigarh, India) 811 Diffusion tensor imaging of idiopathic normal-pressure hydrocephalus and the cerebrospinal fluid tap test H.W.Lee, P.W.Ko, D.Choi, K.Kang, U.Yoon (Daegu, Korea) 812 Cognitive impairments associated with morphological changes in cortical and subcortical structures in multiple system atrophy of the cerebellar type M.J.Lee, J.H.Shin, J.K.Seoung, J.H.Lee, U.Yoon, J.H.Oh, D.S.Jung, E.J.Kim (Busan, Korea) 813 Retinal nerve fiber layer and retinal thickness changes in multiple system atrophy J.Y.Lee, J.Ahn, T.W.Kim (Seoul, Korea) 814 The contribution of cerebellar cortex to cognitive impairment in multiple system atrophy using a probabilistic MR atlas-based topographic analysis J.J.Lee, D.K.Lee, J.H.Ham, J.M.Lee, Y.H.Sohn, P.H.Lee (Seoul, Korea) 815 American multiple system atrophy natural history study P.A.Low, S.G.Reich, J.Jankovic, C.W.Shults, M.B.Stern, P.Novak, C.M.Tanner, S.Gilman, F.J.Marshall, F.Wooten, B.Racette, T.Chelimsky, W.Singer, S.May, D.M.Sletten, P.Sandroni, J.Mandrekar (Rochester, MN, USA) 816 PROMESA: Progression rate of MSA under EGCG supplementation as anti-aggregation-approach S.Maass, J.Levin, M.Schuberth, A.Giese, U.Mansmann, F.Krismer, G.Wenning, K.Bötzel, G.Höglinger (Munich, Germany) 817 The visual estimation of midbrain to pons ratio combined with cerebrospinal fluid biomarkers improves the diagnostic accuracy of PSP N.Magdalinou, H.Ling, A.Noyce, L.Massey, R.Paterson, J.Schott, I.Davagnanam, C.Micallef, N.Fox, T.Warner, H.Zetterberg, A.Lees (London, United Kingdom) 818 Movements disorders due to toxoplasma abscess in patients with AIDS A.M.Magnerou, V.Sini, P.Ongolo-zogo, Y.Fogang, L.Kaptue (Dakar, Senegal) 819 Elimination of neurotoxic gangliosides protects against MPTP-induced neurodegeneration and executive dysfunction in mouse model of Parkinson’s disease P.Maiti, M.P.McDonald, T.Rex (Memphis, TN, USA) 820 Meningioma presenting as Parkinsonism S.A.McMahan, N.Galvez (Weston, FL, USA)
93
Abstracts by Topic
806 Things better than levodopa in post-encephalitic Parkinsonism R.Kim, C.W.Shin, H.J.Kim, B.S.Jeon (Seoul, Korea)
808 Diagnostic accuracy of multiple system atrophy: An autopsy study of 134 patients S.Koga, N.Aoki, R.J.Uitti, J.A.van Gerpen, W.P.Cheshire, K.A.Josephs, Z.K.Wszolek, W.Langston, D.W.Dickson (Jacksonville, FL, USA)
Abstracts by Topic 821 Unusual phenotype of pathologically confirmed progressive supranuclear palsy K.Mensikova, L.Tuckova, J.Ehrmann, P.Kanovsky (Olomouc, Czech Republic) 822 Fahr’s syndrome presenting with atypical Parkinsonian signs: Case report N.F.Mercan, S.Ozdemir, H.Uyanik, N.Oztekin, F.Ak (Ankara, Turkey) 823 Underlying dopaminergic deficit in suspected drug-induced Parkinsonism is associated with olfactory impairment J.F.Morley, G.Cheng, J.Bubroff, J.R.Wilkinson, J.E.Duda (Philadelphia, PA, USA) 824 Clinical feature of progressive supranuclear palsy with cerebellar ataxia M.Nagai, T.Tsujii, H.Iwaki, R.Andoh, H.Yabe, N.Nishikawa, M.Nomoto (Toon, Japan) 825 Low serum uric acid levels in progressive supranuclear palsy J.M.Oropesa, S.Jesus, I.Huertas, M.Caceres, F.Carrillo, M.Carballo, P.GomezGarre, P.Mir (Seville, Spain) 826 Highly specific radiographic marker predates clinical diagnosis in progressive supranuclear palsy E.K.Owens, K.N.Krecke, J.E.Ahlskog, R.D.Fealey, A.Hassan, K.A.Josephs, B.T.Klassen, J.Y.Matsumoto, J.H.Bower (Rochester, MN, USA) 827 Clinical and pathological characteristics of progressive supranuclear palsy (PSP) clinically misdiagnosed as synucleinopathy: A preliminary analysis A.Pantelyat, L.Rosenthal, K.Mills, G.Pontone, C.Bakker, J.Troncoso, Z.M.Mari (Baltimore, MD, USA) 828 Corticobasal syndrome in a female in a FXTAS family M.Paucar, S.Beniaminov, P.Svenningsson (Stockholm, Sweden) 829 Subacute anterocollis in dementia with Lewy bodies J.Paulson, Y.Zabar, J.Leegwater-Kim (Burlington, MA, USA) 830 Movement disorders in basal ganglia infarction I.Petrov (Skopje, Macedonia) 831 Nigrostriatal degeneration and response to L-dopa in amyotrophic lateral sclerosis: A single patient report P.Pita Lobo, S.Reimão, M.de Carvalho, J.J.Ferreira (Torres Vedras, Portugal)
Abstracts by Topic
832 Role of Manganese in hepatolenticular degeneration: Another pespective of epatic encephalopaty, case report D.Rebolledo, A.Espay, S.Contreras, Z.Rebolledo, J.Esquivel (Toluca, Mexico) 833 Benign progressive supranuclear palsy: A clinicopathological analysis of cases with prolonged survival G.Respondek, C.Kurz, M.Stamelou, L.W.Ferguson, A.Rajput, W.Z.Chiu, J.C.Van Swieten, C.Troakes, S.al Sarraj, E.Gelpi, C.Gaig, E.Tolosa, S.Wagenpfeil, A.Giese, T.Arzberger, G.Hoeglinger (Munich, Germany)
836 Coenzyme Q10 levels are reduced in the cerebellum of multiple system atrophy patients L.V.Schottlaender, C.Bettencourt, A.Kiely, A.Chalasani, V.Neergheen, J.L.Holton, I.P.Hargreaves, H.Houlden (London, United Kingdom) 837 Clinicopathological features and diagnostic criteria for progressive supranuclear palsy with predominant cerebellar ataxia T.Shimohata, M.Kanazawa, H.Takahashi, M.Nishizawa (Niigata, Japan) 838 Heterozygous GBA mutation in a patient with MSA-C: A clinicopathologic report M.Sklerov, A.Vinuela, E.Cortes, R.Kornreich, J.P.Vonsattel, R.Alcalay (New York, NY, USA) 839 Focal 123I-FP-CIT SPECT abnormality in a patient with midbrain vascular Parkinsonism P.Solla, A.Cannas, G.Orofino, R.Arca, M.Meloni, D.Fonti, F.Marrosu (Cagliari, Italy) 840 Multiple system atrophy: About one case P.E.Sounga Bandzouzi, M.A.Magnerou, K.Toure, M.Ndiaye (Dakar, Senegal) 841 Some aspects of life quality improvement in the patients with Parkinson’s disease who underwent treatment using embryo-fetal preparations N.S.Sych, M.A.Klunnyk, E.V.Ivankova, I.G.Matiyashchuk (Kyiv, Ukraine) 842 Pick’s disease presenting with corticobasal syndrome: A review of Parkinsonian features in 23 patients P.Tacik, M.Sanchez Contreras, A.Wojtas, R.B.Perkerson, M.C.Baker, P.Brown, A.J.Strongosky, K.M.Hinkle, S.Fujioka, M.DeTure, N.Kouri, M.E.Murray, N.R.Graff-Radford, R.Rademakers, O.A.Ross, Z.K.Wszolek, D.W.Dickson (Jacksonville, FL, USA) 843 Did Charcot have vascular Parkinsonism? H.A.G.Teive, F.M.B.Germiniani, R.P.Munhoz (Curitiba, PR, Brazil) 844 The effectiveness of zolpidem in progressive supranuclear palsy D.S.Y.Tsui, F.C.F.Chang, N.Mahant, S.D.Kim, J.M.Griffith, M.Drury, V.S.C.Fung (Westmead, Australia) 845 Reversibility of the putaminal dopamine (DA) denervation process during Parkinsonian syndrome: A clinical case report with DA tranporter imageries F.Viallet, D.Gayraud, J.B.Puech, P.Desvignes, S.Siles, B.Bonnefoi (Aix en Provence, France)
PARKINSON’S DISEASE: COGNITION
846 Validation of predictors of dementia in Parkinson’s disease J.B.M.Anang, S.R.Romenets, T.Nomura, R.B.Postuma (Montreal, QC, Canada)
834 Exploring the link between serum uric acid levels, clinical factors, transcranial sonography and cardiac MIBG uptake in Parkinson’s disease and related disorders H.Sakuta, K.Suzuki, A.Numao, M.Miyamoto, T.Miyamoto, Y.Watanabe, H.Fujita, K.Hirata (Mibu, Japan)
847 Urinary dysfunction in progressive supranuclear palsy in comparison to Parkinson’s disease and multiple system atrophy T.Yamamoto, M.Asahina, T.Uchiyama, S.Hirano, Y.Yamanaka, M.Fuse, Y.Koga, M.Yanagisawa, R.Sakakibara, S.Kuwabara (Chiba, Japan)
835 DeglutiSom- Software assist in the clinical evaluation of swallowing in patients with Parkinson’s disease R.S.Santos, M.S.Aoki, A.R.Aoki, C.V.Moraes, H.G.Teive (Curitiba, Brazil)
848 Demographic factors in pre- and post-surgical DBS neuropsychological evaluation S.A.Anderson, C.Bermudez, C.Ghilain, N.Sun-Suslow, M.Forte, I.Babakhanyan, B.Gallo, C.Luca, J.Jagid, C.Singer, B.E.Levin (Miami, FL, USA)
94
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 849 Is it possible to improve cognitive functions through complex gait training in patients with Parkinson’s disease? C.Bedeschi, K.Guedes, F.Iotti, D.Bauer, A.Manfredi, L.Rodrigues, M.E.Piemonte (São Paulo, Brazil)
862 POSET based cognitive function impairment (pCFI): A novel approach for delineating heterogeneity of cognitive impairment in Parkinson’s disease D.K.Gupta, J.G.Goldman, J.Jaeger, C.Tatsuoka (Cleveland, OH, USA)
850 Progression of mobility impairment and motor related quality of life in individuals with Parkinson’s disease: Results from NPF-QII J.Ben, A.Stone, M.S.Okun, J.Nocera, P.Schmidt, S.S.Wu, Q.Pei, C.J.Hass, NPF QII Investigators (Gainesville, FL, USA)
863 Deficits in communication between attentional networks in patients with visual hallucinations in Parkinson’s disease J.M.Hall, J.M.Shine, C.O’Callaghan, A.J.Muller, C.C.Walton, J.Phillips, A.A.Moustafa, S.J.G.Lewis (Camperdown, Australia)
851 PD-MCI: Application of the level I criteria and prediction of PDD J.A.Boel, J.Hoogland, R.M.A.de Bie, J.G.Goldman, B.Schmand, A.I.Tröster, D.J.Burn, I.Litvan, G.J.Geurtsen, The MDS PD-MCI Validation Study Group (Amsterdam, Netherlands) 852 High-frequency exercise improves executive function in individuals with Parkinson’s disease M.C.Caciula, M.Horvat, R.Croce (Statesboro, GA, USA) 853 Subcortical functioning and its relationship to “risk detection” in patients with Parkinson’s disease on different cognitive impairment S.Cano Galindo, D.A.Manjarrez Garduño, H.Durán Meza, M.López, E.Soto Abraham, F.Velasco Campos, D.Trejo Martínez, D.Santana d (Mexico, Mexico) 854 Association of serum uric acid level with cognitive function among patients with multiple system atrophy B.Cao, Q.Wei, R.Ou, J.Yang, B.Zhao, H.Shang (Chengdu, China) 855 Increasing arm motion when walking enhances lower limb coordination in individuals with Parkinson’s disease C.Dalton, J.Nantel (Ottawa, ON, Canada) 856 Language-mediated eye movements in Parkinson’s disease M.Delgado-Alvarado, J.A.Duñabeitia, H.Jimenez-Urbieta, B.Gago, C.Caballero, M.Carreiras, M.C.Rodriguez-Oroz (San Sebastián, Spain) 857 Cognitive impairment and fall rate in Parkinson’s disease (PD) in Nigeria T.H.Farombi, J.O.Yaria, M.O.Owolabi, A.Ogunniyi (Ibadan, Nigeria) 858 Visual hallucinations in Parkinson´s disease with mild cognitive impairment do not imply a more severe cognitive deficit but a more severe cerebral hypometabolism C.Gasca-Salas, P.Clavero, D.García-García, R.González-Redondo, J.Obeso, M.C.Rodríguez-Oroz (Toronto, ON, Canada)
860 Dissociable roles of beta and theta rhythms in the subthalamic nucleus in response inhibition A.Ghahremani, B.Neagu, K.Udupa, U.Saha, A.M.Lozano, S.Najafi, M.Hodaie, S.K.Kalia, R.Chen (Toronto, Canada) 861 Are emotional factors associated with cognitive outcome following DBS? C.Ghilain, S.A.Anderson, N.Sun-Suslow, C.Bermudez, M.Forte, I.Babakhanyan, B.Gallo, C.Luca, J.Jagid, C.Singer, B.E.Levin (Miami, FL, USA)
865 Substantia nigra hyperechogenicity and cognitive functions: Results from the TREND study S.Heinzel, R.Yilmaz, I.Liepelt-Scarfone, B.Roeben, R.Niebler, G.W.Eschweiler, A.J.Fallgatter, F.G.Metzger, W.Maetzler, D.Berg (Tuebingen, Germany) 866 Impact of STN-DBS on cognitive functions in Parkinson´s disease patients: Long-term follow-up study E.Herrera, F.Seijo, E.Suárez-San Martín, F.Cuetos, R.Renée (Oviedo, Spain) 867 Predictive validity of level II PD-MCI criteria for PDD J.Hoogland, J.A.Boel, R.M.A.de Bie, J.G.Goldman, B.Schmand, A.I.Tröster, D.J.Burn, I.Litvan, G.J.Geurtsen, The MDS PD-MCI Validation Study Group (Amsterdam, Netherlands) 868 The effect of dopaminergic medication on perceptual decision-making in Parkinson’s disease as a function of task difficulty and speed-accuracy instructions Y.T.Huang, D.Georgiev, M.Speekenbrink, T.Foltynie, P.Limousin, M.Jahanshahi (London, United Kingdom) 869 Deep brain stimulation of the subthalamic nucleus is associated with lower response thresholds when patients with Parkinson’s disease act under speed pressure M.Jahanshahi, I.Pote, M.Torkamani, Z.M.Kefalopoulou, L.Zrinzo, P.Limousin, T.Foltynie, M.Speekenbrink (London, United Kingdom) 870 Relationship between neuropsychological function and speech in individuals with Parkinson’s disease C.B.Johnson, J.E.Huber, G.C.Sprehn, S.E.Zauber (Indianapolis, IN, USA) 871 Leptin and insulin; biomarkers for cognitive impairment in Parkinson’s disease? ICICLE-PD 36 month interim analysis F.A.Johnston, R.A.Lawson, T.K.Khoo, A.J.Yarnall, G.W.Duncan, S.Coleman, D.Brooks, R.A.Barker, D.J.Burn (Newcastle upon Tyne, United Kingdom) 872 Can we improve attention in Parkinson’s disease? A pilot study S.A.H.Jones, J.Green, G.A.Eskes (Halifax, NS, Canada) 873 Cognitive impairment in Parkinson’s disease with SWEDDs S.J.Kang, J.Y.Ahn, H.Choi, H.T.Kim (Seoul, Korea) 874 Cerebral hypometabolism based on a cutoff point on the mini-mental status examination for cognitive impairment in de novo PD S.J.Kim (Busan, Korea) 875 Withdrawn by Author
95
Abstracts by Topic
859 Using virtual reality to investigate the deficits in voluntary gait initiation and cessation in patients with Parkinson’s disease and freezing of gait M.J.Georgiades, M.Gilat, J.M.Shine, S.J.G.Lewis (Sydney, Australia)
864 Ecological validity of executive functions: Predicting disability in Parkinson’s disease B.Hanna-Pladdy, K.Mordecai, T.Hill, M.Mickens, F.Ivey, L.Shulman (Baltimore, MD, USA)
Abstracts by Topic 876 Sensitivity of the Greek version of the Montreal cognitive assessment (MoCA) in the dementia of Parkinson’s disease K.Konstantopoulos, E.Petsa, T.Stefanaki, T.Doskas (Nicosia, Cyprus) 877 Does prolonged use of anticholinergic medication contribute to cognitive impairment in early Parkinson’s disease? R.A.Lawson, A.J.Yarnall, G.W.Duncan, D.P.Breen, T.K.Khoo, D.Brooks, R.A.Barker, D.Collerton, J.P.Taylor, D.J.Burn (Newcastle upon Tyne, United Kingdom)
890 Usefulness of MoCA in cognitive function evaluation of Parkinson’s disease patients M.Saruwatari, K.Hasegawa, A.Kumon, Y.Kobayashi (Sagamihara, Japan)
878 Cognitive change in Parkinson’s disease and progression of frontal-striatal deficits S.A.T.Levy, J.J.Tanner, M.S.Okun, D.Bowers, C.C.Price (Gainesville, FL, USA)
891 Effort to reduce postural sway decreases both cognitive performance and postural stability in individuals with Parkinson’s disease R.Sciadas, C.Dalton, J.Nantel (Ottawa, ON, Canada)
879 Plasma epidermal growth factor as a cognitive biomarker in Parkinson’s disease and Alzheimer’s disease N.S.Lim, C.R.Swanson, D.Weintraub, J.Q.Trojanowski, A.S.Chen-Plotkin (Philadelphia, PA, USA)
892 Cognition and depression in Mexican early-onset Parkinson´s disease patients A.N.Seubert Ravelo, G.Yáñez Téllez, R.E.Escartín Pérez, H.Salgado Ceballos, G.A.Neri Nani (Mexico City, Mexico)
880 Daily living functionality and cognitive functions in Parkinson’s disease: Functional diversity across cortical and subcortical systems D.A.Manjarrez, H.Durán, S.Cano, M.López, E.Soto, F.Velasco, D.Trejo, D.Trejo (Mexico, Mexico)
893 Deterioration of semantic memory in Parkinson’s disease and the implications to embodied cognition H.S.Silva, M.S.G.Rocha, R.R.Baradel, M.A.P.Parente, F.F.Godinho, A.Cravo, J.R.Sato, M.T.Carthery-Goulart (São Paulo, Brazil)
881 Gait predicts decline in attention over three years in an incident cohort of Parkinson’s disease R.Morris, J.Bunce, B.Galna, S.Lord, D.Burn, L.Rochester (Newcastle upon Tyne, United Kingdom) 882 Executive dysfunction in a sample of patients with Parkinson´s disease in Cali – Colombia B.E.Muñoz, Y.J.Ariza, J.L.Orozco (Cali, Colombia) 883 Individualised medicine using an abbreviated cognitive screen for dementia prediction in Parkinson’s disease D.J.Myall, K.L.Wood, L.Livingston, T.L.Pitcher, T.R.Melzer, M.R.MacAskill, T.J.Anderson, J.C.Dalrymple-Alford (Christchurch, New Zealand) 884 Contribution of auditory P300 test in the diagnosis of mild cognitive impairment in Parkinson’s disease S.Ozkaynak, F.Yilmaz, E.Barcin (Antalya, Turkey) 885 Cognitive effects of atomoxetine in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)treated macaque model of Parkinson’s disease E.Pioli, J.Schneider, Y.Jianzhong, Q.Li, A.Crossman, E.Bezard, W.Martin (Manchester, United Kingdom) 886 Gray and white matter predictors of cognitive frontal-striatal deficits in Parkinson’s disease C.C.Price, J.J.Tanner, S.A.T.Levy, M.S.Okun, D.Bowers (Gainesville, FL, USA)
Abstracts by Topic
889 Cognition in Parkinson’s disease and essential tremor: A population-based comparative study Á.Sánchez-Ferro, J.Benito-León, I.Contador, J.Hernández-Gallego, V.PuertasMartín, F.Bermejo-Pareja (Cambridge, MA, USA)
887 Improving dementia diagnosis in Parkinson’s disease M.S.G.Rocha, M.O.Oliveira, A.T.Neves, C.D.M.Costa, R.G.Kauark, S.M.D.Brucki (São Paulo, Brazil) 888 Pattern of working memory deficit in REM sleep behaviour disorder is the same as in Parkinson’s disease M.Rolinski, N.Zokaei, C.E.Mackay, M.Husain, M.T.M.Hu (Oxford, United Kingdom)
96
894 Word finding difficulty and its functional significance in Parkinson’s disease: A novel measure using pauses in speech K.M.Smith, S.Ash, M.Grossman (Philadelphia, PA, USA) 895 Visual exploration during gait in Parkinson’s disease and association with cognitive characteristics S.G.Stuart, H.King, B.Galna, A.Godfrey, S.Lord, L.Rochester (Newcastle upon Tyne, United Kingdom) 896 The relationships between mild cognitive impairment and phenotype in Parkinson’s disease J.Y.Y.Szeto, C.O’Callaghan, J.M.Shine, C.C.Walton, S.L.Naismith, G.M.Halliday, S.J.G.Lewis (Camperdown, Australia) 897 Temporal lobe and frontal-subcortical dissociations in non-demented Parkinson’s disease with verbal memory impairment J.J.Tanner, T.H.Mareci, M.S.Okun, D.Bowers, D.J.Libon, C.C.Price (Gainesville, FL, USA) 898 Linguistic ability in patients with Parkinson’s disease: Can it predict future memory deficits? N.Valle Guzman, C.Williams Gray, R.Barker (Cambridge, United Kingdom) 899 Improving cognitive functioning and quality of life through Dance for PD: A pilot intervention trial M.I.Ventura, J.M.Ross, K.E.Lanni, K.A.Sigvardt, E.A.Disbrow (San Francisco, CA, USA) 900 Is exercise more important for cognition and mood in Parkinson’s disease patients than normal elderly? D.M.Wald, J.D.Jones, T.L.Cummings, A.Mikos, R.Rodriguez, M.S.Okun, C.Hass, D.Bowers (Gainesville, FL, USA) 901 Cognitlvely protectlive effects on PD model rats by electrical acupuncture treatment X.Wang, L.Han (Shanghai, China)
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 902 Long-term outcomes for Parkinson’s disease patients with normal cognition D.Weintraub, K.Pigott, J.Rick, S.X.Xie, H.Hurtig, A.Chen-Plotkin, J.Duda, J.Morley, L.Chahine, N.Dahodwala, R.Akhtar, A.Siderowf, J.Trojanowski (Philadelphia, PA, USA)
915 Reliability and discriminant validity of ataxia rating scales in early onset ataxia R.Brandsma, T.F.Lawerman, M.J.Kuiper, J.T.van Geffen, I.J.Lunsing, H.Burger, T.J.de Koning, J.J.de Vries, M.A.J.de Koning-Tijssen, D.A.Sival (Groningen, Netherlands)
903 Frequency of subthalamic nucleus (STN) stimulation in Parkinson’s disease (PD) modifies response accuracy in a decision making task K.Witt, T.Sauer, G.Deuschl (Kiel, Germany)
916 Congenital pyramidal signs and cerebellar ataxia with abnormal pyramidal decussation - A new syndrome A.Castro Caldas, S.Reimão, L.Correia Guedes, M.Miguel Rosa, J.J Ferreira, M.Coelho (Lisbon, Portugal)
904 Characterizing neuropsychological impairment in Parkinson’s disease D.T.Woods, A.C.Kneebone (Sydney, Australia)
917 Impaired brain GABA in spinocerebellar ataxia type 7: A magnetic resonance spectroscopy study H.J.S.Cho, P.Panyakaew, B.P.Brooks, S.G.Horovitz, M.Hallett (Bethesda, MD, USA)
905 The analysis of cognitive impairment associated with Parkinson’s disease (PD-CI) Q.Yang, Z.Mao, S.Ji, H.Ye, Z.Xue (Wuhan, China)
918 Spinocerebellar ataxia type 10 in Peruvian population: Clinical features of 17 families I.F.Cornejo-Herrera, D.M.Veliz-Otani, M.R.Cornejo-Olivas, M.A.Inca-Martinez, K.A.Espinoza-Huertas, V.Marca, O.Oterga, R.Castilhos, G.Bampi, M.Flores, M.L.Saraiva-Pereira, L.B.Jardim, P.Mazzetti (Lima, Peru)
PATHOPHYSIOLOGY (OTHER MOVEMENT DISORDERS)
906 Neurodegeneration or neuroinflammation in Parkinson’s and Huntington diseases. What goes first? D.A.Labunskiy, T.A.Fedotova, V.V.Poleshchuk (Santa Rosa, CA, USA) 907 Analysis of heart rate variability in functional movement disorder patients V.T.Liu, C.W.Maurer, K.LaFaver, R.Toledo, M.Hallett (Bethesda, MD, USA) 908 Frontal gait disorders: DTI corpus callosal integrity correlates with stride width and cognitive function M.Livingston Dale, B.W.Fling, M.Mancini, D.S.Peterson, C.Curtze, K.Smulders, M.Fleming, F.B.Horak, J.G.Nutt (Portland, OR, USA) 909 Detection of alpha-synuclein seeding activity using a novel assay T.R.Yamasaki, B.B.Holmes, J.L.Furman, D.Dhavale, P.T.Kotzbauer, M.I.Diamond (St.Louis, MO, USA)
ATAXIA
910 Anti-glial nuclear antibody (AGNA) associated encephalitis without underlying malignancy presenting with opsoclonus and ataxia L.Avedian, S.Rashid, E.George, O.Oguh, E.Gaitour, N.Shneyder (Detroit, MI, USA) 911 Spinocerebellar ataxia type 6 in Eastern India: A new observation K.B.Bhattacharyya, D.Pulai, D.Guin, G.Ganguly, A.Biswas, A.Pandit, A.Joardar, S.Roy, A.Roy, A.Senapati (Kolkata, India)
913 Psychosis in Machado-Joseph disease: Clinical correlates, pathophysiological discussion and functional brain imaging. Expanding the cerebellar cognitive affective syndrome P.Braga-Neto, J.L.Pedroso, M.R.Laureano, A.Gadelha, C.d.S.Noto, G.E.J.de Garrido, O.G.P.Barsottini (São Paulo, Brazil) 914 The use of adjustments to facilitate writing in patients diagnosed with spinocerebellar ataxia F.M.Branco Germiniani, T.V.Canelossi Rosa, R.Nickel, P.R.S.Liberalesso, H.A.G.Teive (Curitiba, Brazil)
920 Neurotechnology biomarkers in Friedreich’s ataxia S.Nageshwaran, C.Gavriel, A.Sylaidi, P.Lourenco, S.Athanasopoulos, R.Lorenz, A.Thomik, R.Festenstein, A.Faisal (London, United Kingdom) 921 The splenium of the corpus callosum sign in fragile X associated tremor ataxia syndrome (FXTAS) D.Hall, M.Hermanson, M.Jhaveri, G.Stebbins, E.Dunn, D.Merkitch, E.Berry-Kravis (Chicago, IL, USA) 922 Neuropathology of Parkinsonism in spinocerebellar ataxia type 6: A case report D.Kaul, K.W.Morley, M.Pakalniskis, W.F.Hickey, S.L.Lee (Lebanon, NH, USA) 923 Atypical spinal cord atrophy in Friedreich ataxia P.Khemani, Z.Yetkin (Dallas, TX, USA) 924 Clinical evaluation in children with ataxia in a children rehabilitation centre A.P.Kleinert-Altamirano, F.G.Perdomo-Rebollo (Tuxtla Gutiérrez, Mexico) 925 European SARA age validation trial in children -Preliminary resultsT.F.Lawerman, R.Brandsma, N.Barisic, P.Baxter, E.Bertini, V.Brankovic, J.G.M.Burgerhof, G.E.Calabro, C.E.Catsman-Berrevoets, D.Craiu, I.F.M.de Coo, B.Dan, J.Gburek-Augustat, F.F.Kamoun, C.Kennedy, R.J.Lunsing, F.Mancini, M.Mirabelli-Badenier, M.Steinlin, M.Synofzik, C.C.Triki, E.M.Valente, G.Vasco, D.A.Sival (Groningen, Netherlands) 926 Sleep architecture observed in the patients with SCA 10 E.London, A.C.Crippa, H.A.G.Teive, A.Moro, M.Moscovich, T.Ashizawa (Curitiba, Brazil) 927 Wide spectrum of clinical presentation of ataxia with occulomotor apraxia type II S.O.Mittal, D.G.Machado (Cleveland, OH, USA)
97
Abstracts by Topic
912 Ataxia: Classification and epidemiology R.S.Boddepalli, K.Kurako, N.Galvez-Jimenez (Weston, FL, USA)
919 Mutation screening of AFG3L2 in Indian cerebellar ataxia patients: an early onset cerebellar ataxia with digenic mutations in AAAproteases ideintified through whole exome sequencing M.Faruq, R.Kumari, V.Suroliya, A.K.Srivastava (New Delhi, India)
Abstracts by Topic 928 Characteristic movement disorders in patients with spinocerebellar atrophy type 2 N.Miyaue, R.Ando, T.Iwaki, H.Yabe, N.Nishikawa, M.Nagai, M.Kaneda, H.Takashima, M.Nomoto (Tohon Ehime, Japan) 929 Analysis of gait parameter in spino-cerebellar ataxia patients using electronic walkway: With and without cognitive load B.Mondal, S.Choudhury, P.Chatterjee, M.U.Kulsum, S.S.Anand, H.Kumar (Kolkata, India) 930 Idiopathic very late-onset cerebellar ataxia: A Brazilian case series A.Moro, M.M.Moscovich, W.O.Arruda, R.P.Munhoz, H.A.G.Teive (Curitiba, Brazil) 931 Comparison of non-motors symptoms in patients with spinocerebellar ataxia type 10 and type 3 A.Moro, R.P.Munhoz, M.Moscovich, M.Farah, W.O.Arruda, S.Raskin, T.Ashizawa, H.G.Teive (Curitiba, Brazil) 932 HMG-CoA reductase inhibitors – induced cerebellar ataxia. A Brazilian case series M.M.Moscovich, A.Moro, W.O.Arruda, R.P.Munhoz, H.A.G.Teive (Curitiba, Brazil) 933 Cerebellar features in spastic paraplegia: A cohort analysis W.Nachbauer, A.Neureiter, A.Eigentler, W.Poewe, S.Boesch (Innsbruck, Austria) 934 Nicotinamide given once daily is more effective than twice daily at increasing frataxin expression in Friedreich’s ataxia S.Nageshwaran, S.Athanasopoulos, C.Georgiadou, C.Yandim, T.Natisvili, P.P.Law, P.K.Chan, V.Libri, N.Loyse, P.Giunti, R.Festenstein (London, United Kingdom) 935 49 year old male with rapidly progressive cerebellar ataxia secondary to non-paraneoplastic voltage-gated calcium channel antibodies (VGCC): Case report S.Patel, I.Itin (Cleveland, OH, USA)
943 Strabismus and eye movement deficits in Machado-Joseph disease A.G.Shaikh, G.Wilmot, A.Ahmed, F.F.Ghasia (Cleveland, OH, USA) 944 A unique combination of spinocerebellar ataxia type 2 and 3 mutations in a patient S.Shakya, V.Suroliya, M.Faruq, A.K.Srivastava, I.Singh, A.Garg, M.Mukerji, G.Shukla, V.Goyal, M.Behari (New Delhi, India) 945 India share the common mitochondrial lineage with Caucasians with increased load of mitochondrial variations in Friedreich’s ataxia (FRDA) patients I.Singh, S.Shakya, M.Faruq, A.K.Srivastava, M.V.Padma, M.Behari, M.Mukerji (New Delhi, India) 946 Autosomal recessive cerebellar ataxias in India: Genetic heterogeneity and mutation spectrum revealed by whole exome sequencing A.K.Srivastava, M.Faruq, S.Shakya, R.Kumari, P.Dakle, D.Dash, M.Mukerji, A.Garg, G.Shukla, V.Goyal, M.Behari (New Delhi, India) 947 Case of spinocerebellar ataxia type-12 associated with only 43 CAG repeats in PPP2R2B gene A.Takkar, M.Faruq, S.Shakya, A.Garg, A.K.Srivastava (New Delhi, India) 948 Sympathetically induced sudomotor and cold pressor test in patients of spinocerebellar ataxia 2: A preliminary study D.Tamuli, M.Faruq, A.K.Jaryal, A.K.Srivastava, K.K.Deepak (New Delhi, India)
936 A family affected by SCA27 caused by interstitial chromosome 13q33.1 deletion M.Paucar, J.Lundin, P.Svenningsson, E.Iwarsson, Movement Disorder Group (Stockholm, Sweden)
949 Distal hereditary motor neuropathy with HSJ1 chaperone mutation, presenting with peripheral motor neuropathy, associated to Parkinsonism, and cerebellar ataxia. Case report H.A.G.Teive, W.O.Arruda, R.H.Scola, L.C.Werneck, F.Kok (Curitiba, Brazil)
937 A new SCA19/SCA22 family with the T377M variant in the KCND3 gene M.Paucar, M.Nordenskjöld, P.Svenningsson (Stockholm, Sweden)
950 Estimation of skeletal muscle mass in patients with spinocerebellar ataxia H.G.Teive, C.A.Leite, M.E.Schieferdecker, R.M.Vilela, D.S.Macedo (Curitiba, Brazil)
938 Adult-onset cerebellar ataxia as a presentation of Langerhans cell histiocytosis J.M.Pyun, H.Y.Park, K.C.Moon, B.S.Jeon (Seoul, Korea)
951 Anthropometric profile of patients with spinocerebellar ataxia H.G.Teive, C.A.Leite, M.E.Schieferdecker, R.M.Vilela, D.S.Macedo (Curitiba, Brazil)
939 Quantitative gait and balance testing for NPH J.F.Quinn, S.Jewell, M.Fleming, S.O’Connor, M.Mancini (Portland, OR, USA)
952 Deep brain stimulation of the dentate nucleus improves cerebellar ataxia: A double-blind n=1 study M.J.Teixeira, R.G.Cury, R.Galhardoni, V.R.Barboza, E.Alho, C.M.Seixas, G.Lepski, D.Ciampi de Andrade (São Paulo, Brazil)
940 Withdrawn by Author
Abstracts by Topic
942 Sensor-based gait assessment in ataxia: disturbance of armswing and trunk motility does not run in parallel with impaired stepping T.Schmitz-Hübsch, A.U.Brandt, C.Pfueller, A.Seidel, T.Klockgether, F.Paul, A.Kühn, M.Minnerop, S.Doss (Berlin, Germany)
941 Exome sequencing as a diagnostic tool for hereditary ataxias: Our experience in a neurogenetic center from Buenos AiresArgentina S.A.Rodrìguez-Quiroga, C.Marta, D.Gonzalez-Moròn, E.M.Gatto, S.Gonorazky, P.Vega, N.Medina, C.Vazquez Dusefante, T.Arakaki, N.S.Garretto, M.A.Kauffman (Caba, Argentina)
98
953 SCA2 presenting as a focal dystonia H.M.Wied, J.J.Gaul, L.E.Doyle, S.G.Reich (Baltimore, MD, USA) 954 Withdrawn by Author 955 Recurrent episodic isolated nystagmus associated with GAD antibody positivity Z.Xu, P.X.Koh, N.K.Loh, T.Umapathi, J.Y.H.Chia (Singapore, Singapore)
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 956 Clinical characteristics of patients with paraneoplastic cerebellar degeneration Z.Xu, L.C.Tan (Singapore) 957 Neurotological findings prevalent in ataxias hereditary B.S.Zeigelboim, H.A.G.Teive, E.S.Abdulmassih, R.C.Cardoso, G.Santos, M.I.Severiano, R.Sampaio (Curitiba, Brazil) 958 Vestibular disease in patients with Friedreich ataxia B.S.Zeigelboim, H.A.G.Teive, R.C.Cardoso, G.Santos, M.I.Severiano, J.H.Faryniuk (Curitiba, Brazil) 959 Vestibular rehabilitation with virtual reality in spinocerebellar ataxia B.S.Zeigelboim, H.A.G.Teive, R.C.Cardoso, G.Santos, M.I.Severiano, P.B.N.Liberalesso, J.H.Faryniuk, V.R.Fonseca (Curitiba, Brazil)
EDUCATION IN MOVEMENT DISORDERS
960 First Middle East camp for Parkinson’s disease, movement disorders and neuromodulation: Review of outcomes and implications for future directions J.A.Bajwa, H.Khalil (Riyadh, Saudi Arabia) 961 Movement disorders and the media B.R.Barton, K.Kompoliti (Chicago, IL, USA) 962 How can we better educate study participants for an improved informed consent? Taking a look at Parkinson’s disease transplant trials N.Hellmers, I.de Melo-Martin, C.Henchcliffe (New York, NY, USA) 963 Evidence-based, patient-centered physiotherapy for people with Parkinson’s: A pilot implementation of the Dutch ParkinsonNet concept in Germany S.H.J.Keus, M.Munneke, M.J.Nijkrake, K.Krebber, C.Schaffelder, H.Woltjer, F.Radefeld, A.Schniederjan, H.Grehl, B.R.Bloem (Nijmegen, Netherlands) 964 The contributions of continuing education in dysphagia for pediatric nursing care in a teaching hospital V.D.Leonor, R.S.Santos, R.G.Senff, B.S.Zeigelboim, H.G.Teive (Curitiba, Brazil) 965 Efficacy of an education and exercise group on understanding of Parkinson’s and uptake of exercise in people with Parkinson’s disease F.A.Lindop, R.H.Skelly (Derby, United Kingdom) 966 Medication errors prolong length of stay in hospitalized Parkinson’s disease patients D.Martinez-Ramirez, J.C.Giugni, C.Little, J.P.Chapman, B.Ahmed, E.Monari, M.S.Okun (Gainesville, FL, USA)
NEUROIMAGING
968 Parkinson’s progression markers initiative (PPMI) prodromal cohort of REM behavior disorder (RBD) with DAT deficit Parkinson’s Progression Markers Initiative (PPMI) RBD Investigators (New Haven, CT, USA)
970 Arterial spin labelling (ASL) reveals an abnormal cerebral perfusion pattern in Parkinson’s disease K.Abe, T.Hayashi, M.Yamamoto, N.Akiyama, M.Fujita (Nishinomiya, Japan) 971 Brain amyloid-β content is associated with cognitive decline in Parkinson’s disease: A cross sectional study using [F18] FDDNP PET and CSF Aβ levels F.Antonelli, M.T.Buongiorno, Y.Compta, Y.Fernandez, J.Pavia, F.Lomena, J.Garcia, I.Ramirez, A.Camara, M.Fernandez, M.Soler, X.Perez, J.Barrio, M.J.Marti (Barcelona, Spain) 972 Brain connectivity changes associated with t-DCS and cognitive training plus cognitive training in Parkinson’s disease with mild cognitive impairment R.Biundo, L.Weis, E.Fiorenzato, G.Gentile, M.Giglio, M.Campo, R.Schifano, A.Antonini (Venice-Lido, Italy) 973 Substantia nigra echogenicity and oddor discrimination in REM-sleep behavior disorder and Parkinson’s disease J.Carlos, V.Pablo, U.S.Reinaldo, N.Cristobal, S.Julia, G.Jaime (Santiago, Chile) 974 Comparison between oddor discrimination, substantia nigra echogenicity and nigrostriatal dopaminergic activity measured by 18F.PR04 PET in Parkinson’s disease J.Carlos, V.Pablo, C.Pedro, K.Vasko, P.Rosana, A.Horacio (Santiago, Chile) 975 Functional connectivity in Parkinson’s disease is differentially impacted by alpha-synuclein and amyloid D.O.Claassen, S.Rane (Nashville, TN, USA) 976 White matter microstructure in idiopathic craniocervical dystonia A.D’Abreu, G.L.Pinheiro, R.P.Guimarães, B.M.Campos, F.Cendes (Campinas, Brazil) 977 Pattern of regional cortical thickness in patients with Parkinson’s disease and impulse control disorders R.De Micco, G.Santangelo, C.Vitale, A.Tessitore, M.Amboni, D.Corbo, A.Giordano, P.Barone, G.Tedeschi (Naples, Italy) 978 Lead location for subthalamic nucleus deep brain stimulation using a 3d visualization tool M.Del Álamo, I.Avilés, F.Estella, L.Cabañes, I.Regidor (Madrid, Spain) 979 MRI findings in a rare case of sporadic Creutzfeldt-Jacob disease presenting as progressive supranuclear palsy A.Duffy, B.Koo, K.Park, M.Bobinski, L.Zhang (Sacramento, CA, USA) 980 Comparison of baseline 123-I Ioflupane SPECT striatal binding ratios with diffusion tensor images from the Parkinson’s progression marker initiative C.L.Gallagher, J.Sojkova, B.B.Bendlin, O.Okonkwo, A.Alexander, I.W.Wu, N.Schuff (Madison, WI, USA)
Abstracts by Topic
967 Knowledge and awareness regarding Parkinson’s disease in general population – Truth and prejudice I.Telarovic, S.Telarovic (Zagreb, Croatia)
969 Rat brain basal ganglia imaged with optical coherence tomography: Feasibility and future perspectives J.S.dos Ângelos, W.O.C.Lopez, R.C.R.Martinez, P.R.Reis, C.K.Takimura, M.J.Teixeira, P.A.Lemos Neto, E.T.Fonoff (Sao Paulo, Brazil)
981 HemiParkinsonism leading to the discovery of a large epidermoid tumor R.Garcia-Santibanez, H.Sarva, A.Khorsandi, R.K.Shrivastava, W.L.Severt, D.MacGowan (New York, NY, USA)
99
Abstracts by Topic 982 Longitudinal evaluation of brain atrophy in Parkinson’s ‘s disease and Parkinson’s plus syndromes C.Guevara (Providencia, Chile)
995 Longitudinal assessment of subcortical volume and iron content in two variants of multiple system atrophy J.H.Lee, T.H.Kim, T.H.Kim (Yangsan-si, Gyeongsangnamdo, Korea)
983 Metabolic changes associated with slow dopaminergic depletion: A longitudinal PET study in the MPTP primate model of Parkinson’s disease L.F.Hernandez, F.Molinet-Dronda, J.Blesa, C.Juri, M.Collantes, E.Iglesias, I.Peñuelas, J.A.Obeso (Pamplona, Spain)
996 DaTscan: Correlation of clinical phenotype and and scan concordance: A retrospective study K.H.Longfellow, G.Hu, S.Minoshima, S.Elman, D.Lewis (Seattle, WA, USA)
984 Assessment of outcomes in Parkinson’s disease subjects randomized to SPECT imaging of the dopamine transporter P.T.Hickey, M.Kuchibhatla, B.L.Scott, L.Gauger, M.A.Stacy (Durham, NC, USA)
997 The role of the frontal lobe in complex walking tasks in healthy older adults and patients with Parkinson’s disease: An fNIRS study I.Maidan, H.Bernad-Elazari, F.Nieuwhof, M.Reelick, N.Giladi, J.Deutsch, J.Hausdorff, A.Mirelman (Tel Aviv, Israel)
985 The decreasing of dopamine-transporter uptake on the right ipsilateral side of tremor in a patient with Parkinson’s disease E.Hoshiyama, T.Kadowaki, A.Nakamura, K.Suzuki, K.Hashimoto, K.Hirata (Tochigi, Japan)
998 Midbrain MR planimetry in neurodegenerative Parkinsonism: Comparison between 1.5 and 3 Tesla MRI S.Mangesius, A.Hussl, B.Heim, C.Müller, B.Pinter, E.Reiter, M.Schocke, W.Poewe, K.Seppi (Innsbruck, Austria)
986 The role of DaT scan in drug induced Parkinsonism R.Irons, B.M.Joanna, C.K.Apurba (Reading, United Kingdom)
999 Automatic and non-automatic gait: Identifying two different networks using functional MRI V.Marchal, J.Sellers, C.Gallea, E.Bertasi, R.Valabregue, P.Leboucher, B.Lau, M.L.Welter, E.Bardinet, C.Karachi (Paris, France)
987 Longitudinal imaging and phenoconversion in the PARS prodromal cohort D.Jennings, M.Stern, A.Siderowf, S.Eberly, D.Oakes, K.Marek, PARS Investigators (New Haven, CT, USA) 988 Quantitative assessment of iron deposition in Parkinson’s disease using enhanced T2 star weighted angiography (ESWAN) Q.S.Ji, S.Zhang, J.Z.Mao, Y.H.Han, M.Q.Yang, Z.W.Zhu, Q.S.Zhu, Z.Xue (Wuhan, China)
1001 Longitudinal functional MRI studies of Parkinson’s disease patients with and without mild cognitive impairment O.Monchi, M.Al-Azzawi, A.Nagano-Saito, B.Mejia-Constain, C.Degroot, A.Hanganu, A.L.Lafontaine (Calgary, AB, Canada)
989 Longitudinal [11C]BF-227 PET study in MSA-C patients A.Kikuchi, N.Okamura, M.Tashiro, S.Furumoto, T.Hasegawa, S.Watanuki, K.Hiraoka, Y.Funaki, T.Baba, M.Kobayashi, N.Sugeno, M.Konno, E.Miura, R.Oshima, S.Yoshida, R.Iwata, S.Takahashi, H.Fukuda, Y.Itoyama, H.Arai, Y.Kudo, K.Yanai, M.Aoki, A.Takeda (Sendai, Japan)
1002 Anatomical differences in white matter integrity between idiopathic normal pressure hydrocephalus and secondary obstructive hydrocephalus: Diffusion tensor study N.Nishida, H.Toda, R.Okumura, H.Hashikata, N.Ikeda, Y.Kang, M.Ishikawa, K.Iwasaki (Osaka, Japan)
990 Cognitive impairment and its structural correlates in the Parkinsonian subtype of multiple system atrophy J.S.Kim, J.J.Yang, D.K.Lee, J.M.Lee, J.Youn, Y.E.Huh, J.W.Cho (Seoul, Korea)
1003 GABA (gamma-aminobutyric acid) in essential tremor: An MR spectroscopy study P.Panyakaew, H.J.Cho, S.Horovits, M.Hallett (Bethesda, MD, USA)
991 Diagnosis of Parkinsonism with 3T MR image of nigrosome-1: Correlation between susceptibility-weighted imaging and ¹²³I-FP-CIT-SPECT findings K.J.Kim, J.M.Kim (Seongnam, Korea)
1004 First Latin American experience in the assessment of striatal dopaminergic uptake in patients with Parkinson’s disease by means of co-registered 18F-DOPA PET/CT and MRI images M.C.Peralta, D.Menna, M.Aguilar, H.Corradini, A.Perez, A.Valda, F.Biafore, J.A.Gili, M.J.Bastianello (Caba, Argentina)
992 Diagnosis of Parkinsonism by 7 Tesla MRI J.M.Kim, K.J.Kim, Y.J.Bae, E.Kim, S.Y.Kang, E.S.Oh, H.J.Jeong, S.E.Kim, Z.H.Cho, B.S.Jeon (Seongnam, Korea)
Abstracts by Topic
1000 Mechanisms underlying impaired self-agency in functional movement disorders: A resting state fMRI study C.W.Maurer, S.Horovitz, K.LaFaver, M.Hallett (Bethesda, MD, USA)
993 A functional neuroradiological study in an adult case of betapropeller protein-associated neurodegeneration S.Kumada, I.Hayakawa, Y.Nakata, E.Yoshida-Kasai, S.Uchino, Y.Hachiya, E.Kurihara, F.Yokochi (Tokyo, Japan) 994 The usefulness of magnetic resonance imaging on Parkinsonian multiple system atrophy before the occurrence of autonomic dysfunction W.W.Lee, J.Shin, H.J.Kim, H.Park, C.W.Shin, B.S.Jeon (Seoul, Korea)
100
1006 Transcranial sonography of the substantia nigra in Parkinson’s disease (PD) and controls: Distinguishing PD and controls by two different measurement strategies M.Pondal, A.E.Lang, C.Marras (Toronto, ON, Canada) 1007 Neural substrates for head movements in cervical dystonia: A functional magnetic resonance imaging study C.N.Prudente, R.Stilla, S.Singh, C.Buetefisch, X.Hu, E.J.Hess, K.Sathian, H.A.Jinnah (Atlanta, GA, USA) 1008 Region-of-interest analysis of multimodal MR imaging at 3 Tesla differentiating between Parkinson´s disease (PD) and atypical Parkinsonian syndromes (APS) E.Reiter, C.Mueller, B.Pinter, R.Esterhammer, W.Poewe, C.Scherfler, K.Seppi, M.Schocke (Innsbruck, Austria)
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 1009 Motor and non-motor features of Parkinson’s disease in idiopathic REM sleep behaviour disorder M.Rolinski, L.Griffanti, K.Szewczyk-Krolikowski, R.A.Menke, T.Quinnell, Z.Zaiwalla, C.E.Mackay, M.T.M.Hu (Oxford, United Kingdom)
1020 Case of a man with early Parkinson’s disease with a history of essential tremor running in the family G.Avagyan, A.Sahakyan, I.Gabrielyan, S.Khachaturyan, K.Harutyunyan, H.Manvelyan, A.Voskanyan, A.Nazaryan (Yerevan, Armenia)
1010 Dopamine transporter scan (DaTscan) and clinical global impression of severity of Parkinson’s disease: Data from a non motor natural history study A.Sauerbier, P.Martinez-Martin, M.Politis, A.Rizos, N.Troja, N.Mulholland, G.Vivian, B.Cocoran, D.Trivedi, L.Perkins, R.Inniss, M.Parry, A.Martin, R.Brown, K.Ray Chaudhuri (London, United Kingdom)
1021 TOMM40 SNPs and multiple types of dementia L.Bekris, D.Tsuang, J.Leverenz, C.E.Yu, O.Lopez, R.Hamilton, D.Bennett, J.Schneider, A.Buchman, E.Larson, P.Crane, J.Kaye, P.Kramer, R.Woltjer, J.Trojanowski, D.Weintraub, A.Chen-Plotkin, D.Irwin, J.Rick, G.Schellenberg, S.Watson, W.Kukull, P.Nelson, G.Jicha, J.Neltner, D.Galasko, E.Masliah, J.Quinn, K.Chung, D.Yearout, I.Mata, K.Edwards, T.Montine, C.Zabetian (Cleveland, OH, USA)
1011 Imaging neurodegeneration in movement disorders: A VBM study M.Saxena, B.Rana, A.Juneja, S.S.Kumaran, R.Agrawal, M.Behari (New Delhi, India) 1012 Resting state fMRI differentiates essential tremor patients from controls Q.Shen, P.Pattany, S.Sargolzaei, A.Sarou, B.Fortes, H.Islam, P.Kundu, A.Avila, F.B.Nahab (La Jolla, CA, USA) 1013 Unilateral blepharospasm associated with invasive lacrimal gland tumor H.A.G.Teive, G.Fabiani (Curitiba, Brazil) 1014 Altered response to reward in non-manifesting carriers of the G2019S LRRK2 mutation A.Thaler, A.Mirelman, R.C.Helmich, B.F.L.Van Nuenen, T.Gurevich, A.OrrUrtreger, K.Marder, S.Bressman, B.R.Bloem, T.Hendler, N.Giladi (Tel-Aviv, Israel) 1015 The dynamic change in substantia nigra hyperechogenicity in Parkinson´s disease is associated with age and disease duration T.Toomsoo, A.H.Pool, I.Liepelt-Scarfone, L.Kadastik-Eerme, T.Asser, D.Berg, P.Taba (Tallinn, Estonia) 1016 Brain microstructural grey and white matter alterations in patients with cortico-basal syndrome N.Upadhyay, A.Suppa, F.Di Stasio, M.C.Piattella, N.Petsas, G.Fabbrini, C.Colosimo, P.Pantano, A.Berardelli (Roma, Italy) 1017 Structural assessment in craniocervical dystonia: global and differential analyses L.Vilany, T.J.Rezende, L.G.Piovesana, L.S.Campos, F.R.Torres, M.C.França, Jr., A.C.Amato-Filho, I.Lopes-Cendes, F.Cendes, A.D’Abreu (Campinas, Brazil) 1018 Amyloid-β imaging in Parkinson’s disease: Comparison of analytic techniques D.Weintraub, J.Dubroff, I.Nasrallah, R.Goldmann Gross, J.Rick, R.S.Akhtar, H.Hurtig, A.Chen-Plotkin, L.M.Chahine, N.Dahodwala, J.E.Duda, J.F.Morley, J.Q.Trojanowski (Philadelphia, PA, USA)
1019 Comprehensive evaluation of immune mediated inflammation biomarker and IL-10 promoter DNA polymorphisms in sporadic PD patients K.K.Alagamuthu, A.Meyyazhagan, M.A.Shafi Ahammed Khan, P.Krishnan, S.Keshavaroa, B.Vellingiri (Coimbatore, India)
1023 Clinical and genetic analysis of a large pedigree with Parkinson’s disease from an isolated Trentino valley L.Borellini, M.C.Malaguti, E.Monfrini, V.Melzi, R.Di Giacopo, G.Franco, I.Trezzi, D.Ottaviani, M.Pellegrini, S.Ferrari, G.P.Comi, A.Di Fonzo (Milan, Italy) 1024 Investigating prodromal markers of Parkinson’s disease in adults with hemizygous 22q11.2 deletions N.J.Butcher, C.Marras, M.Pondal, P.Rusjan, L.Christopher, A.P.Strafella, A.E.Lang, A.S.Bassett (Toronto, ON, Canada) 1025 Genetic variants of SNCA are associated with the susceptibility of Parkinson’s disease but not for amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population Y.Chen, Q.Wei, R.Ou, B.Cao, X.Chen, B.Zhao, K.Chen, W.Song, H.Shang (Chengdu, China) 1026 Mitochondria-related genes and the risk of Parkinson’s disease and Alzheimer’s disease: Gene-gene interaction analysis S.J.Chung, J.Kim, Y.J.Kim, K.Kim, S.You, M.J.Kim, H.S.Ryu, S.Y.Kim, J.H.Lee (Seoul, Korea) 1027 Polymorphisms of dopamine receptor genes are associated to increased risk of visual hallucinations in Italian Parkinson’s disease patients C.Comi, M.Ferrari, F.Marino, G.Riboldazzi, S.Rosa, R.Cantello, G.Bono, M.Cosentino (Novara, Italy) 1028 Effect of catecho-O-metyltransferase (COMT) genotype on the response to bilateral subthalamic deep brain stimulation (DBS-STN) in Parkinson’s disease (PD) F.Cormier-Dequaire, S.Bureau, K.Tahiri, G.Mangone, J.Kraemmer, A.Welaratne, C.Karachi, A.Birce, M.L.Welter, J.C.Corvol (Paris, France) 1029 Using a GBA deficient drosophila model to understand pathogenic mechanisms in PD M.Y.Davis, K.Trinh, R.Thomas, B.Whittley, T.Montine, L.Pallanck (Seattle, WA, USA) 1030 DNA methylation as an epigenetic biomarker for Parkinson’s and Alzheimer’s diseases E.Driver-Dunckley, B.Meechoovet, R.Caselli, C.Adler, T.Beach, T.Dunckley (Scottsdale, AZ, USA)
101
Abstracts by Topic
PARKINSON’S DISEASE: GENETICS
1022 Expanding the phenotype of PLA2G6 related Parkinson’s subtypes S.Bohlega, B.Tawil, L.Al-Jomaa, A.Magrashi, T.Alkhairallah, N.Al Tassan (Riyadh, Saudi Arabia)
Abstracts by Topic 1031 Substantia nigra hyperechogenicity in LRRK2 G2019S mutation carriers A.Drobnis, J.Hagenah, R.A.Ortega, A.Glickman, C.Wang, A.Deik, J.SotoValencia, B.Johannes, M.Barrett, D.Raymond, L.J.Ozelius, K.Marder, N.Giladi, S.B.Bressman, R.Saunders-Pullman (New York, NY, USA)
1043 Olfaction in Parkin compound and single heterozygotes in young onset United Kingdom PD patients N.Malek, K.A.Grosset, M.A.Lawton, C.R.Smith, N.Bajaj, R.A.Barker, Y.BenShlomo, C.Bresner, D.J.Burn, T.Foltynie, H.R.Morris, N.Williams, N.W.Wood, D.G.Grosset, On Behalf of PRoBaND Collaborators (Glasgow, United Kingdom)
1032 Withdrawn by Author
1044 Tracking Parkinson’s: A United Kingdom cohort study in Parkinson’s disease N.Malek, K.A.Grosset, M.A.Lawton, N.Bajaj, R.A.Barker, Y.Ben-Shlomo, D.J.Burn, T.Foltynie, H.R.Morris, N.M.Williams, N.W.Wood, D.G.Grosset, On Behalf of the ProBaND Collaborators (Glasgow, United Kingdom)
1033 Genetic loci of Parkinson’s disease in rapid eye movement sleep behavior disorder Z.Gan-Or, S.L.Girard, A.Noreau, C.S.Leblond, J.F.Gagnon, I.Arnulf, Y.Dauvilliers, A.Desautels, V.Cochen De Cock, B.Frauscher, C.Monaca, B.Hogl, P.A.Dion, R.B.Postuma, J.Y.Montplaisir, G.A.Rouleau (Montreal, QC, Canada) 1034 Postural control alterations in healthy LRRK2 G2019S mutation carriers N.Giladi, Y.Beck, K.Brockmann, D.Berg, B.J.Warø, J.Aasly, C.Pont Sunyer, D.Vilas, A.K.Rao, K.S.Marder, R.Sunders-Pullman, S.B.Bressman, A.Orr-Urtreger, J.M.Hausdorff, A.Mirelman (Tel Aviv-Yafo, Israel) 1035 The SNP rs11868035 may not confer genetic risk toward Parkinson’s disease in central China C.Han, J.Huang, N.Xiong, L.Liu, G.Zhang, H.Jiang, J.Yang, J.Li, X.Xu, Y.Shen, T.Wang (Wuhan, China) 1036 CSF derived exosomal microRNA profile in patients with Parkinson’s disease T.Hasegawa, N.Sugeno, A.Kikuchi, R.Oshima, S.Yoshida, A.Takeda, M.Aoki (Sendai, Japan) 1037 Association between PARK16 variants and Parkinson’s disease in central China: A case-control study H.Jiang, J.Huang, N.Xiong, L.Liu, G.Zhang, C.Han, J.Yang, X.Xu, J.Li, Y.Shen, T.Wang (Wuhan, China) 1038 The tyrosine hydroxylase Val81Met polymorphism is associated with motor symptom severity in de novo patients with Parkinson’s disease J.Kraemmer, F.Cormier-Dequaire, A.Brice, J.C.Corvol, PPMI Genetic Working Group (Paris, France) 1039 Whole-exome sequencing for mutation discovery in an African-American pedigree with Parkinson’s disease M.S.LeDoux, S.R.Vemula, J.Xiao, O.A.Ross, Z.W.Wszolek (Memphis, TN, USA)
Abstracts by Topic
1040 Genetic variation and cognitive impairment in Parkinson’s disease patients from Uruguay A.Lescano, V.Raggio, E.Dieguez, B.Aguiar, L.Bocos, N.González, F.Saldaña, J.Sburlati, J.M.Carrasco, F.Brunet, I.Amorín, R.Aljanati, M.Martinovic, L.Roche, R.Buzó, S.Dansilio, M.Inca-Martinez, B.A.Cholerton, C.P.Zabetian, I.F.Mata (Montevideo, Uruguay) 1041 Leucine-rich repeat kinase 2 (LRRK2) interacts with vacuolar protein sorting 35 (Vps35) to regulate autophagy R.Linhart, Y.J.Ho, D.Kaing, E.Hou, D.Sohal, R.Eismati, J.Rosales, R.Fedrizzi, A.Tsang, D.Fong, A.Dawson, K.Venderova (Stockton, CA, USA) 1042 Genetic variation in GAPDH confers susceptibility to sporadic Parkinson’s disease in central Chinese population L.Liu, J.Huang, N.Xiong, G.Zhang, X.Xu, C.Han, J.Li, H.Jiang, J.Yang, Y.Shen, T.Wang (Wuhan, China)
102
1045 Association of GBA mutations with tau pathology in dementia with Lewy bodies K.S.Marder, L.N.Clark, R.N.Alcalay, J.P.Vonsattel, L.S.Honig (New York, NY, USA) 1046 A missense mutation in RAB39b causes X-linked dominant Parkinson’s disease I.F.Mata, Y.Jang, C.H.Kim, D.Hanna, M.O.Dorschner, J.Witt, A.Samii, K.A.Chung, D.R.Shprecher, A.J.Espay, F.J.Revilla, S.A.Factor, O.Klepitskaya, D.S.Higgings, I.Litvan, J.B.Leverenz, J.W.Roberts, P.Agarwal, D.Yearout, M.Inca-Martinez, E.Martinez, T.R.Thompson, B.A.Cholerton, S.C.Hu, K.L.Edwards, K.S.Kim, C.P.Zabetian (Seattle, WA, USA) 1047 A pilot study in chromosomal alteration and association study of HTRA2 gene mutations in Parkinson’s patients (PD) A.Meyyazhagan, M.Subramaniam, B.Subramanian, P.Krishnan, G.Changrathil, S.Keshavarao, B.Vellingiri (Coimbatore, India) 1048 Four copies of SNCA responsible of autosomal dominant Parkinson’s disease in two Italian siblings N.Modugno, R.Ferese, R.Campopiano, S.Zampatti, E.Giardina, M.Santilli, A.Nardone, D.Postorivo, S.Ruggieri, F.Fornai, G.Novelli, S.Gambardella (Pozzilli, Italy) 1049 Identification of neurotransmitter levels and vitamin D receptor gene (VDR) polymorphism in sporadic Parkinson’s disease in South India S.Mohana Devi, M.Arun, S.Sureshkumar, I.Mahalaxmi, I.H.Kim, V.Balachandar (Cheonan, Korea) 1050 Parkinson’s disease variant database K.Nuytemans, L.Wang, G.W.Beecham, C.Van Broeckhoven, J.M.Vance (Miami, FL, USA) 1051 Noncoding variants contributing to the PARK10 locus K.Nuytemans, G.W.Beecham, W.K.Scott, E.R.Martin, L.Wang, J.M.Vance (Miami, FL, USA) 1052 Development of biomarker battery to discriminate LRRK2 mutation carriers R.A.Ortega, R.Alcalay, A.Mirelman, C.Pont Sunyer, C.Wang, Q.Yu, J.Hagenah, D.Raymond, A.Glickman, M.Pullman, B.Johannes, N.Doan, L.J.Ozelius, S.Pullman, K.Marder, N.Giladi, E.Tolosa, S.B.Bressman, R.Saunders-Pullman (New York, NY, USA) 1053 Increased oligomeric alpha-synuclein in Gaucher disease: Possible explanation for the link with Parkinson’s disease S.N.Pchelina, A.K.Emelyanov, E.P.Nuzhnyi, T.S.Usenko, T.M.Boukina, M.A.Nikolaev, A.F.Yakimovskii, E.Y.Zakharova (St.Petersburg, Russia)
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 1054 Clinical and genetic features of an early-onset Parkinson’s disease Peruvian cohort E.H.Sarapura, C.Cosentino, M.A.Inca-Martinez, M.R.Cornejo-Olivas, L.Torres, V.Marca, O.Ortega, D.M.Velit-Otani, K.A.Espinoza-Huertas, D.Yearout, H.Huston, C.Zabetian, I.F.Mata, P.Mazzetti (Lima, Peru)
1066 Multiple LRRK2 variants modulate risk of sporadic Parkinson’s disease susceptibility: A replication study in a central Han Chinese case-control study G.Zhang, N.Xiong, J.Huang, L.Liu, C.Han, H.Jiang, J.Yang, X.Xu, J.Li, Y.Shen, T.Wang (Wuhan, China)
1055 Screening of spontaneous genomic alterations and P53 gene polymorphism in new onset of Parkinson’s disease M.A.Shafi Ahammed Khan, K.K.Alagamuthu, A.Meyyazhagan, Y.Mohd, M.Iyer, S.Keshavarao, B.Vellingiri (Coimbatore, India)
1067 ALDH2 genetic variation is associated with the risk for Parkinson’s disease X.Zhang, Y.L.Ye, Y.N.Wang, F.F.Liu, X.S.Zhuang, X.X.Liu, B.L.Hu, J.H.Zhu (Wenzhou, China)
1056 Cognitive deficit and neuropsychiatric features in early Parkinsonism due to homozygous PINK1 mutation: A case report C.Siri, E.Reali, G.Sacilotto, S.Goldwurm, E.Scarpini, G.Pezzoli (Milan, Italy)
1068 MicroRNA-mediated DNA methyltransferase 1 deregulates SNCA methylation in Parkinson’s disease J.H.Zhu, X.Zhang, J.Y.Wang, X.Cheng, B.L.Hu (Wenzhou, China)
1057 Methylomic analysis in A53T transgenic PD mouse model C.Song, Q.Xu, Y.Hu, B.Tang (Changsha, China) 1058 Withdrawn by Author 1059 Oxidative stress and cytogenetic analysis compared with PARK8 gene in Parkinson’s disease patients B.Vellingiri, A.Meyyazhagan, K.K.Alagamuthu, K.Siva, M.Iyer, S.N.Dharwadkar, S.Keshavarao (Coimbatore, India) 1060 Leucine-rich repeat kinase 2 (LRRK2) impairs function of the retromer-associated WASH complex K.Venderova, D.Kaing, R.Eismati, R.Joseph, L.Radek, H.Yu-Ju, H.Emily, T.Ariel, F.Ryan, F.Derek (Stockton, CA, USA) 1061 Parkinsonism with early disautonomic symptoms and normal MIBG scintigraphy related to LRRK2 mutation D.Vilas, Á.Muxí, E.Tolosa, Y.Compta (Barcelona, Spain) 1062 Genome wide pleiotropic study in 144,701 subjects reveals shared genetic variants between Parkinson’s disease and immune-mediated diseases A.W.Witoelar, Y.Wang, R.Desikan, W.Thompson, A.J.Schork, V.Zuber, E.Ellinghaus, A.Franke, B.A.Lie, L.K.McEvoy, T.H.Karlsen, IPDGC, S.Djurovic, A.Brice, N.Wood, P.Heutink, J.Hardy, A.Singleton, A.M.Dale, T.Gasser, O.A.Andreassen, M.Sharma (Oslo, Norway) 1063 Genetic variants of TOR1A gene are not associated with sporadic PD susceptibility: A replication study in a central Han Chinese study X.Xu, N.Xiong, J.Huang, L.Liu, G.Zhang, H.Jiang, C.Han, J.Yang, J.Li, Y.Shen, T.Wang (Wuhan, China)
1065 Genetic variants of SNCA gene are associated with sporadic PD susceptibility: A replication study in a central Han Chinese study G.Zhang, N.Xiong, J.Huang, L.Liu, C.Han, H.Jiang, J.Yang, X.Xu, J.Li, Y.Shen, T.Wang (Wuhan, China)
1070 Evaluating the use of the online bradykinesia-akinesia Incoordination (BRAIN) test in Parkinson’s disease in “on” and “off” states D.S.Athauda, H.Hasan, A.Noyce, T.Foltynie (London, United Kingdom) 1071 Correlation between the functional independence measure (FIM) and the scale for assessment and rating of ataxia (SARA) for the evaluation of spinocerebellar ataxia F.M.Branco Germiniani, T.V.Canelossi Rosa, R.Nickel, P.B.N.Liberalesso, H.A.G.Teive (Curitiba, Brazil) 1072 The Pennsylvania daily activities questionnaire: Development, reliability and validity of a new item bank for cognitive instrumental activities of daily living in Parkinson’s disease L.Brennan, J.D.Rubright, J.Rick, N.Dahodwala, J.E.Duda, H.Hurtig, M.Stern, S.X.Xie, L.Rennert, J.Karlawish, J.A.Shea, J.Q.Trojanowski, D.Weintraub (Philadelphia, PA, USA) 1073 UPDRS motor subscales provide a measure of key locomotor function C.Curtze, J.G.Nutt, P.Carlson-Kuhta, M.Mancini, F.B.Horak (Portland, OR, USA) 1074 Development of the Parkinson’s disease medication beliefs scale (PD-Rx) J.E.Fleisher, N.A.Dahodwala, S.X.Xie, J.A.Shea (New York, NY, USA) 1075 Handling missing values in the MDS-UPDRS C.G.Goetz, S.Luo, L.Wang, B.C.Tilley, N.R.LaPelle, G.T.Stebbins (Chicago, IL, USA) 1076 Predictive validity of facial masking for experienced stigma in Parkinson’s disease S.D.Gunnery, M.Saint-Hilaire, C.A.Thomas, L.Tickle-Degnen (Medford, MA, USA) 1077 Minimal clinically important difference on the Parkinson’s disease sleep scale 2nd version (PDSS-2) N.Kovács, Z.Aschermann, P.Ács, G.Deli, J.Janszky, S.Komoly, B.Faludi, K.Horváth (Pécs, Hungary)
103
Abstracts by Topic
1064 HLA polymorphisms may be one of the susceptibility genes in Chinese sporadic PD J.Yang, J.Huang, N.Xiong, L.Liu, C.Han, G.Zhang, H.Jiang, X.Xu, J.Li, Y.Shen, T.Wang (Wuhan, China)
RATING SCALES
1069 Determining the reliability of performing the modified unified Parkinson’s disease rating scale (UPDRS) remotely in a pilot virtual visit study in the home K.L.Andrzejewski, M.T.Bull, P.Auinger, V.Venkataraman, M.J.Grana, B.P.George, C.M.Boyd, C.Beck, B.Rajan, E.R.Dorsey, K.Biglan (Rochester, NY, USA)
Abstracts by Topic 1078 Health and aging in Parkinson’s disease: Management of selfcare like social responsibility factor L.A.Leandro, H.G.Teive (Curitiba, Brazil) 1079 Parkinson’s disease impact on frailty and physical vulnerability of the octagenarian elderly people L.A.Leandro, H.G.Teive (Curitiba, Brazil) 1080 Inter-rater reliability of the hemifacial spasm severity scale (HFS-SS) E.C.Lim, A.M.Quek, L.L.Yeo, L.Shen, A.W.Chow, R.C.Seet (Singapore) 1081 Spatial and temporal variability during spirography M.Memedi, J.Westin (Borlänge, Sweden) 1082 Automatic spiral analysis for objective assessment of motor symptoms in Parkinson’s disease M.Memedi, A.Johansson, F.Bergquist, D.Nyholm (Borlänge, Sweden) 1083 Vowel production deficit in cases of dysarthria due to Parkinson’s disease D.Misra, M.Behari, V.Narang (New Delhi, India) 1084 Comparing the psychometric properties of the paper and e-based versions of the 39-item Parkinson’s disease questionnaire (PDQ-39) D.Morley, S.Dummett, L.Kelly, J.Dawson, C.Jenkinson (Oxford, United Kingdom)
1093 Carrier mediated delivery system bearing dopamine for effective management of Parkinsonism S.Bhargava, V.Bhargava (Kanpur, India) 1094 Decreased “OFF” time and improved Parkinson’s disease symptoms with the gastroprokinetic camicinal as an adjunct to L-DOPA based treatment; a pilot study D.J.Burn, S.L.Marrinan, T.Otiker, L.S.Vasist, R.A.Gibson, B.K.Sarai, M.E.Barton, D.B.Richards, P.M.Hellström, D.Nyholm, G.E.Dukes (Newcastle upon Tyne, United Kingdom) 1095 Mucuna pruriens for the treatment of Parkinson’s disease in low income countries: Very low cost seed preparation without pharmaceutical technology E.Cassani, M.Barichella, R.Cilia, J.Laguna, F.Sparvoli, A.Akpalu, K.Ofosu Budu, M.T.Scarpa, E.Cereda, L.Iorio, G.Pezzoli (Milan, Italy) 1096 Mucuna pruriens therapy in Parkinson’s disease: A doubleblind, placebo-controlled, randomized, crossover study R.Cilia, J.Laguna, E.Cassani, E.Cereda, G.Pezzoli (Milano, Italy)
1085 Pretesting the Oxford participation and activities questionnaire: Results from an expert review D.Morley, S.Dummett, L.Kelly, J.Dawson, R.Fitzpatrick, C.Jenkinson (Oxford, United Kingdom)
1097 Pilot study to evaluate transcranial direct current stimulation (tDCS) during sleep for the treatment of Parkinson’s disease D.A.Heldman, C.L.Pulliam, L.M.Blassucci, J.P.Giuffrida, C.L.Comella (Cleveland, OH, USA)
1086 PDSS-2 cut-off scores for the severity of sleep disturbances in PD Patients M.L.Muntean, H.Benes, F.Sixel-Döring, C.Trenkwalder (Kassel, Germany)
1098 Rapid titration impact on length of stay for Parkinson’s disease patients with orthostatic hypotension A.D.Hohler, M.C.Ponce de Leon, T.DePiero, D.Katz, A.Deb (Boston, MA, USA)
1087 Continuous motion sensor assessment of Parkinson’s disease during activities of daily living C.L.Pulliam, D.A.Heldman, M.A.Burack, T.O.Mera (Cleveland, OH, USA)
1099 Psychometric validation of the Polish version Parkinson’s disease questionnaire-39 (PDQ-39) and its short form (PDQ8) A.T.Krygowska-Wajs, A.Gorecka-Mazur, K.A.Tomaszewski, K.Potasz, A.Furgala (Cracow, Korea)
1088 A multicentre study of the patient’s perspective: The first Parkinson’s disease pain questionnaire (King’s PD pain quest) A.M.Rizos, P.Martinez-Martin, S.Pal, C.Carroll, D.Martino, C.Falup-Pecurariu, B.Kessel, A.Sauerbier, A.Martin, M.Parry, R.Inniss, L.Perkins, D.Trivedi, P.Odin, A.Antonini, K.Ray Chaudhuri (London, United Kingdom) 1089 How to screen for dysphagia in Parkinson’s disease? The Munich dysphagia test (MDT-PD) – A patient reported outcome questionnaire J.A.Simons, A.Waldmann, U.M.Fietzek (Lübeck, Germany)
Abstracts by Topic
THERAPY IN MOVEMENT DISORDERS: MEDICAL
1092 Clinical outcomes of step synchronized vibration training in Parkinson’s disease patients R.Aggarwal, M.Behari, S.Agrawal, I.Pretzer-Aboff, K.Winfree, G.Dhankar, T.Shiva, V.Vashista (Delhi, India)
1090 High-risk defining clinical parameters for dysphagia in Parkinson’s disease J.A.Simons, N.Eisemann, U.M.Fietzek, A.Katalinic (Lübeck, Germany) 1091 The PowerGlove: Assessment of hand and finger movements in Parkinson’s disease patients K.J.van Dijk, R.Verhagen, J.C.van den Noort, L.J.Bour, P.H.Veltink, C.Heida (Enschede, Netherlands)
104
1100 Dalfampridine extended release in patients with Parkinson’s disease related gait dysfunction: A randomized double blind trial C.C.Luca, G.Nadayil, C.Dong, E.Field-Fotte, C.Singer (Miami, FL, USA) 1101 A novel levodopa dry powder inhaler for treatment of off periods in Parkinson’s disease patients M.Luinstra, F.Grasmeijer, P.Hagedoorn, H.W.Frijlink, A.H.de Boer (Groningen, Netherlands) 1102 Mapping the availability, price and affordability of drugs used to treat Parkinson’s disease in Kenya J.Mokaya, W.K.Gray, R.W.Walker (Nairobi, Kenya) 1103 Zonisamide improves Parkinsonism in patients with DLB: A double-blind randomized placebo-controlled study M.Murata, T.Odawara, K.Hasegawa, Y.Tamai, M.Nakamura, R.Shimazu, K.Kosaka (Tokyo, Japan)
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 1104 Impact of therapeutic area specific data standards for Parkinson’s disease J.Neville, S.Kopko, J.Odenkirchen, W.Galpern, K.Marek, D.Burn, Y.Ben Shlomo, D.G.Grosset, M.Farrer, K.Romero, E.Aviles, S.Dubman, M.F.Gordon, A.Roach, D.Stephenson (Tucson, AZ, USA)
1117 Comparing symptoms and patterns of Parkinson’s disease between leading teaching hospitals from Eastern and Western Nigeria O.I.Agunbiade, T.T.Lekan-Agunbiade, P.Henry John, A.O.Adebambo (Ile-Ife, Nigeria)
1105 Helicobacter pylori infection in Parkinson’s disease patients detected by 14C –urea breath test, a new nucleer medicine test E.E.Okuyucu, H.Yalcin, B.Ozer, S.Yilmazer, M.Demirci, I.Melek, T.Duman (Hatay, Turkey)
1118 Factors determining wearing-off in Thai Parkinson’s disease patients: The report of the Thai PD registry database involving 6,623 patients R.Bhidayasiri, O.Jitkritsadakul, N.Wannachai, K.Boonpang, J.Sringean, L.Kaewwilai, P.Jagota, P.Panyakaew, S.Singmaneesakulchai, S.Petchrutchatachart (Bangkok, Thailand)
1106 Treatment of secondary freezing of gait with rivastigmine P.Paiva, E.H.Molho, A.Ramirez-Zamora (Albany, NY, USA) 1107 The Parkinson’s progression marker initiative (PPMI) – Developing a sample size estimate for Parkinson’s disease therapeutic trials Parkinson’s Progression Marker Initiative (New Haven, CT, USA) 1108 Continuous delivery of ropinirole by subdermal ProNeura™ implants S.Sreedharan, K.Bankiewicz, R.Patel (South San Francisco, CA, USA) 1109 Effects of amantadine on postural instability in Parkinson’s disease B.Topcular, A.Altinkaya, A.Kaymaz, A.Yabalak, B.Altunrende, Z.Matur, O.Gungor Tuncer, E.Altindag, D.Orken, G.Akman-Demir (Istanbul, Turkey) 1110 Anticholinergics are still effective in early stage of male PD patients Y.Tsuboi, S.Fujioka, T.Mishima, R.Onozawa, J.Fukae, Y.Yamaguchi (Fukuoka, Japan) 1111 Drug candidates promoting O-linked glycosylation of tau for the treatment of tauopathies C.Wiessner, A.Quattropani, M.Neny, S.Ousson, J.Hantson, A.Sand, B.Permanne, D.Beher (Lausanne, Switzerland) 1112 Moving health care to the patients home: An innovative approach to introduce levodopa-carbidopa intestinal gel (LCIG) treatment T.Willows, K.Groth, J.Bjorkehag, M.Andersson, J.Larsson, J.Permert (Stockholm, Sweden) 1113 Clinical efficacy of istradefylline on psychiatric symptoms in Parkinson’s disease T.Yamamoto, T.Furuya, K.Ikeda, A.Miyake, T.Mitsufuji, T.Kimura, A.Tanaka, K.Takahashi, N.Tamura, N.Araki (Iruma-gun, Japan)
EPIDEMIOLOGY
1115 Frequency and pattern of Parkinson’s disease in Obafemi Awolowo University Teaching Hospitals, Ile-Ife, Nigeria O.I.Agunbiade, M.A.Komolafe, O.E.Popoola (Ile-Ife, Nigeria) 1116 Trends and pattern of Parkinson’s disease in Obafemi Awolowo University Teaching Hospitals, Ile-Ife, Nigeria between 1984-2004 and 2010-2013 O.I.Agunbiade, M.A.Komolafe, T.T.Lekan-Agunbiade (Ile-Ife, Nigeria)
1120 Military service and Agent Orange exposure in PSP: A casecontrol study T.de la Riestra, P.Lees, C.Cunningham, E.A.Carl, S.D.Edland, I.Litvan (La Jolla, CA, USA) 1121 Clinical and epidemiological factors associated with mortality in Parkinson’s disease in a Brazilian cohort G.C.Fernandes, M.Socal, C.R.M.Rieder, A.F.S.Schuh, M.D.B.Londero (Porto Alegre, Brazil) 1122 Remote TBI is a risk factor for recent falls among older veterans R.C.Gardner, C.B.Peltz, K.Kenney, R.Diaz-Arrastia, K.Yaffe (San Francisco, CA, USA) 1123 Genetic and gene-environment associations with Parkinson’s disease (PD) in an Alaska native population S.M.Goldman, C.M.Tanner, B.Trimble, M.Korell, G.W.Ross, A.B.Singleton, C.Meng, D.Guest, R.D.Abbott (San Francisco, CA, USA) 1124 Brain magnetic resonance imaging measures are associated with progression of mild Parkinsonian signs in communitydwelling older adults J.Han, S.Jain, A.L.Metti, K.Yaffe, A.L.Rosso, L.J.Launer, S.B.Kritchevsky, R.M.Boudreau, H.J.Aizenstein, A.B.Newman, C.Rosano (Pittsburgh, PA, USA) 1125 Accuracy of death certification in the Denbighshire cohort at 16 years P.J.Hobson, J.R.Meara (Rhyl, United Kingdom) 1126 Mild cognitive impairment in Parkinson’s disease and its progression onto dementia; a 16-year outcome evaluation of the Denbighshire cohort P.J.Hobson, J.R.Meara (Rhyl, United Kingdom) 1127 Incidence of Parkinson’s disease and various movement disorders in a general neurology OPD clinic in a South Indian superspeciality private hospital by a fresh general neurologist S.K.Jaiswal (Hyderabad, India)
Abstracts by Topic
1114 Pattern of movement disorders in a general neurology practice in Southwestern Nigeria: A 6 month review A.M.Adebiyi, M.A.Komolafe, M.B.Fawale, A.A.Adebowale (Ile-Ife, Nigeria)
1119 Risk factors for pneumonia development in Parkinson’s disease — A nationwide population-based study Y.P.Chang, J.H.Tsai (Kaohsiung, Taiwan)
1128 Prevalence, incidence and risk factors associations of Parkinson’s disease in an elderly population in Cuba J.J.Llibre Guerra, J.C.Llibre Guerra, J.J.Llibre Rodriguez, M.Guerra Hernandez, L.Garcia Arjona (La Habana, Cuba)
105
Abstracts by Topic 1129 Priorities in movement disorder research M.M.Macas, C.L.Go, J.C.Navarro (Manila, Philippines) 1130 Mortality in Parkinson’s disease and atypical Parkinsonian disorders A.D.Macleod, C.E.Counsell (Aberdeen, United Kingdom) 1131 Predictors of institutionalisation in an incidence-based cohort of Parkinson’s disease A.D.Macleod, C.E.Counsell (Aberdeen, United Kingdom) 1132 Movement disorders in non-Wilsonian cirrhotic patients; the report of prevalence and risk factors from the medical school in agricultural-based community K.Methawasin, C.Wongjitrat, P.Chonmaitree, S.Rattanamongkolgul, T.Asawavichienjinda (Ongkharak, Thailand) 1133 Movement disorders in non-Wilsonian hepatic cirrhosis patients at HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University, Ongkharak campus; the subgroup analysis of various phenotypes of movement disorders and associated risk factors K.Methawasin, C.Wongjitrat, P.Chonmaitree, S.Rattanamongkolgul, T.Asawavichienjinda (Ongkharak, Thailand) 1134 Frequency and pattern of movement disorders at a tertiary care hospital in Enugu, Southeast Nigeria O.A.Molokwu, B.A.Ezeala, I.O.Onwuekwe, O.S.Ekenze, A.C.Nwabueze (Enugu, Nigeria) 1135 New onset movement disorders in type 2 diabetes mellitus patients presenting in hyperglycemic crisis at a tertiary hospital in Enugu, South East Nigeria O.A.Molokwu, I.O.Onwuekwe, B.A.Ezeala, O.S.Ekenze, A.C.Nwabueze (Enugu, Nigeria) 1136 Prevalence and treatment pattern of Parkinson’s disease dementia in Korea Y.S.Oh, J.S.Kim, I.S.Park, Y.S.Shim, I.U.Song, J.W.Park, P.H.Lee, C.H.Lyoo, T.B.Ahn, H.I.Ma, Y.D.Kim, S.B.Koh, S.J.Lee, K.S.Lee (Seoul, Korea) 1137 Comparing patterns of presentation and appropriateness of diagnosis of movement disorders between the teaching hospitals in Osun State, Western Nigeria O.J.Ojo, O.I.Agunbiade, T.T.Lekan Agunbiade (Osogbo, Nigeria)
Abstracts by Topic
1138 Parkinson’s and pesticides: A study on gene-environment interactions in Egypt T.W.Rösler, M.M.Salama, A.Eltantawy, A.Shalash, G.Fawe, E.Khedr, A.Elmotayam, E.Elsaeedy, G.U.Höglinger (Munich, Germany) 1139 Accuracy of clinical diagnosis of Parkinson’s disease: A systematic review and Bayesian meta-analysis G.Rizzo, D.Martino, S.Arcuti, M.Copetti, A.Fontana, G.Logroscino (Tricase, Italy) 1140 The impact of hospital Parkinson’s disease volume on patient safety events: Should we regionalize PD inpatient care? D.Safarpour, D.Thibault, A.Willis (Philadelphia, PA, USA) 1141 COPPADIS-2015 (COhort of Patient´s with PArkinson´s DIsease in Spain, 2015): A global Parkinson´s disease project underway D.Santos García, T.de Deus Fonticoba, P.Mir, E.Cubo, L.Vela, M.C.Rodríguez-Oroz, J.M.Arbelo (Ferrol, Spain)
106
1142 Familial aggregation of Parkinson’s disease in Utah: A population-based analysis R.Savica, S.Pulst, L.A.Cannon-Albright (Salt Lake City, UT, USA) 1143 The decline of the amyotrophic lateral sclerosis/ Parkinsonism-dementia complex (ALS/PDC) of Guam and the recent identification of Huntington’s chorea in the families of Umatac village J.C.Steele, C.G.Quinata, L.Q.Cruz, R.Carlos, M.Farrer (Covina, CA, USA) 1144 Vagotomy and subsequent risk of Parkinson’s disease E.Svensson, E.Horváth-Puhó, R.W.Thomsen, J.C.Djurhuus, L.Pedersen, P.Borghammer, H.T.Sørensen (Aarhus N, Denmark) 1145 Persistent organic pollutants (POPs) and Parkinson’s disease (PD) in an Alaska native population C.M.Tanner, S.M.Goldman, B.Trimble, M.Korell, G.W.Ross, C.Meng, D.Guest, R.D.Abbott (San Francisco, CA, USA) 1146 Utility of electronic medical record databases using ICD-9 criteria for recruitment in clinical research: From rare to common disease T.Thacker, A.R.Wegele, S.Pirio Richardson (Albuquerque, NM, USA) 1147 Prevalence of Parkinson’s disease in Ukraine in 2013 Y.O.Trufanov, N.K.Svyrydova, A.I.Galusha, O.V.Popov (Kyiv, Ukraine) 1148 Longitudinal study of mild Parkinsonian signs in elderly people in Japan K.Wada-Isoe, K.Tanaka, M.Kishi, S.Nakashita, Y.Tajiri, S.Tagashira, M.Yamamoto, K.Nakashima (Yonago, Japan) 1149 Mortality of Parkinson’s disease from a five-year follow up study in Shanghai G.Wang, S.Chen (Shanghai, China) 1150 Prevalence of non-motor symptoms of essential tremor in a rural area, Shanghai China: A population-based, door-todoor survey Y.W.Wu, X.Wang, W.Cheng, Q.Sun, N.Song, Y.Zhou, Q.Jiang, Y.Qiao, J.Xu, L.Liang, H.Tang, J.Ma, X.Gao, S.Chen (Shanghai, China)
GENETICS
1151 Glucocerebrosidase mutations and atypical Parkinsonism: A multi-centre exploratory study R.Álvarez Velasco, P.Giraldo, P.Irún, E.Viedma Guiard, J.López Sendón, I.Avilés Olmos, G.García Ribas, P.J.García-Ruiz, L.Vela Desojo, J.C.Martínez Castrillo, A.Alonso Cánovas (Madrid, Spain) 1152 C9ORF72 expansion in neurodegenerative disorders characterized by Parkinsonism and chorea N.Y.Abramycheva, E.Y.Fedotova, M.S.Stepanova, S.A.Klyushnikov, Y.A.Seliverstov, S.N.Illarioshkin (Moscow, Russia) 1153 Phosphorylated pS1292 LRRK2 to total LRRK2 concentration ratio in urine exosomes distinguishes LRRK2-PD and idiopathic PD R.N.Alcalay, K.B.Fraser, A.West (New York, NY, USA)
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 1154 Glucocerebrosidase activity in Parkinson’s disease with and without GBA mutations R.N.Alcalay, O.A.Levy, C.Waters, S.Fahn, B.Ford, S.H.Kuo, P.Mazzoni, M.W.Pauciulo, W.Nichols, Z.Gan-Or, G.A.Rouleau, W.K.Chung, P.Wolf, P.Oliva, J.Kreutzer, K.S.Marder, X.K.Zhang (New York, NY, USA)
1167 The impact of rare variants in FUS and HTR2A in essential tremor F.Hopfner, G.Stevanin, S.H.Müller, E.Mundwiller, M.Bungeroth, A.Durr, M.Pendziwiat, M.Anheim, S.A.Schneider, L.Tittmann, S.Klebe, D.Lorenz, G.Deuschl, A.Brice, G.Kuhlenbäumer (Kiel, Germany)
1155 Double homozygous mutations (R275W and M432V) in the Parkin gene associated with late onset PD J.Carr, B.Sihaam, T.Chris, B.Soraya, F.Matt (Cape Town, South Africa)
1168 Association of MAPT single nucleotide polymorphism with corticobasal syndrome C.L.Huang, S.C.Lai, Y.W.Lin, Y.H.Wu-Chou, C.S.Lu, T.H.Yeh (Taoyuan, Taiwan)
1156 Establishment and validation of the first stable human ATP7B knockout hepatoma cell line: A Wilson disease cell model G.Chandhok, V.Sauer, A.Aggarwal, M.Bhatt, A.Zibert, H.H.J.Schmidt (Münster, Germany)
1169 Systematic mutational analysis of glucocerebrosidase gene in a Parkinson’s disease population from Southern Spain S.Jesus, P.Gomez-Garre, I.Huertas-Fernandez, I.Bernal-Bernal, M.BonillaToribio, M.T.Caceres-Redondo, F.Carrillo, L.Vargas-Gonzalez, M.Gomez-Llamas, E.Calderón, M.Carballo, P.Mir (Seville, Spain)
1157 Phenotypic characterization of patients with p.C271* Wilson disease mutation; the most frequent ATP7B mutation in India G.Chandhok, A.Zibert, H.H.J.Schmidt, M.Bhatt, A.Aggarwal (Münster, Germany) 1158 No association of GPNMB rs156429 polymorphism with Parkinson’s disease, amyotrophic lateral sclerosis and multiple system atrophy in Chinese population Y.Chen, R.Ou, Q.Wei, B.Cao, X.Chen, K.Chen, B.Zhao, H.Shang (Chengdu, China) 1159 LRRK2 and GBA variants influence rate of motor progression in Parkinson’s disease M.Y.Davis, C.Johnson, J.B.Leverenz, D.Weintraub, J.Q.Trojanowski, A.ChenPlotkin, V.M.Van Deerlin, S.Factor, C.Wood-Siverio, J.F.Quinn, K.A.Chung, A.L.Peterson-Hiller, L.S.Rosenthal, T.M.Dawson, M.S.Albert, J.G.Goldman, G.T.Stebbins, B.Bernard, D.Yearout, S.Hu, B.A.Cholerton, T.J.Montine, K.L.Edwards, C.P.Zabetian (Seattle, WA, USA) 1160 Novel GNAL variant in a Brazilian patient with sporadic dystonia P.M.de Carvalho Aguiar, C.Oliveira dos Santos, F.P.da Silva- Junior, S.C.Azevedo Silva, E.R.Barbosa, V.Borges, M.S.G.Rocha, H.B.Ferraz (São Paulo, Brazil) 1161 Novel compound heterozygous mutations in PRKRA cause pure dystonia P.de Carvalho Aguiar, V.Borges, H.B.Ferraz, L.J.Ozelius (São Paulo, Brazil) 1162 Novel recruitment strategy to enrich for LRRK2 mutation carriers T.Foroud, D.Smith, J.Jackson, J.Verbrugge, C.Halter, L.Wetherill, K.Sims, W.Xin, V.Arnedo, S.Lasch, K.Marek (Indianapolis, IN, USA) 1163 Association study of GWAS top hits in late-onset Alzheimer’s disease with the susceptibility to Parkinson’s disease in a Chinese population J.F.Guo, Y.Wang, X.X.Yan, B.Tang (Changsha, China)
1165 Secondary paroxysmal kinesigenic dyskinesia associated with CLCN2 gene mutation H.A.Hanagasi, B.Bilgic, T.E.M.Abbink, F.Hanagasi, Z.Tufekcioglu, H.Gurvit, N.Basak, M.S.van der Knaap, M.Emre (Istanbul, Turkey) 1166 A novel mutation for McLeod neuroacanthocytosis V.N.Holiday, A.Hiller (Portland, OR, USA)
1171 Dopamine receptor (DRD3 rs6280) polymorphism and the risk of impulse control disorders in an Indian Parkinson’s disease cohort A.Kishore, S.Moorthy, S.Krishnan, G.Sarma, S.Sarma, M.Banerjee (Trivandrum, India) 1172 C9orf72 mutation in a patient with a movement disorder presentation N.Licking, R.Woltjer, T.Bird, J.Quinn (Portland, OR, USA) 1173 SPG11 mutations cause autosomal recessive axonal CharcotMarie-Tooth disease T.Lo Giudice, C.Montecchiani, M.Di Lullo, M.Mearini, A.Casella, F.Gaudiello, C.Terracciano, R.Massa, E.Rogaeva, P.H.St George-Hyslop, J.L.Pedroso, O.G.P.Barsottini, T.Kawarai, A.Orlacchio (Rome, Italy) 1174 Exome sequencing in 25 index cases of congenital mirror movements A.Méneret, E.A.Franz, O.Trouillard, R.J.M.Gardner, C.Depienne, S.P.Robertson, E.Roze, D.Markie (Paris, France) 1175 A missense mutation in the KCTD17 gene causes autosomal dominant myoclonus-dystonia N.E.Mencacci, I.Rubio-Augusti, A.Zdebik, F.Asmus, M.Ludtmann, A.K.Hauser, V.Plagnol, A.Pittman, S.Bandres-Ciga, M.Soutar, K.Peall, H.Morris, D.Trabzuni, M.Ryten, M.Tekman, H.Stanescu, R.Kleta, M.Carecchio, N.Nardocci, B.Garavaglia, E.Lohmann, A.Weissbach, C.Klein, J.Hardy, A.Y.Abramov, T.Foltynie, T.Gasser, K.P.Bhatia, N.W.Wood (London, United Kingdom) 1176 Methodology for assessment of genetic-environmental interaction in epigenesis of early onset Parkinson’s disease in Arab ancestry A.A.Peer Zada, S.Nahrir, J.A.Bajwa (Riyadh, Saudi Arabia) 1177 The Contursi family 20 years later: Intrafamilial variability in a kindred with A53T mutation of SCNA gene L.Ricciardi, S.Petrucci, D.Di Giuda, M.C.Sensi, F.Cocciolillo, M.Ginevrino, E.M.Valente, A.Fasano (London, United Kingdom)
107
Abstracts by Topic
1164 Exon dosage analysis of parkin gene in Chinese sporadic Parkinson’s disease J.F.Guo, X.Dong, X.X.Yan, B.Tang (Changsha, China)
1170 Phenotypic and molecular characterisation of autosomal recessive spastic paraplegias E.Kara, J.Hardy, H.Houlden, For the Institute of Neurology HSP Collaboration (London, United Kingdom)
Abstracts by Topic 1178 Exome association study and 2nd SNP-GWAS of Japanese Parkinson’s disease W.Satake, Y.Ando, M.Suzuki, H.Tomiyama, Y.Nagai, K.Kashihara, S.Murayama, H.Mochizuki, K.Nakashima, K.Hasegawa, A.Takeda, K.Wada, S.Tsuji, M.Yamamoto, M.Murata, N.Hattori, T.Toda (Kobe, Japan) 1179 Association analysis of the GRN rs5848 and MAPT rs242557 polymorphisms in Chinese patients with PD, ALS and MSA H.Shang, Y.Chen, B.Cao, X.Chen, B.Zhao, Q.Wei, R.Ou, X.Guo (Chengdu, China) 1180 A novel tau mutation, p.K317N, and globular glial tauopathy P.M.Tacik, M.DeTure, W.L.Lin, M.Sanchez Contreras, A.Wojtas, K.M.Hinkle, S.Fujioka, M.C.Baker, R.Walton, Y.Carlomagno, P.Brown, A.Strongosky, N.Kouri, M.E.Murray, L.Petrucelli, K.A.Josephs, R.Rademakers, O.Ross, Z.Wszolek, D.W.Dickson (Jacksonville, FL, USA) 1181 Juvenile Parkinsonism and epilepsy due to homozygous mutations in DNAJC6 P.Termsarasab, T.S.Pearson (New York, NY, USA) 1182 Gene expression in rat brain by GSM900 MHz N.K.Tiwari, V.P.Sharma, A.Pathak (Barabanki, India)
1193 Withdrawn by Author 1194 Physical activity correlates with disease severity among new onset Parkinson’s disease patients P.Gonzalez-Latapi, J.D.Ciolino, T.Simuni (Boston, MA, USA) 1195 New observations in the Fragile-X associated tremor/ataxia syndrome (FXTAS) phenotype D.A.Hall, A.Y.Fraint, P.Vittal, A.Szewka, B.Bernard, E.Berry-Kravis (Chicago, IL, USA) 1196 4-year longitudinal changes in clinical rating, medication and quantitative motor assessment in mild and moderate Parkinson’s disease: Results from the MODEP study S.Heinzel, F.Bernhard, M.Maechtel, T.Heger, S.Nussbaum, W.Maetzler, D.Berg (Tuebingen, Germany)
1183 C9orf 72 repeat expansions in a Canadian provincial cohort A.Venkitachalam, S.Hume, S.Ashtiani, S.Christian, O.Suchowersky (Edmonton, AB, Canada)
1197 Primary familial brain calcification (PFBC) with known gene mutations – A systematic review M.Kasten, V.Tadic, A.Domingo, D.Alvarez Fischer, A.Westenberger, C.Klein (Lübeck, Germany)
1184 Interaction between SNCA, LRRK2 and GAK increases susceptibility to Parkinson’s disease in a Chinese population W.Yu, N.Li, L.Chen, L.Wang, E.K.Tan, R.Peng (Chengdu, China)
1198 Movement disorder emergencies – Experience of tertiary care Neuropsychiatry Center in North India S.Kushwaha, A.Anthony, S.Maheswari (Delhi, India)
PHENOMENOLOGY AND CLINICAL ASSESSMENT OF MOVEMENT DISORDERS
1199 Dysphagia in PD: Response to continuous dopaminergic stimulation A.López, J.P.Cabello, R.Ibáñez, J.Olmedo, J.Vaamonde (Ciudad Real, Spain)
1185 Modulation of dystonia during sleep E.Antelmi, R.Ferri, K.Bhatia, F.Mignani, C.Scaglione, F.Provini, P.Martinelli, R.Liguori (Bologna, Italy)
1200 Two patients with radiographic NPH and idiopathic Parkinson’s disease H.S.Lee, M.F.Lew (Los Angeles, CA, USA)
1186 Implementing a Delphi panel to improve understanding of patient characteristics of advanced Parkinson’s disease A.Antonini, P.Odin, L.Kleinman, A.Skalicky, T.Marshall, K.Sail, K.Onuk (Venice, Italy)
1201 Psychogenic movement disorders in veterans: Phenomenology and psychiatric comorbidity J.D.Mack, J.Quinn, S.O’Connor, B.Lobb, C.Murchison (Portland, OR, USA)
1187 Levodopa responsive Parkinsonism in a subject affected by facioscapulohumeral muscular dystrophy 1 S.Beniaminov, M.Paucar, P.Svenningsson (Stockholm, Sweden) 1188 Assessment of dose failure and delayed-ON with the timeto-ON questionaire (TOQ) and Parkinson’s KinetiGraph in PD patients with motor fluctuations S.Brillman, S.H.Isaacson (Boca Raton, FL, USA)
Abstracts by Topic
1192 The utilization of smartphone devices to enhance clinical interventions J.M.Dean, M.Silverman (Boulder, CO, USA)
1202 Impact of different baseline motor features on prognosis in Parkinson’s disease A.D.Macleod, C.E.Counsell (Aberdeen, United Kingdom) 1203 Voluntary control of facial musculature in Parkinson’s disease M.Marneweck, G.Hammond (New York, NY, USA) 1204 The “Whack-a-Mole” sign in functional movement disorders J.E.Park, C.W.Maurer, M.Hallett (Bethesda, MD, USA)
1189 Hyperkinetic prehension in patients with Parkinson’s disease and levodopa-induced dyskinesias M.A.Burack, C.Geraci, J.Mink (Rochester, NY, USA)
1205 Postural movement strategy for maintaing balance in early Parkinson’s disease with mild postural instability J.H.Park, Y.J.Kang, T.K.Lee, K.B.Sung (Bucheon-si, Korea)
1190 A posturography analysis while dual task differentiates Parkinson’s disease patients from healthy controls B.De la Casa-Fages, F.Alonso-Frech, F.Grandas (Madrid, Spain)
1206 Velopharyngeal dystonia: An unusual focal task-specific dystonia A.Patel, L.Sulica, S.Frucht (New York, NY, USA)
1191 A simple approach to monitoring of Parkinson’s disease state using a Smart phone platform J.M.Dean, M.Silverman (Boulder, CO, USA)
1207 Learning more from finger tapping in Parkinson’s disease: Up and down from dyskinesia to bradykinesia M.Picillo, G.B.Vincos, D.S.Kern, S.H.Fox, A.E.Lang, A.Fasano (Toronto, ON, Canada)
108
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 1208 Clinical features of late-stage early-onset Parkinson´s disease: 38 years of follow-up B.Pinter, A.Diem-Zangerl, G.K.Wenning, W.Oberaigner, K.Seppi, W.Poewe (Innsbruck, Austria) 1209 Falls in ambulatory non-demented patients with Parkinson’s disease O.Rascol, S.Perez-Lloret, P.Damier, A.Delval, P.Derkinderen, A.Destée, W.G.Meissner, F.Tison, L.Negre-Pages (Toulouse, France)
RARE GENETIC AND METABOLIC DISEASES
1221 Replacement therapy with rotigotine in tetrahydrobiopterin deficiency: A case report R.Alberto, P.Francesco, A.Serena, D.M.Francesca, A.Carlo Alberto, B.Andrea, M.Aristide, Z.Maurizio, S.Marco, L.Leonardo, R.Mario Giorgio (Torino, Italy) 1222 Dystonic symptoms in child with GNAO1 mutation respond to bilateral GPi deep brain stimulation R.D.Bhardwaj, J.Badhiwala, N.Remec, F.Shelley, S.Johan (Phoenix, AZ, USA)
1210 Movement quantification for evaluation of gait in Parkinson’s disease using a RGB-D camera system M.J.Rosas, J.P.Cunha, A.Rocha, H.Choupina, J.M.Fernandes, R.Vaz (Porto, Portugal)
1223 Drug response to zinc and D-penicillamine in ATP7B mutant hepatic cell lines G.Chandhok, J.Horvath, A.Aggarwal, M.Bhatt, A.Zibert, H.H.J.Schmidt (Münster, Germany)
1211 Non-motor symptoms profiles of different ethnic groups with Parkinson’s disease: A study comparing the UK, Thailand, Nigeria and Kuwait A.Sauerbier, O.Jitkritsadakul, R.Bhidayasiri, J.Y.Al-Hashel, W.A.Kamel, A.Kilany, T.Farombi, P.Martinez-Martin, R.Brown, M.Parry, A.Martin, R.Inniss, L.Perkins, D.Trivedi, L.Klingelhöfer, A.Rizos, P.Zis, K.Ray Chaudhuri (London, United Kingdom)
1224 Rapidly progressive Parkinsonism in a patient with incontinentia pigmenti J.Y.Chen, V.S.Oza, R.Gopi, C.W.Christine (San Francisco, CA, USA)
1212 Unawareness of hyposmia in elderly people with and without Parkinson’s disease H.A.Shill, J.G.Hentz, J.N.Caviness, E.Driver-Dunckley, S.Jacobson, C.Belden, M.N.Sabbagh, T.G.Beach, C.H.Adler (Sun City, AZ, USA) 1213 Variability of motor symptoms assessments in Parkinson’s disease and levodopa’s effect L.Sid-Otmane, M.Panisset (Montreal, QC, Canada) 1214 The clinical spectrum of PARKIN disease (PARK2) and heterozygous gene mutation carriers R.Stark, J.Walch, B.Tettenborn, G.Kägi (St.Gallen, Switzerland) 1215 Clinical characteristics of Parkinson’s disease with and without family history of essential tremor B.Tserensodnom (Ulaanbaatar, Mongolia) 1216 Stiff-limb syndrome affecting the arm; case report E.Urrea-Mendoza, E.Dornoff, F.J.Revilla (Cincinati, OH, USA) 1217 Identification of freezing of gait in Parkinson’s disease using waist mounted accelerometry H.Zach, A.M.Janssen, A.H.Snijders, A.Delval, M.U.Ferraye, E.Auff, V.Weerdesteyn, B.R.Bloem, J.Nonnekes (Vienna, Austria)
1225 Compound heterozygosity (c.352_353delAG and c.3517A>G) for Niemann-Pick type C1 disease presenting as sporadic adult-onset cerebellar ataxia, dystonia and supranuclear ocular paresis M.Coelho, A.D.Magalhães, L.Correia-Guedes (Lisbon, Portugal) 1226 Neurologic manifestations of Lesch Nyhan syndrome improved with bilateral deep brain stimulation, a case report R.A.Falconer, S.L.Rogers, Y.Yaghi-Torres, K.Grajny, C.Kalhorn, F.Amjad (Washington, DC, USA) 1227 Dystonia and seizures as first manifestations of primary hypoparathyroidism in children: Report of two cases J.Gonzalez Mujica, C.Cosentino Esquerre (Lima, Peru) 1228 A novel PANK2 gene mutation in a patient with pantothenate kinase-associated neurodegeneration J.M.Hatcher-Martin, A.R.Rosen, S.A.Factor (Atlanta, GA, USA) 1229 Familial Creutzfeldt-Jakob disease: A novel phenotype associated with E200K-129M mutation D.Kaul, M.Feldman (Lebanon, NH, USA) 1230 Niemann-Pick type C presenting with psychosis S.Y.Lee, H.J.Lee, S.M.Cheon, J.W.Kim (Busan, Korea) 1231 A Japanese family of hereditary geniospasm R.Miyamoto, T.Kawarai, R.Oki, Y.Miyazaki, Y.Izumi, R.Kaji (Tokushima, Japan) 1232 Triheptanoin dramatically reduces the frequency of paroxysmal movement disorders in GLUT1 deficiency F.Mochel, E.Hainque, D.Gras, I.Adanyeguh, S.Caillet, D.Rinaldi, B.Heron, E.Kaphan, J.Y.Hogrel, L.Servais, E.Roze (Paris, France)
1219 Comparing wearable activity sensors and self-report measures of mobility L.F.Zhu, P.Boissy, C.Lavigne-Pelletier, M.Jog, R.Edwards, C.Duval, M.Speechley (London, ON, Canada)
1233 Niemann Pick C disease in a 20 year old female V.K.Palmadottir, D.Pratt, K.L.Poston (Stanford, CA, USA)
1220 Do distribution and co-existent myoclonus and dystonia aid in the identification of SGCE mutations? R.Zutt, J.M.Dijk, K.Peall, H.Speelman, Y.E.M.Dreissen, M.F.Contarino, M.A.J.Tijssen (Groningen, Netherlands)
Abstracts by Topic
1218 Improving mobility assessment of Parkinson’s patients using the WIMuGPS system L.F.Zhu, P.Boissy, C.Lavigne-Pelletier, M.Jog, R.Edwards, C.Duval, M.Speechley (London, ON, Canada)
1234 Dystonia-spasticity in a patient with a novel SLC25A12 mutation M.Parnes, L.Robak, J.M.Shulman, A.Stocco, J.Jankovic (Houston, TX, USA) 1235 How a flexible differential yielded an elusive diagnosis: A case report K.Ross, J.Axman, A.Harrington, S.Khurana (Miami, FL, USA)
109
Abstracts by Topic 1236 Spectrum of movement disorders in mitochondrial cytopathy patients S.R.Schreglmann, G.Kaegi, F.Riederer, C.R.Baumann, D.Waldvogel, H.H.Jung (St.Gallen, Switzerland) 1237 Adult onset phenylketonuria with rapidly progressive dementia and Parkinsonism Z.Tufekcioglu, A.Cakar, B.Bilgic, H.A.Hanagasi, H.I.Gurvit, M.Emre (Istanbul, Turkey) 1238 Progressive myoclonic epilepsy in a case of adult-onset Leigh syndrome due to T14487C mutation M.Velez, C.Cosentino, M.Flores, J.Montoya, D.Segura, L.Torres (Lima, Peru) 1239 Investigation of factors affecting respiratory suppression in a patient with Perry syndrome under mechanical ventilation K.Yi, R.Kurisaki, K.Nakahara, H.Koide, T.Yamashita, K.Uekawa, Y.Tsuboi (Uki, Japan)
RESTLESS LEGS SYNDROME AND OTHER SLEEP DISORDERS
1240 The prevalence of RLS and severity of symptoms in patients with Idiopatic Parkinson’s disease in the Republic of Macedonia A.Doneva, S.Mancevska, V.Donev (Skopje, Macedonia) 1241 Acute restless legs syndrome and kleptomania after liposuction surgery G.Fabiani, H.A.G.Teive (Curitiba, Brazil) 1242 Decision making in Parkinson’s disease with and without REM sleep behavior disorder M.L.Fantini, P.Beudin, M.Figorilli, A.R.Marques, T.Vidal, B.Debilly, P.Derost, U.Miguel, M.Puligheddu, F.Durif (Clermont-Ferrand, France) 1243 Unilateral restless legs symptoms in neurosyphilis E.B.George, P.Bansal (Detroit, MI, USA) 1244 Reflection impulsivity in patients with restless legs syndrome B.Heim, L.Zamarian, A.Heidbreder, A.Stefani, M.T.Pertl, E.Brandauer, K.Seppi, M.Delazer, W.Poewe, A.Djamshidian, B.Högl (Innsbruck, Austria) 1245 Deep brain stimulation (DBS) of the subthalamic nucleus (STN) improves restless leg syndrome (RLS) in patients with Parkinson’s disease (PD) O.S.Klepitskaya, Y.Liu, S.H.Sillau, J.Tsai, A.S.Walters (Aurora, CO, USA)
Abstracts by Topic
1246 Optic nerve head, retinal nerve fiber layer and macular thickness measurements in patients with restless legs syndrome A.Koskderelioglu, T.Kusbeci, O.Kusbeci, M.Gedizlioglu (Izmir, Turkey) 1247 Frequent causes of misdiagnosis of restless legs syndrome in clinical practice D.Y.Kwon, H.K.Yoon, M.H.Song (Ansan-city, Korea) 1248 Restless legs syndrome leads to reduced quality of life in patients with multiple sclerosis M.Minár, D.Petrleničová, P.Valkovič (Bratislava, Slovakia)
1249 Association between dementia and probable REM sleep behavior disorder (RBD) using the Japanese version of the RBD screening questionnaire in patients with Parkinson’s disease T.Nomura, Y.Tajiri, K.Wada, Y.Inoue, K.Nakashima (Yonago, Japan) 1250 Restless legs syndrome in end-stage renal disease patients in Aracaju - Sergipe: Preliminary results R.C.P.Prado, L.C.Ferreira, L.C.P.Prado (Aracaju, Brazil) 1251 Comparative analysis of restless legs syndrome in end-stage renal disease patients undergoing peritoneal dialysis and hemodialysis in Aracaju - Sergipe: Preliminary results R.C.P.Prado, L.C.Ferreira, L.C.P.Prado (Aracaju, Brazil) 1252 Familial impulse control disorders associated with dopaminergic agonist therapy for RLS M.Schonberger, C.Sidiropoulos, P.LeWitt (West Bloomfield, MI, USA) 1253 Effects of comorbidities on the risk of restless leg syndrome A.Tiltak, F.Genç, F.Kurtulus, N.Uzun, Y.B.Gömceli, A.Yaman (Antalya, Turkey) 1254 Periodic leg movements of sleep under general anesthesia N.Vanegas, M.Hallett, K.A.Zaghloul, C.Lungu (Bethesda, MD, USA) 1255 Post-stroke restless leg syndrome and periodic limb movement disorder H.G.Woo, D.Lee, T.B.Ahn (Seoul, Korea)
TICS/STEREOTYPIES
1256 Goal-directed and habitual behaviour systems in Gilles de la Tourette syndrome C.Delorme, A.Salvador, S.Palminteri, S.de Wit, E.Roze, A.Hartmann, Y.Worbe (Paris, France) 1257 Differential responsiveness of attention, OCD, and tics to medications for Tourette syndrome D.D.Duane, S.Leblang, M.A.Tokuyama (Scottsdale, AZ, USA) 1258 Involuntary movements in adult patients with attention hyperactivity deficit disorder ( AHDH) M.Farah, N.T.Mendes, M.M.Moscovich, A.Moro, R.P.Munhoz, H.A.G.Teive (Curitiba, Brazil) 1259 Premonitory urge to tic in Tourette’s is associated with interoceptive awareness C.Ganos, A.Garrido, I.Navalpotro, L.Ricciardi, D.Martino, M.J.Edwards, M.Tsakiris, P.Haggard, K.P.Bhatia (London, United Kingdom) 1260 The somatotopy of tic inhibition: Where and how much? C.Ganos, J.Bongert, L.Asmuss, D.Martino, P.Haggard, A.Münchau (London, United Kingdom) 1261 Sensory phenomena in tic disorders: Dimensions and clinical associations D.G.Lichter, S.G.Finnegan (Buffalo, NY, USA) 1262 Hand stereotypies in Wilson’s disease S.O.Mittal, A.Ranpura, A.Salardini, B.Jabbari (Cleveland, OH, USA) 1263 The clinical and morphometric featuresof tic hyperkinesis S.E.Munasipova, Z.A.Zalyalova, S.Munasipova (Kazan, Russia)
110
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 1264 Tic attacks: Panic disorder in Tourette syndrome? S.Robinson, P.Hindley, T.Hedderly (London, United Kingdom)
1277 Status of working memory in patients of Parkinson’s disease A.Pal, M.Behari, R.Sharma (New Delhi, India)
1265 Neural correlates of Tourette syndrome within the centromedian thalamus, premotor and primary motor cortices J.Shute, P.J.Rossi, C.de Hemptinne, K.Foote, M.Okun, A.Gunduz (Gainesville, FL, USA)
1278 Cerebral microbleeds in dementia with Lewy bodies and Alzheimer disease and their influence on cognitive decline T.Poliakova, N.Trusova, A.Arablinskiy, O.Levin (Moscow, Russia)
THERAPY IN MOVEMENT DISORDERS: GENE AND CELL-BASED THERAPIES
1266 Enhancement of lysosomal biogenesis reverse A53T mutant α-synuclein induced toxicity M.Bourdenx, S.Dovero, M.Bastide, G.Porras, N.Dutheil, Q.Li, A.Ballabio, E.Bezard, B.Dehay (Bordeaux, France) 1267 From the bedside to the bench: Stem cells from non-familial young-onset patients with Parkinson’s disease S.Sances, W.Lv, M.Tagliatti, C.Svendsen (Los Angeles, CA, USA) 1268 Optogenetic modulation of striatal dopaminergic cell transplants in Parkinsonian rats T.Subramanian, K.Venkiteswaran, T.P.Gilmour, B.Zhang, C.A.Lieu, M.Dawson, Z.Liu, M.P.Subramanian, E.Handly, C.Ramakrishnan, K.Deisseroth (Hershey, PA, USA)
COGNITIVE DISORDERS
1269 The effects of the facial expression of emotions on time perception in patients with Parkinson’s disease L.Bartolomei, G.Mioni, F.Stablum, L.Malesani, L.Meligrana (Vicenza, Italy) 1270 Parkinson’s disease study with virtual week manipulated for emotional valence L.Bartolomei, L.Meligrana, G.Mioni, F.Stablum (Vicenza, Italy) 1271 Pallidal deep brain stimulation improves memory in patients with cervical dystonia: Is the effect on the nucleus basalis of Meynert? M.Chung, R.Huh, I.U.Song (Incheon, Korea) 1272 Age-dependent distribution change of amyloid-beta protein in macaque brains K.Kimura, K.Inoue, F.Tanaka, M.Takada (Yokohama, Japan) 1273 Parkinson’s disease and cognitive reserve F.Mancini, S.Guzzetti, L.G.Manfredi, A.Caporali, R.Daini, A.Antonini (Milano, Italy)
1279 Learning effect plays a significant role in performance on the Montreal cognitive assessment in patients with Parkinson’s disease J.P.Squires, E.Nosova, K.Co, A.Book, O.Yu, V.Silva, C.Thompson, V.O’Neill, S.Yardley, S.Burden, M.McKeown, A.J.Stoessl, S.A.Cresswell (Vancouver, BC, Canada) 1280 A new perspective in cervical dystonia: Neurocognitive impairment Y.Sucullu Karadag, P.Kurt, S.Bilen, N.Subutay Oztekin, F.Ak (Ankara, Turkey)
DYSTONIA
1281 Focal hand dystonia after stroke: Sooner or later? M.Batule Dominguez (Santa Clara, Cuba) 1282 Depression in blepharospasm – A question of facial feedback? J.R.Bedarf, S.Kebir, J.P.Michelis, B.Wabbels, S.Paus (Bonn, Germany) 1283 Using the oculus rift for recording head turns I.M.Beiser, B.Quinlivan, L.J.Williams, E.M.McGovern, S.O’Riordan, J.S.Butler, R.B.Reilly, M.Hutchinson (Dublin, Ireland) 1284 Anatomical basis for the application of onabotulinumtoxinA(BoNT-A) in dystonias M.Bendersky, N.S.Garretto, J.V.Humberto, T.Arakaki, R.Q.Sergio (Buenos Aires, Argentina) 1285 Neural responses during reflexive blinking are abnormal in blepharospasm (BSP) B.D.Berman, D.Kelly, E.Shelton (Aurora, CO, USA) 1286 Non-parametric bootstrapping method for measuring the temporal discrimination threshold for movement disorders J.S.Butler, L.Williams, I.Beiset, E.McGovern, A.Molloy, B.Quinlivan, S.O’Riordan, M.Hutchinson, R.B.Reilly (Dublin, Ireland) 1287 Excitatory motor cortical circuitry in focal hand dystonia and its modulation following incobotulinumtoxinA treatment R.F.H.Cash, K.Udupa, N.Phielipp, C.A.Gunraj, R.Pellicciari, R.Chen (Toronto, ON, Canada) 1288 The evolution of cervical dystonia and patient satisfaction with repeat botulinum toxin therapy: An interim analysis from the INTEREST IN CD2 study D.Charles, V.P.Misra, C.Colosimo, S.Om, P.Maisonobe (Nashville, TN, USA)
1275 Effects of early iron deficiency on catecholaminergic transporters in rat brain W.Mohamed (Shebin el Kom, Egypt)
1289 Temporal patterns of pallidal deep-brain stimulation parameters in patients with cervical dystonia M.Chung, R.Huh, I.U.Song (Incheon, Korea)
1276 Parkinsonism in fragile X-associated tremor/ataxia syndrome (FXTAS) is associated with impaired implicit verbal memory and reduced N400 word repetition effect J.M.Olichney, X.H.Wang, J.C.Yang, R.Hagerman, L.Zhang (Davis, CA, USA)
1290 Correlation between Tsui tremor scores and the Toronto western spasmodic torticollis rating scale (TWSTRS): An analysis of data from the ongoing INTEREST IN CD2 study C.Colosimo, D.Charles, V.P.Misra, P.Maisonobe, S.Om (Rome, Italy)
111
Abstracts by Topic
1274 Characteristic of cognitive and emotional personality disorders in patients with essential tremor R.J.Matmurodov, K.K.Khalimova (Tashkent, Uzbekistan)
Abstracts by Topic 1291 Patient survey in cervical dystonia (CD): Insights into burden of illness and treatment in the United States C.L.Comella, D.Charles (Chicago, IL, USA) 1292 Characteristics of dystonia in multiple system atrophy E.A.Coon, J.E.Ahlskog, M.Suarez, P.A.Low, W.Singer (Rochester, MN, USA) 1293 Athlete’s dystonia J.K.Cutsforth-Gregory, J.H.Bower (Rochester, MN, USA) 1294 What predicts progression of idiopathic adult-onset dystonia? A.D´Abreu, L.Piovesana, I.Lopes-Cendes, L.Marc, N.Sharma (Campinas, Brazil) 1295 Neuropsychological and psychiatric outcome of GPi-deep brain stimulation in dystonia – Preliminary report C.M.de Gusmao, L.E.Pollak, N.Sharma (Boston, MA, USA) 1296 Rapid onset dystonia-Parkinsonism: Report of 3 cases and novel mutation associated with ataxia and cerebellar atrophy C.M.De Gusmao, M.E.Dy, T.J.Multhaupt-Buell, N.Sharma (Boston, MA, USA) 1297 Psychiatric features of GNAL and THAP1 mutation dystonia E.Deegan, A.Glickman, H.Sarva, R.A.Ortega, D.Raymond, L.J.Ozelius, M.Groves, S.B.Bressman, R.Saunders-Pullman (New York, NY, USA) 1298 ICA shows enhanced functional connectivity between cerebellum and thalamus in writer’s cramp C.Dresel, J.Kraenbring, V.Wilzeck, V.Riedl, C.Zimmer, B.Haslinger (Muenchen, Germany) 1299 Genotype-phenotype correlation in X-linked dystoniaParkinsonism (XDP/DYT3) M.E.Dy, M.E.Talkowski, T.J.Multhaupt-Buell, L.R.Paul, D.C.Bragg, N.Sharma (Boston, MA, USA) 1300 Ranking of dystonia severity by pairwise video comparison – A useful method to select items for automated movement analysis T.Ellermeyer, K.Otte, F.Heinrich, S.Mansow-Model, P.Krause, B.Kayser, K.Lauritsch, F.Paul, A.A.Kühn, A.U.Brandt, T.SSchmitz-Hübsch (Berlin, Germany) 1301 Sensory rehabilitation in pseudoathetosis and secondary dystonia. A report of two cases T.Emara, H.Mohsen (Cairo, Egypt) 1302 Primary writing tremor is a dystonic trait: Evidence from a single family R.Erro, M.Ciocca, A.Batla, J.Rothwell, K.P.Bhatia (London, United Kingdom)
Abstracts by Topic
1303 The role of TorsinA in developing neurons B.Fabry, K.Bretzel, T.Ott, K.Grundmann-Hauser, O.Rieß (Tübingen, Germany)
1306 Lack of association between cancer and THAP1 mutation dystonia A.Glickman, R.A.Ortega, H.Sarva, M.San Luciano, D.Raymond, L.J.Ozelius, S.B.Bressman, R.Saunders-Pullman (New York, NY, USA) 1307 Long-term clinical and radiological evolution and DBS therapy outcome in rapid-onsed dystonia Parkinsonism: A case report V.Gonzalez, L.Cif, A.Flaire, E.Sanrey, E.Le Bars, N.Menjot de Champfleur, P.Coubes (Montpellier, France) 1308 Malignant Wilsons disease: Extensive cerebral parenchymal involvement on MRI brain, severe neurological disability and poor therapeutic response S.Gupta, A.Aggarwal, M.Munshi, D.Sanghvi, M.Bhatt (Mumbai, India) 1309 Dystonia in Arab ancestry S.Hanif, T.M.Muhammad, S.Kalantan, J.A.Bajwa (Riyadh, Saudi Arabia) 1310 Eye hand coordination abnormalities in patients with writer’s cramp K.R.Jhunjhunwala, R.Kotikalapudi, A.Lenka, J.Saini, R.Yadav, M.Netravathi, P.K.Pal (Bangalore, India) 1311 Long-term results of the treatment of craniofacial dystonia with onabotulinumtoxinA A.Jochim, F.Castrop, C.Huber, B.Haslinger (Munich, Germany) 1312 Comparative study of spread of A1 and A2 subtypes of botulinum toxin preparations for blepharospasm: Proof-ofconcept randomized controlled trial R.Kaji, A.Miyashiro, S.Kaji, T.Takeuchi (Tokushima, Japan) 1313 The Burke-Fahn-Marsden movement scale is age-dependent in healthy children M.J.Kuiper, L.Vrijenhoek, R.Brandsma, R.J.Lunsing, H.Eggink, K.J.Peall, M.F.Contarino, J.D.Speelman, M.A.J.Tijssen, D.A.Sival (Groningen, Netherlands) 1314 The Babinski-2 sign in hemifacial spasm. A report from a movement disorder clinic in El Salvador J.R.López-Castellanos, J.R.López-Contreras (San Salvador, El Salvador) 1315 Bilateral hemifacial spasm: Report of 6 cases in El Salvador J.R.Lopez-Castellanos, J.R.Lopez-Contreras (San Salvador, El Salvador) 1316 Mutations in ANO3 and GNAL gene in thirty-three isolated dystonia families L.Ma, L.Wang, Y.Yang, T.Feng, X.Wan (Beijing, China) 1317 Mutations in GNAL gene in 214 cases with isolated dystonia L.Ma, L.Wang, Y.Yang, T.Feng, X.Wan (Beijing, China)
1304 Case series of platysmal dystonia J.Y.Fang, K.E.Bradley, C.M.Tolleson, F.T.Phibbs, P.Hedera, T.L.Davis (Nashville, TN, USA)
1318 FMRI during standardized sensory stimulation reveals overactivity and topographic changes in the somatosensory system in patients with embouchure dystonia T.A.Mantel, C.Dresel, E.Altenmüller, C.Zimmer, B.Haslinger (München, Germany)
1305 XCiDaBLE: Observational, prospective trial evaluating xeomin (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the USA H.H.Fernandez, J.Jankovic, F.Pagan, D.Greeley, K.Sethi, A.Verma (Cleveland, OH, USA)
1319 A functional magnetic imaging study of the response in the superior colliculus to looming stimuli in cervical dystonia patients and their relatives E.M.Mc Govern, J.S.Butler, S.Narasimham, L.J.Williams, I.Beiser, R.B.Reilly, S.O’Riordan, M.Hutchinson (Dublin, Ireland)
112
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 1320 Hiker’s cramp: A rare adult-onset isolated focal dystonia due to overuse E.M.Mc Govern, L.J.Williams, I.Beiser, M.Hutchinson, S.O’ Riordan (Dublin, Ireland) 1321 Ultrasound in the treatment of levator scapulae muscle in cervical dystonia with botulinum neurotoxin A: A randomized trial J.P.Michelis, J.R.Bedarf, S.Paus (Bonn, Germany) 1322 Clinical characteristics of cervical dystonia patients presenting for treatment with abobotulinumtoxinA (Dysport®): A meta-analysis comparing data from the US and Europe V.P.Misra, R.Trosch, S.Om, P.Maisonobe (London, United Kingdom) 1323 Which are the most frequently injected muscles in cervical dystonia? An interim analysis of data from the INTEREST IN CD2 observational study V.P.Misra, C.Colosimo, D.Charles, P.Maisonobe, S.Om (London, United Kingdom) 1324 Cervical dystonia and work productivity: Results from the cervical dystonia patient registry for the observation of onabotulinumtoxinA efficacy E.S.Molho, M.Stacy, P.Gillard, D.Charles, C.H.Adler, J.Jankovic, M.Schwartz, M.F.Brin (Albany, NY, USA) 1325 Sun exposure is an environmental factor for the development of blepharospasm A.Molloy, L.Williams, O.Kimmich, J.Butler, I.Beiser, E.McGovern, S.O’Riordan, R.B.Reilly, C.Walsh, M.Hutchinson (Dublin, Ireland) 1326 Relationships among reproductive health variables and cervical dystonia C.C.Nazor, M.M.Thompson, M.S.LeDoux (Memphis, TN, USA) 1327 Clinical profile of writer’s cramp patients S.Pandey, N.Sarma, G.Soni (New Delhi, India) 1328 First report of two brothers with Panay ancestry with MohrTraenbjaerg syndrome J.M.G.Penamora-Destriza, R.L.Rosales, A.Domingo, C.Klein (Quezon City, Philippines) 1329 A literature review of possible environmental factors in the pathogenesis of dystonia D.A.Peterson, T.J.Sejnowski (La Jolla, CA, USA)
1331 A case of severe dystonia secondary to pediatric hemolytic uremic syndrome T.Pham (Portland, OR, USA) 1332 Whole exome sequencing in a case of rapidly progressive generalized dystonia with Parkinsonian features T.T.Pham (Portland, OR, USA)
1334 Abnormal cerebellar plasticity in primary cervical dystonia, a preliminary report P.Porcacchia, F.J.Palomar, J.F.Martin-Rodriguez, I.Huertas-Fernandez, M.A.RuizRodriguez, M.Gomez-Crespo, F.Carrillo, M.T.Caceres-Redondo, G.Koch, P.Mir (Sevilla, Spain) 1335 Electrophysiological and behavioural measures of the dynamics of motor learning: implications for probing learning in neurological conditions B.Quinlivan, J.S.Butler, A.R.Ridwan, L.Williams, I.Beiser, E.McGovern, S.O’Riordan, M.Hutchinson, R.B.Reilly (Dublin, Ireland) 1336 Multifocal task specific dystonia in a 61-year-old-female: A case report with sensory trick physiology V.F.M.L.Ramos, A.L.Holmes, B.I.Karp, C.I.Lungu, K.Alter, H.Mark (Bethesda, MD, USA) 1337 Comparison of the safety and efficacy of botulinum toxin type-A and anticholinergics in the treatment of cervical dystonia patients M.Relja, J.Bozikov (Zagreb, Croatia) 1338 A study of motor and non-motor gains following placement of a deep brain stimulator in a pediatric non-ambulatory patient with dystonia N.Remec, K.Wing, R.Bhardwaj, S.Flecky, J.Semanta (Phoenix, AZ, USA) 1339 Neurochemical and behavioral dysfunction in a new mouse model of dopa-responsive dystonia S.J.Rose, X.Y.Yu, H.A.Jinnah, E.J.Hess (Decatur, GA, USA) 1340 Kinematic biomechanical characterization guides incobotulinumtoxinA treatment in cervical dystonia patients O.Samotus, H.Vafadar, F.Rahimi, M.Jog (London, ON, Canada) 1341 Adult-onset axial dystonia responds to globus pallidus deep brain stimulation A.G.Shaikh, K.Mewes, H.A.Jinnah, M.R.DeLong, R.E.Gross, S.Triche, A.Freeman, S.A.Factor (Cleveland, OH, USA) 1342 Ocular palatal tremor plus dystonia – A novel syndromic entity A.G.Shaikh, F.F.Ghasia, M.R.DeLong, H.A.Jinnah, A.Freeman, S.A.Factor (Cleveland, OH, USA) 1343 Neural correlates of GNAL mutation in laryngeal dystonia K.Simonyan, G.Putzel, T.Fuchs, E.Rubien-Thomas, A.Blitzer, S.J.Frucht, L.Ozelius (New York, NY, USA) 1344 Effectiveness of onabotulinumtoxinA in patients with cervical dystonia naive to botulinum toxin treatment C.Singer, R.Barbano, M.Schwartz, M.F.Brin, C.H.Adler (Miami, FL, USA) 1345 DBS in dystonic camptocormia: A case report and review P.Surathi, A.Zafar, R.Yadav, D.Srinivas, P.K.Pal (Bangalore, India) 1346 Zolpidem in movement disorder after cardiac arrest H.A.G.Teive, M.S.Silva, D.B.Bertholdo, W.O.Arruda (Curitiba, Brazil)
113
Abstracts by Topic
1330 Baseline characteristics and health-related quality of life in patients treated with onabotulinumtoxinA for cervical dystonia in a multicentre, prospective, observational study: POSTURe M.Petitclerc, S.Dhani, M.Bhogal, L.Belle Blagrove (Saint-Romuald, QC, Canada)
1333 Molecular investigation in dystonia: A new THAP1 mutation and the questionable role of a polymorphism in the TOR1A gene L.G.Piovesana, F.R.Torres, P.C.Azevedo, T.P.Amaral, M.M.V.Rosa, M.C.França, Jr., I.Lopes-Cendes, A.D’Abreu (Campinas, Brazil)
Abstracts by Topic 1347 Depression is an under-recognized feature in X-linked dystonia Parkinsonism P.Termsarasab, A.Patel, S.J.Frucht, W.Tse (New York, NY, USA) 1348 Embouchure dystonia: Phenomenology, natural history and mimicks P.Termsarasab, S.J.Frucht (New York, NY, USA) 1349 Do positive family history influence on the characteristics of the adult onset dystonia? S.Tomic, T.Gilman Kuric, M.Petek, T.Pucic, S.Juric, S.Butkovic Soldo (Osijek, Croatia) 1350 Botulinum toxin for neurogenic thoracic outlet syndrome A.T.Tran, R.Koopot, G.Moguel-Cobos, A.Lieberman, A.T.Tran (Phoenix, AZ, USA) 1351 Patterns of cervical dystonia: A meta-analysis of three large observational studies R.Trosch, P.Misra, S.Om, P.Maisonobe (Farmington Hills, MI, USA) 1352 TWSTRS scores in cervical dystonia patients previously treated with botulinum neurotoxin A (BoNT-A) versus those naïve to treatment R.Trosch, P.Misra, P.Maisonobe, S.Om (Farmington Hills, MI, USA)
1361 A novel THAP1 sequence variant does not co-segregate with blepharospasm in a large African-American pedigree J.Xiao, M.M.Thompson, S.R.Vemula, M.S.LeDoux (Memphis, TN, USA) 1362 The Addenbrooke’s cognitive examination-revised detects cognitive deficits in primary blepharospasm J.Yang, N.Shao, W.Song, Q.Wei, X.Guo, R.Ou, B.Cao, H.Shang (Chengdu, China) 1363 Dystonic head tremor in a musician playing “daegeum”, Korean traditional bamboo woodwind H.J.Yang, B.J.Gwon, W.J.Kim, J.H.Kwon, H.J.Kim, B.S.Jeon (Ulsan, Korea) 1364 Pregnancy in a series of dystonia patients treated with deep brain stimulation (DBS): Outcomes and management recommendations N.Ziman, R.R.Coleman, P.A.Starr, H.Walker, M.Volz, S.Guthrie, J.L.Ostrem (San Francisco, CA, USA)
HUNTINGTON’S DISEASE
1353 Botulinum toxin modulates motor cortical potentiation and depotentiation in focal hand dystonia K.Udupa, N.Phielipp, R.F.H.Cash, C.Gunraj, R.Pellicciari, T.Hoque, R.Chen (Toronto, ON, Canada)
1365 Investigating disinhibited behaviour in Huntington’s disease (HD): Subjective ratings and motor and cognitive correlates S.C.Andrews, D.Craufurd, R.Reilmann, S.J.Tabrizi, J.C.Stout, Track HD Investigators (Melbourne, Australia)
1354 Increased excitatory parietal and dorsal premotor connections to the primary motor cortex during action planning in focal hand dystonia M.Vesia, G.Jegatheeswaran, R.Isayama, R.Pellicciari, R.Chen (Toronto, ON, Canada)
1366 Multisensory cues could be effective to improve balance and gait in Huntington´s disease? T.T.C.Capato, M.S.Haddad, M.E.P.Piemonte, E.R.Barbosa (São Paulo, Brazil)
1355 Task specific oromandibular dystonia secondary to chewing khat (cantha edulis) P.M.Wadia, J.N.Khanna (Mumbai, India) 1356 Thalamic volume is reduced in multiple types of dystonia J.L.Waugh, J.K.Kuster, J.M.Levenstein, N.Makris, T.J.Multhaupt-Buell, L.Sudarsky, H.C.Breiter, N.Sharma, A.J.Blood (Boston, MA, USA) 1357 Capturing what is important to patients with dystonia: A systematic review and assessment of health-related quality of life (hrqol) measures N.Wickert, S.Walleser Autiero (Tolochenaz, Switzerland)
Abstracts by Topic
1360 Women do it better: Sexual dimorphism in temporal discrimination: Biological implications L.Williams, A.Molloy, O.Kimmich, D.Bradley, I.Beiser, E.McGovern, R.Reilly, S.O’Riordan, J.S.Butler, M.Hutchinson (Dublin, Ireland)
1358 A SPECT study of type 2 dopamine receptors in patients with adult onset primary torsion dystonia and their unaffected first degree relatives L.Williams, O.Kimmich, A.Molloy, I.Beiser, E.McGovern, R.Killeen, S.Skehan, C.Collins, J.Butler, R.Reilly, S.O’Riordan, M.Hutchinson (Dublin, Ireland) 1359 Characterisation of adult onset isolated focal dystonia in an Irish population L.Williams, A.Molloy, O.Kimmich, E.McGovern, I.Beiser, R.Walsh, D.Healy, H.Moore, F.Molloy, J.Butler, L.Cassidy, P.Moriarty, S.O’Riordan, M.Hutchinson (Dublin, Ireland)
114
1367 Can the mutant huntingtin gene product spread from cell to cell: Evidence from neuronal allografts in Huntington’s disease patients F.Cicchetti, S.Lacroix, G.Cisbani, N.Vallières, M.Saint-Pierre, I.St-Amour, R.Tolouei, J.N.Skepper, R.A.Hauser, D.Mantovani, R.A.Barker, T.B.Freeman (Québec, QC, Canada) 1368 Clinical characteristics and motivations of individuals undergoing predictive testing for Huntington’s disease (HD) J.Corey-Bloom, S.K.Nam, A.Herndon, L.Korty (La Jolla, CA, USA) 1369 The Huntington’s disease-behavioral questionnaire (HD-BQ): A new screening tool for behavioral disturbances in HD J.Corey-Bloom, A.Herndon, A.Lam, P.Gilbert (La Jolla, CA, USA) 1370 Assessing psychiatric symptoms in individuals with, and at risk for, Huntington’s disease J.Corey-Bloom, S.J.Howell, A.Herndon (La Jolla, CA, USA) 1371 Relationship of body mass index with Huntington´s disease severity. A Spanish multicenter study E.Cubo, J.Rivadeneyra, D.Armesto, R.Camara, N.Mariscal-Pérez (Burgos, Spain) 1372 Outcomes of bilateral GPi DBS in three patients with Huntington’s disease C.Delorme, A.Dürr, C.Karachi, J.Yelnik, M.L.Welter, D.Grabli (Paris, France)
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 1373 PPAR- α activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: Possible neuroprotective mechanisms D.K.Dhull, D.Bhateja, A.Sidhu, B.V.K.Reddy, S.S.V.Padi, A.Kumar (Chandigarh, India) 1374 Alternative for reducing chorea in Huntington disease (ARCHD): Results from the Switch cohort S.Frank, Huntington Study Group/ARC-HD Switch Investigators (Boston, MA, USA) 1375 First time use of SD-809 in Huntington disease (first-HD) S.Frank, Huntington Study Group/First-HD Investigators (Boston, MA, USA) 1376 Determining Huntingtin’s endogenous functions using drosophila and mammalian systems E.Furr Stimming, Y.N.Rui, Z.Xu, Z.Chen, D.Chen, Y.Sun, A.Tito, S.Zhang (Houston, TX, USA) 1377 Progressive degeneration of nigrostriatal pathway in Huntington disease. A 123I-FP-CIT SPECT three-year follow-up study J.Gamez, O.De Fabregues, C.Lorenzo-Bosquet, G.Cuberas-Borros, M.Salvado, F.Carmona, J.Alvarez-Sabin, J.Castell-Conesa (Barcelona, Spain) 1378 Time perception in Huntington disease E.M.Gatto, P.Agostino, M.Cesarini, A.Sanguinetti, J.L.Etcheverry, D.Golombek (Buenos Aires, Argentina) 1379 Circadian rhythm and chronotype in Huntington’s disease C.O.Godeiro, Jr., J.E.Rosado, Jr., L.A.Freire, R.A.Lucena, T.L.Silva, J.A.Fontenele (Natal, Brazil) 1380 Using a brief balance assessment to estimate disease onset in Huntington’s disease A.Herndon, J.Corey-Bloom, A.Lam, C.Heil, S.K.Nam, P.Gilbert, D.Goble (La Jolla, CA, USA) 1381 Examining cognitive processing speed in Huntington’s disease (HD) A.Herndon, A.S.Nathan, J.Corey-Bloom (La Jolla, CA, USA) 1382 Objective measurement of gait abnormalities in Huntington disease using a shoe-worn inertial sensor P.Hogarth, A.Lenahan, A.Portillo, R.K.Ramachandran, K.A.Stenson, A.T.R.Legedza, M.C.Botfield, F.B.Horak, J.McNames, M.El-Gohary (Portland, OR, USA) 1383 Effects of motor rehabilitation on walking economy in patients with Huntington’s disease J.L.Kubica, J.Szymura, E.Mirek, M.Filip, M.Rudzińska, K.Banaszkiewicz, M.Maciejczyk, M.Więcek, U.Pustułka-Piwnik, J.Stożek, S.Pasiut (Krakow, Poland)
1385 Microglial dysfunction plays a critical role in Huntington disease pathogenesis B.R.Leavitt, C.Connolly, A.Hill, L.Hayardeny, M.R.Hayden (Vancouver, BC, Canada)
1387 Metabolic brain correlates of apathetic symptoms in premanifested Huntington’s disease: An 18-FDG PET study S.Martinez-Horta, J.Perez-Perez, F.Sampedro-Santalo, R.Fernandez-Bobadilla, M.Carceller, J.Pagonabarraga, A.Campolongo, B.Gomez-Anson, B.PascualSedano, V.Camacho-Marti, D.Lopez-Mora, J.Kulisevsky (Barcelona, Spain) 1388 PET/CT findings along premanifested and early symptomatic Huntington’s disease J.Pérez-Pérez, S.Martínez-Horta, F.Sanpedro-Santalo, M.Carceller-Sindreu, J.Pagonabarraga, B.Pascual-Sedano, A.Campolongo, V.Camacho, D.Alonso, B.Gómez-Anson, J.Kulisevsky (Barcelona, Spain) 1389 Functional limitations of the upper limb in prodromal and early manifest Huntington’s disease A.K.Rao, J.Uddin, C.C.Chen, K.S.Marder (New York, NY, USA) 1390 Gait speed modulation in prodromal and early manifest Huntington’s disease: Role of internal and external cues A.K.Rao, F.Porciuncula, J.Uddin, K.S.Marder (New York, NY, USA) 1391 Design of the LEGATO-HD study: A multinational, randomized, double-blind, placebo-controlled, parallelgroup study to evaluate the efficacy and safety of laquinimod (0.5, 1.0 and 1.5 mg/day) as treatment in patients with Huntington’s disease R.Reilmann, S.Tabrizi, B.Leavitt, J.C.Stout, P.Piccini, K.E.Anderson, A.Feigin, M.Hayden, M.Grozinski-Wolff, E.Eyal, A.Wickenberg (Tuebingen, Germany) 1392 Longitudinal assessment of PDE10 in Huntington disease (HD) using [18F]MNI-659 PET imaging D.S.Russell, D.L.Jennings, O.Barret, G.D.Tamagnan, V.M.Carroll, D.Alagille, T.J.Morley, C.Papin, J.P.Seibyl, K.L.Marek (New Haven, CT, USA) 1393 The effect of olanzapine on cognition in Huntington’s disease L.Schwab, S.Mason, R.Barker (Cambridge, United Kingdom) 1394 A genetically-proven case of Huntington’s disease in the Philippines M.L.D.Supnet, A.F.Diaz (Manila, Philippines) 1395 Abnormal electrophysiological motor responses in Huntington’s disease: Evidence of premanifest compensation L.M.Turner, R.Croft, A.Churchyard, J.C.L.Looi, D.Apthorp, N.Georgiou-Karistianis (Canberra, Australia) 1396 Dopamine D2 receptor and phosphodiesterase 10A loss in Huntington´s disease measured with high-resolution PET and partial volume effect correction C.Fitzer-Attas, A.Varrone, P.Fazio, M.Schain, L.Mrzljak, J.Bronzova, B.Landwehrmeyer, N.Al-Tawil, S.Martinsson, C.Halldin, C.Sampaio, EHDN Recruting sites (Stockholm, Sweden) 1397 Callosal thickness progressively changes in Huntington disease: 30 month IMAGE-HD data F.A.Wilkes, M.Walterfang, C.Adamson, J.C.L.Looi, M.L.Seal, D.Velakoulis, J.Stout, A.Churchyard, P.Chua, G.F.Egan, N.Georgiou-Karistianis (Canberra, Australia)
115
Abstracts by Topic
1384 Safety of pridopidine when taken with antidepressants or antipsychotics: Pooled analysis from two Huntington’s disease clinical trials G.B.Landwehrmeyer, S.Zhao, V.Abler (Ulm, Germany)
1386 What determines the behavioral onset in Huntington’s disease? Insight from 90 genetically confirmed patients A.Lenka, N.L.Kamble, S.Venugopal, K.R.Jhunjhunwala, R.Yadav, M.Netravathi, M.Kandasamy, N.Moily, M.Purushottam, S.Jain, P.K.Pal (Bangalore, India)
Abstracts by Topic QUALITY OF LIFE/CAREGIVER BURDEN IN MOVEMENT DISORDERS
1398 Impact of cognitive dysfunction on dysphagia and dysarthria in Parkinson’s disease: A study in Uruguay B.Aguiar, J.Higgie, R.Aljanti, M.Martinovic, R.Buzo, V.Raggio, A.Ojeda, G.Montado, V.Pomar, G.Nogueira, L.Aguerre, E.Cortinas, F.Martinez (Montevideo, Uruguay) 1399 Socioeconomical analysis in a population of Parkinson´s disease patients in a public hospital of Argentina M.L.Assante, S.A.Rodríguez-Quiroga, M.J.Casen, C.Christie, M.Mancuso, V.Díaz Aragunde, T.Arakaki, N.S.Garretto (Ciudad Autónoma de Buenos Aires, Argentina) 1400 Quality of life’s evaluations in Parkinson’s disease: Self and caregiver agreement Y.Balash, A.D.Korczyn, J.Knaani, T.Gurevich (Tel Aviv, Israel) 1401 Parkinson’s and parenting: The impact on children, teens and young adults E.S.Book (Vancouver, BC, Canada) 1402 Quality of life, motor symptoms and subthalamic deep brain stimulation in Parkinson’s disease. How do they interact with each other? J.F.Daneault, C.Duval, A.F.Sadikot (Montreal, QC, Canada) 1403 Rehospitalization in Parkinson’s disease patients S.De Jesus, L.Shahgholi, S.S.Wu, Q.Pei, A.Hassan, P.Schmidt, M.Okun (Gainesville, FL, USA)
1412 Collaboration and consultation, improving quality of care and life for people with Parkinson’s V.McConvey, B.Wotherspoon, T.Osborn, N.Graham (Cheltenham, Australia) 1413 Evaluating mortality in hospitalised patients with Parkinson’s disease M.Modi, K.Dean, A.Chatterjee (Reading, United Kingdom) 1414 End-of-life treatment preferences in Parkinson’s disease H.L.Ng, W.Li, A.N.Piano, S.Abdul Karim, W.Li, K.Y.Tay, W.L.Au, L.C.S.Tan (Singapore) 1415 Evaluating a new multidisciplinary movement disorders clinic J.S.Riley, A.K.Chatterjee, S.E.Williams, A.Plowman, J.Caffrey (Reading, United Kingdom) 1416 Economic burden of Parkinson’s disease (PD) on caregivers K.Sail, J.Signorovitch, R.Sorg, F.Mu, T.Marshall (North Chicago, IL, USA) 1417 Health care disease burden severity among caregivers of Parkinson’s disease patients in an Arab cohort Y.A.Seddeq, N.H.Al-Shammari, T.M.Mohammad, M.S.Bashir, J.A.Bajwa (Riyadh, Saudi Arabia)
1404 Measuring community mobility of people with Parkinson’s disease and their spouse using WIMuGPS C.Duval, L.Zhu, P.Boissy, C.Lavigne-Pelletier, M.Jog, R.Edwards, M.Speechley (Montréal, QC, Canada)
1418 Gender differences in health care disease burden severity among caregivers of Parkinson’s disease patients in an Arab cohort Y.A.Seddeq, N.H.Al-Shammari, T.M.Mohammad, M.S.Bashir, J.A.Bajwa (Riyadh, Saudi Arabia)
1405 Improvement of individual quality of life in caregivers and patients under L-dopa/carbidopa duodenal infusion therapy C.Ehlers, H.Honig, P.Odin (Bremen, Germany)
1419 Parkinson’s disease impact on quality of life of individuals in mild and moderate stages R.C.P.Silva e Moreira, M.B.Zonta, H.A.G.Teive (Curitiba, Brazil)
1406 Anxiety and depressive symptoms are independent predictors of physical health related quality of life in a Brazilian sample of Parkinson’s disease patients evaluated for deep brain stimulation F.C.Freitas, A.P.Diaz, M.E.R.O.Thais, F.Z.S.Areas, P.E.L.Vieira, R.Guarnieri, R.D.S.Prediger, M.N.Linhares, R.Walz (Florianópolis, Brazil)
1420 The quality of life in Korean hemifacial spasm patients S.K.Song, J.H.Kang (Jeju, Korea)
1407 Burden in caregivers of patients with Parkinson’s disease D.Grün, V.Pieri, M.Vaillant, N.J.Diederich (Luxembourg, Luxembourg)
Abstracts by Topic
1411 Mood disorders and health-related quality of life in Parkinson’s disease T.Maeda, T.Shinoda, D.Takano, T.Yamazaki, Y.Fujimaki, Y.Satoh, K.Nagata (Akita, Japan)
1408 Factors influencing the poor quality of life in patients with Parkinson’s disease M.I.Khalil, M.R.Rahman, M.Hakim, N.C.Kundu, P.C.Das, M.M.Islam (Dhaka, Bangladesh) 1409 Translation into Polish and validation of two quality of life assessment modules for patients with Parkinson’s diseaseQLSM-MD and QLSM-DBS A.T.Krygowska-Wajs, K.A.Tomaszewski, A.Gorecka-Mazur, W.Pietraszko, K.Potasz (Cracow, Poland) 1410 Quality of life predictors in Parkinson’s disease at the Lagos University Teaching Hospital T.A.Lawal, N.U.Okubadejo, O.O.Ojo, M.A.Danesi (Lagos, Nigeria)
116
1421 Advance care planning: Perspectives of people living with Parkinson’s disease (PD) M.P.Sritharan (Bristol, United Kingdom) 1422 Interdisciplinary home visits to improve outcomes for advanced Parkinson’s disease patients B.Stone, A.C.Lemen, M.M.Sweeney, J.Fleisher, G.Dacpano, M.Harris, R.M.Gilbert, M.J.Nirenberg, A.Di Rocco (New York, NY, USA) 1423 Translation of the 39-item Parkinson’s disease questionnaire to Filipino C.T.R.Suratos, G.M.Saranza, R.D.G.Jamora, D.G.Sumalapao (Manila, Philippines) 1424 The effects of movement disorders affecting cervico-facial region on quality of life F.Tokucoglu, B.Selbes, M.M.Ozcelik, N.Tuncay (Izmir, Turkey) 1425 Life sustaining treatment orders, location of death, and comorbid conditions for Oregon decedents with Parkinson’s disease K.K.Tuck, D.M.Zive, T.A.Schmidt, J.Nutt, J.Carter, E.K.Fromme (Portland, OR, USA)
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Abstracts by Topic 1426 Withdrawn by Author 1427 A systematic review of self-management of Parkinson’s disease, as a chronic disease S.A.Wherry, C.Das, P.Dugdale, C.Lueck (ACT, Australia) 1428 Evaluation of sarcopenia in Parkinson’s disease O.Yilmaz Kusbeci, B.Donmez Colakoglu, I.Inci, E.Duran, R.Cakmur (Izmir, Turkey)
SPASTICITY
1429 Usefulness of communication calendar for botulinum toxin therapy of spasticity in an outpatient setting F.Adib Saberi, H.Pickenbrock, D.Dressler (Hamburg, Germany) 1430 Systematic literature review of abobotulinumtoxinA in clinical trials for lower limb spasticity J.J.Chen, K.Dashtipour, H.Walker, M.Y.Lee (Fullerton, CA, USA) 1431 Botolinum toxin injection to the upper limb indirectly improves gait in patients with post-stroke spasticity O.S.Cohen, E.Shprits, S.Hassin-Baer, Y.Dotan-Marom, G.Yahalom, O.Marzeliak, L.Ephraty, H.Strauss, E.Stein, H.Baransi, R.Inzelberg, M.Plotnik (Ramat-Gan, Israel) 1432 Prevalence and treatment of spasticity among veterans living in a long-term care facility A.D.Currie, M.Turchan, T.S.Hudson, J.D.Roach, L.E.Heusinkveld, F.T.Phibbs, C.M.Tolleson, A.L.Molinari, C.E.Gill, D.Charles (Nashville, TN, USA) 1433 Safety profile of repeat onabotulinumtoxinA doses of 400U for the treatment of upper limb spasticity L.James, R.Dimitrova, G.Pan, C.Asare, C.Thompson (Irvine, CA, USA) 1434 Comparative clinical study of A1 and A2 subtypes of botulinum toxin preparations for post-stroke spasticity: Proof-of-concept randomized controlled phase 2/3 trial R.Kaji, A.Miyashiro, T.Furumoto, N.Sato, W.Sako, S.Kaji (Tokushima, Japan) 1435 Long-term treatment of spasticity with onabotulinumtoxinA in intellectually and developmentally disabled adults A.L.Molinari, M.Turchan, A.D.Currie, C.E.Gill, H.M.Taylor, D.Charles (Nashville, TN, USA) 1436 Phenotypical variability in a family with PLA2G6 p.R747W mutation J.K.Park, T.O.Son, Y.E.Huh, H.T.Kim, J.W.Cho (Seoul, Korea) 1437 Is onabotulinum toxin effective in long-term spasticity? I.Reuter, S.Mehnert (Giessen, Germany)
1439 Brachial plexus botulinum toxin a injection - Case report Z.Sycz (Wroclaw, Poland)
1441 OnabotulinumtoxinA improves pain in post-stroke spasticity patients: Findings from a randomized controlled trial J.Wissel, V.Ganapathy, J.Ma, A.B.Ward, J.Borg, P.Ertzgaard, A.Fulford-Smith, P.Gillard (Berlin, Germany)
TREMOR
1442 Fahn-Tolosa-Marin scale, digitizing tablet and accelerometry have comparable minimum detectable change E.Akano, T.Zesiewicz, R.Elble (Springfield, IL, USA) 1443 A simultaneous case of Parkinson’s disease (PD) and essential tremor (ET) H.Amirjanyan, K.Harutyunyan, I.Gabrielyan, H.Manvelyan (Nor Hachen, Armenia) 1444 Rate-controlled syllable repetitions improve comparability of DBS-induced dysarthria between on- and off-state in patients with essential tremor J.Becker, D.Mücke, A.Hermes, T.A.Dembek, A.F.Josten, I.Meister, V.VisserVandewalle, M.Grice, L.Timmermann, M.T.Barbe (Cologne, Germany) 1445 Smartphone apps provide a simple, accurate bedside screening tool for orthostatic tremor D.Bhatti, R.Thompson, A.Hellman, C.Penke, J.M.Bertoni, D.Torres-Russotto (Omaha, NE, USA) 1446 EEG analysis in 30 patients with orthostatic tremor D.Bhatti, N.Murr, A.Hellman, R.Iske, J.M.Bertoni, D.Torres-Russotto (Omaha, NE, USA) 1447 Frequency of tremor in postural orthostatic tachycardia syndrome A.Deb, A.Hohler (Boston, MA, USA) 1448 Fahn-Tolosa-Marin tremor scale and digitizing tablet have comparable minimum detectable change R.Elble, T.Zesiewicz (Springfield, IL, USA) 1449 Hypertrophic olivary degeneration does not reduce essential tremor A.Elkouzi, J.C.Kattah, R.J.Elble (Springfield, IL, USA) 1450 The long-term outcome of orthostatic tremor C.Ganos, L.Maugest, E.Apartis, C.Gasca-Salas, M.T.Cáceres-Redondo, R.Erro, I.Navalpotro, A.Batla, E.Antelmi, B.Degos, E.Roze, M.L.Welter, T.Mestre, F.J.Palomar, C.Cordivari, P.Mir, A.E.Lang, S.H.Fox, K.P.Bhatia, M.Vidailhet (London, United Kingdom) 1451 Hereditary geniospasm in a Central American family E.Haberfeld, L.Timothy (Philadelphia, PA, USA) 1452 A case of misdiagnosed essential tremor (ET) K.Harutyunyan, I.Gabrielyan, H.Amirjanyan, S.Khachaturyan, A.Voskanyan, G.Avagyan, H.Manvelyan (Yerevan, Armenia) 1453 Electromyographic assessment of essential and Parkinsonian hand tremor E.Ivanova, P.Fedin, A.Broutian, I.Ivanova-Smolenskaya, S.Illarioshkin (Moscow, Russia)
117
Abstracts by Topic
1438 Rationale and design of a randomised, double-blind, placebo-controlled study to assess the impact of early use of abobotulinumtoxinA (Dysport®) on spasticity progression in adults with post-stroke upper limb spasticity in Asia (ONTIME study) R.L.Rosales, J.Balcaitiene, P.Maisonobe, K.H.Kong, K.J.Goh, W.Kumthornthip (Manila, Philippines)
1440 Hereditary spastic paraplegia: Characterization of an Albertan cohort A.Venkitachalam, E.McKenzie, S.Ashtiani, C.Huculak, L.McLaren, O.Suchowersky (Edmonton, AB, Canada)
Abstracts by Topic 1454 Different features of iron deposition in subcortical nuclei between essential tremor and tremor-dominant Parkinson’s disease L.Jin, J.Wang, G.Fei, C.Zhong (Shanghai, China)
1468 Longitudinal kinematic characterization of upper limb essential tremor to effectively guide incobotulinumtoxinA treatment O.Samotus, J.Lee, F.Rahimi, M.Jog (London, ON, Canada)
1455 The efficacy of electrical muscle stimulation in various tremor syndromes: An open-label, pilot study including 68 patients O.Jitkritsadakul, C.Thanawattano, C.Anan, R.Bhidayasiri (Bangkok, Thailand)
1469 Improvement of repeated Archimedes spirals in essential tremor: Evidence for a learning effect? N.Schuhmayer, C.Weber, M.Kieler, W.Pirker, E.Auff, D.Haubenberger (Vienna, Austria)
1456 Evaluation of retinal nerve fiber layer in essential tremor and Parkinson’s disease with optical coherence tomography H.Kaleagasi, H.Fidanci, U.Adiguzel, O.Dogu (Mersin, Turkey)
1470 Elderly onset essential tremor and cognitive impairment H.A.Shill, J.G.Hentz, J.N.Caviness, E.Driver-Dunckley, S.Jacobson, C.Belden, M.N.Sabbagh, T.G.Beach, C.H.Adler (Sun City, AZ, USA)
1457 Case report: Replacement therapy of head shaking syndrome by transcranial magnetic stimulation B.B.Khodaie, M.M.Ahmadi, M.M.Lotfinia, A.A.A.A.Lotfinia (Tehran, Iran)
1471 A patient with bilateral cerebellar tremors secondary to a unilateral brainstem lesion A.T.Tran, G.Moguel-Cobos, N.Salins, A.Deep, A.Lieberman (Phoenix, AZ, USA)
1458 The involvement of dopamine receptors in the regulation of harmaline-induced tremor measured by force plate actimeters B.Kosmowska, U.Głowacka, J.Wardas, K.Ossowska (Kraków, Poland)
1472 Induced jaw and hand tremor and their relationship with motor asymmetry in Parkinson’s disease E.Wang, C.Considine, L.Verhagen (Chicago, IL, USA)
1459 Climbing fiber-Purkinje cell synaptic changes correlate with clinical features in essential tremor S.H.Kuo, R.J.Louis, C.Y.Lin, A.H.Koeppen, P.L.Faust, E.D.Louis (New York, NY, USA) 1460 Essential tremor in patients with Parkinson’s disease K.Kurako, S.McMahan, N.Galvez-Jimenez (Weston, USA) 1461 Upper limb kinematics guides longitudinal, incobotulinumtoxinA therapy of Parkinson’s disease tremor J.Lee, O.Samotus, F.Rahimi, M.Jog (London, ON, Canada) 1462 Gait variability changes after unilateral VIM DBS in essential tremor patients are correlated with changes in midline and upper extremity tremor H.Morita, M.Higuchi, L.A.Zukowski, R.Roemmich, K.D.Foote, C.J.Hass, M.S.Okun (Gainesville, FL, USA) 1463 Non-motor symptoms of essential tremor are independent of tremor severity and have an impact on quality of life T.Musacchio, V.Purrer, A.Papagianni, A.Fleischer, D.Mackenrodt, C.Malsch, G.Gelbrich, F.Steigerwald, J.Volkmann, S.Klebe (Würzburg, Germany) 1464 Possibility of differential diagnosis between functional and organic tremor N.M.Pavlyshyna, O.M.Stoyanov (Odessa, Ukraine)
Abstracts by Topic
1465 Functional connectivity in the sensorimotor cortex in Parkinson’s patients with and without tremor S.E.Qasim, C.de Hemptinne, N.Swann, P.A.Starr (San Francisco, CA, USA) 1466 Head tremor in essential tremor: “Yes-yes”, “no-no”, or round and round? D.Robakis, L.D.Elan (New York, NY, USA) 1467 Unilateral palatal tremor in a patient with brainstem vasculitis F.A.S.Sallem, S.C.B.Casagrande (São Paulo, Brazil)
118
1473 Saccade-related modulation of beta oscillation in the human thalamus A.Yugeta, W.D.Hutchison, R.Chen (Tokyo, Japan)
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Late-Breaking Abstracts LBA 01 - Occurrence of Impulsive Compulsive Behaviours in Patients with Parkinson’s Disease Treated with Apomorphine LBA 02 - A panel of 16 biomarkers from multiple modalities separates Parkinson’s disease patients with and without dementia LBA 03 - Deep brain stimulation of the globus pallidus pars interna or subthalamic nucleus for Parkinson’s disease: 3-year followup of a randomized controlled trial LBA 04 - Clinical outcomes in Parkinson’s disease for asleep deep brain stimulation with electrodes placed using intraoperative imaging versus awake deep brain stimulation with microelectrode recording LBA 05 - Genome-wide expression profiling identifies potential molecular pathways involved in X-linked dystoniaparkinsonism (XDP, DYT3) LBA 06 - Neuronal Plasmalemmal Disruptions Induce Alterations in Dopaminergic Neurons and Alpha-Synuclein Expression Following Traumatic Brain Injury in Swine LBA 07 - Marked parasympathetic denervation in the gut of de novo Parkinson’s disease - A [11C]donepezil PET study LBA 08 - Stable levodopa plasma levels with ND0612 (levodopa/ carbidopa for subcutaneous infusion) in Parkinson’s disease (PD) patients with motor fluctuations LBA 09 – Alpha-synuclein genetic variability: A biomarker for dementia in Parkinson’s disease LBA 10 - The ReSPonD trial: Rivastigmine to stabilise gait in Parkinson’s Disease. A phase II, randomised, double blind, placebo-controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson’s disease who have fallen LBA 11 – A non-human primate model of Parkinson’s disease based on viral vector mediated overexpression of alpha-synuclein LBA 12 - Functional NIRS-mediated neurofeedback for cerebellar ataxia: potential therapy for augmenting rehabilitative intervention
LBA 13 – Loss of phosphodiesterase 10A signaling is associated with progression and severity in patients with Parkinson’s disease LBA 14 - PREDICT-PD: Identifying Risk of Parkinson’s disease in the Community LBA 15 - Initiating regular exercise behaviors is associated with slower decline in quality of life in Parkinson’s disease (National Parkinson Foundation Quality Improvement Initiative data) LBA 16 - Veering in Hemi-Parkinson’s Disease: Primacy of Visual over Motor Contributions LBA 17 - Motor speech impairment indicates prodromal neurodegeneration in REM sleep behaviour disorder LBA 18 - Evaluation of dual-phase 123I-FP-CIT SPECT imaging in parkinsonism LBA 19 - Results From a Randomized, Double-Blind, PlaceboControlled, Single Ascending-Dose Study in Healthy Subjects With PRX002, an Anti–Alpha-Synuclein Monoclonal Antibody LBA 20 - Tau-PET Imaging in Progressive Supranuclear Palsy Using [18F] AV-1451 LBA 21 - Incident impulse control disorder behaviors and serial dopamine transporter imaging in early Parkinson disease LBA 22 – Comparison of the effects on cognition and behavior in patients with Parkinson’s disease treated with subthalamic stimulation or with continuous levodopa duodenal infusion LBA 23 - Cognitive impairment as a feature of prodromal Parkinson’s disease: evidence from the PARS study LBA 24 - ApoE genotype mediates recurrent falls risk in early Parkinson’s disease LBA 25 - Submandibular Gland Needle Biopsy for the Diagnosis of Early Parkinson’s Disease
Late-Breaking Abstracts
119
MDS Study Group Abstracts SG 01 - The Movement Disorders Society-Endorsed PSP Study Group SG 02 - A non-interventional study to assess the presence of impulsive-compulsive behaviors in an outpatient population with Parkinson’s disease SG 03 - Diagnostic discriminating power of cortical and subcortical MR indices in Multiple System Atrophy: A cross-sectional MODIMSA multicenter study SG 04 - Early subthalamic neurostimulation improves quality of life of elderly patients with Parkinson’s disease SG 05 - Subthalamic stimulation lead coordinates correlate with non-motor effects in Parkinson’s disease SG 06 - A multicentre study of the patient’s perspective: The first Parkinson’s disease pain questionnaire (King’s PD pain quest)
120
SG 07 - Non-motor symptoms profiles of different ethnic groups with Parkinson’s disease: A study comparing the UK, Thailand, Nigeria SG 08 - Dopamine transporter scan (DaTscan) and clinical global impression of severity of Parkinson’s disease: Data from a non motor SG 09 - Effect of acute non-oral dopaminergic (apomorphine and levodopa) treatment on non-motor symptoms in Parkinson’s disease SG 10 - Sleep assessment in Parkinson’s disease - The use of Parkinson’s KinetiGraph SG 11 - PD-MCI: application of the Level I criteria and prediction of PDD SG 12 - Predictive Validity of Level II PD-MCI Criteria for PDD SG 13 - Benign Progressive Supranuclear Palsy: a clinicopathological analysis of cases with prolonged survival
Almost a billion people suffer from neurologic conditions worldwide.
They are what motivates us. What makes us different makes a difference. For over 100 years, we’ve committed ourselves to not only designing products that have a meaningful impact on the lives of patients, but thinking beyond our products by developing programs and initiatives that hold the patient’s needs at their center. We are proud of how we think differently, act differently, and
TM
collaborate differently. We have a unique culture of ownership and ambition that allows innovation and creativity to bloom.
To learn more, visit us at www.MerzUSA.com. © 2014 Merz North America, Inc. 5033235-00 (04/2014)
We care.
Our research for your health.
apomorphine hydrochloride Britannia Pharmaceuticals Ltd
APO-go® Apomorphine hydrochloride PRESCRIBING INFORMATION Consult Summary of Product Characteristics before prescribing. Uses Treatment of motor fluctuations (“on-off” phenomena) in patients with Parkinson’s disease which are not sufficiently controlled by oral anti-Parkinson medication Dosage and Administration Apomorphine hydrochloride is administered subcutaneously either as an intermittent bolus injection or by continuous subcutaneous infusion. Its rapid onset (5-10 mins) and duration of action (about 1 hour) may prevent an “off” episode which is refractory to other treatments. Apomorphine should be initiated in the controlled environment of a specialist clinic. The patient should be supervised by a physician experienced in the treatment of Parkinson’s disease (e.g. neurologist). Please refer to the Summary of Product Characteristics for full details before initiating therapy. Treatment with domperidone (typical dosage 20mg three times a day) before and during apomorphine HCl therapy is essential. The optimal dosage of apomorphine HCl has to be determined on an individual patient basis; individual bolus injections should not exceed 10mg and the total daily dose should not exceed 100mg. Do not use if the solution has turned green. The solution should be inspected visually prior to use. Only clear, colourless and particle free solution should be used. Contraindications Children and adolescents (up to 18 years of age). Known sensitivity to apomorphine or any other ingredients of the product. Respiratory depression, dementia, psychotic disease or hepatic insuffi ciency. Intermittent apomorphine HCl treatment is not suitable for patients who have an “on” response to levodopa which is marred by severe dyskinesia or dystonia. Pregnancy and lactation Apomorphine should not be used in pregnancy unless clearly necessary. Breast-feeding should be avoided during apomorphine HCl therapy. Interactions Patients should be monitored for potential interactions during initial stages of apomorphine therapy. Particular caution should be given when apomorphine is used with other medications that have a narrow therapeutic window. It should be noted that there is potential for interaction with neuroleptic and antihypertensive agents. It is recommended to avoid the administration of apomorphine with other drugs known to prolong the QT interval. Apomorphine can increase the antihypertensive effects of domperidone. Precautions Use with caution in patients with renal, pulmonary or cardiovascular Date of preparation: January 2015
Rapid reliable ‘on’ for Parkinson’s disease disease, or who are prone to nausea or vomiting. Extra caution is recommended during initiation of therapy in elderly. and/or debilitated patients. Since apomorphine may produce hypotension, care should be exercised in patients with cardiac disease or who are taking vasoactive drugs, particularly when pre-existing postural hypotension is present. Neuropsychiatric disturbances are common in Parkinsonian patients. APO-go should be used with special caution in these patients. Apomorphine has been associated with somnolence and episodes of sudden sleep onset, particularly in patients with Parkinson’s disease. Patients must be informed of this and advised to exercise caution whilst driving or operating machines during treatment with apomorphine. Haematology tests should be undertaken at regular intervals as with levodopa with given concomitantly with apomorphine. Patients should be regularly monitored for the development of impulse control disorders. Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including apomorphine. Dose reduction/tapered discontinuation should be considered if such symptoms develop. Since apomorphine, especially at high dose, may have the potential for QT prolongation, caution should be exercised when treating patients at risk for torsades de pointes arrhythmia. Apomorphine has been associated with local subcutaneous effects that can be reduced by rotation of injection sites or use of ultrasound on areas of nodularity and induration. Contains sodium metabisulphite which rarely causes severe allergic reactions and broncospasm. Side Effects Local induration and nodules (usually asymptomatic) often develop at subcutaneous site of injection leading to areas of erythema, tenderness, induration and panniculitus. Irritation, itching, bruising and pain may also occur. Rarely injection site necrosis and ulceration have been reported. Pruritus may occur at the site of injection. Drug-induced dyskinesias during “on” periods can be severe, and in a few patients may result in cessation of therapy. Postural hypotension is seen infrequently and is usually intransient. Transient sedation following each dose of apomorphine may occur at the start of therapy, but this usually resolves after a
few weeks of treatment. Dizziness and light-headedness have also been reported. Nausea and vomiting may occur, particularly when APO-go treatment is initiated, usually as a result of the omission of domperidone. Neuropyschiatric disturbances (including transient mild confusion and visual hallucinations) have occurred during apomorphine therapy and neuropsychiatric disturbances may be exacerbated by apomorphine. Positive Coombs’ tests and haemolytic anaemia and thrombocytopenia have been reported in patients receiving apomorphine and levodopa. Local and generalised rashes have been reported. Eosinophilia has occurred in only a few patients during treatment with apomorphine HCl. Patients treated with dopamine agonists, including apomorphine, have been reported as exhibiting signs of pathological gambling, increased libido and hypersexuality (especially at high doses). Apomorphine is associated with somnolence. Yawning and breathing diffi culties have been reported as has peripheral oedema. Prescribers should consult the Summary of Product Characteristics in relation to other side effects Presentation and Basic NHS Cost APO-go ampoules contain apomorphine hydrochloride 10mg/ml, as follows: 20mg in 2ml – basic NHS cost £37.96 per carton of 5 ampoules. 50mg in 5ml – basic NHS cost £73.11 per carton of 5 ampoules. APO-go pens (disposable multiple dosage injector system) contain apomorphine hydrochloride 10mg/ml, as follows: 30mg in 3ml – basic NHS cost £123.91 per carton of 5 pens. APO-go Pre-filled syringes contain apomorphine hydrochloride 5mg/ml, as follows: 50mg in 10ml – basic NHS cost £73.11 per carton of 5 syringes. Marketing Authorisation Numbers: APO-go Ampoules: PL 06831/0245 APO-go Pens: PL 06831/0246 APO-go Pre filled syringes: PL 06831/0247 Legal Category POM Date of last revision: December 2014 For further information please contact: Britannia Pharmaceuticals, Park View House, 65 London Road, Newbury, Berkshire, RG14 1JN, UK Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Medical Information on 0870 851 0207 or [emailprotected] Version Number: APG.PI.V22 Item code: APO1-0115-0551
APOKYN has new options for patient access. In-home initiations are now available!*
Stop by
BOOTH 701
to Learn More. *In accordance with applicable state regulations. Indication APOKYN is indicated for the acute, intermittent treatment of hypomobility, off episodes (end-of-dose wearing-off and unpredictable on-off episodes) associated with advanced Parkinson’s disease. APOKYN has been studied as an adjunct to other medications. Important Safety Information Contraindication: Concomitant use of APOKYN with 5HT3 antagonists is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron. Contraindication: APOKYN is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients (notably sodium metabisulfite). SC Injection: APOKYN should be administered by subcutaneous injection, NOT intravenously, because serious adverse events like thrombus formation and pulmonary embolism may occur. Patients and care partners must receive detailed instructions in the preparation and injection of doses, with particular attention paid to the correct use of the dosing pen. Nausea and Vomiting: At recommended doses of apomorphine, severe nausea and vomiting can be expected. Therefore, trimethobenzamide hydrochloride should be started 3 days prior to the initial dose of APOKYN and continued for at least 2 months. In clinical trials, 50% of patients (262/522) discontinued trimethobenzamide hydrochloride after 2 months of APOKYN. Falling Asleep During Activities of Daily Living (ADL): There have been reports of patients treated with apomorphine subcutaneous injections who suddenly fell asleep while engaged in ADL. Patients should be advised not to drive or participate in potentially dangerous activities until it is known how APOKYN affects them. Patients should be continually reassessed for daytime drowsiness or sleepiness. Symptomatic Hypotension: Dopamine agonists, including APOKYN, can cause hypotension, orthostatic hypotension, and syncope. Alcohol, antihypertensive medications, and vasodilating medications may potentiate the hypotensive effect of apomorphine. These adverse events occurred with initial dosing and long-term treatment. Whether hypotension contributes to other significant events seen (e.g., falls) is unknown. Falls: Patients wth Parkinson’s disease (PD) are at risk of falling due to the underlying postural instability and concomitant autonomic instability seen in some patients with PD, and from syncope caused by the blood pressure lowering effects of the drugs used to treat PD. Hallucinations / Psychotic-Like Behavior: APOKYN has been associated with new or worsening mental status and behavioral changes, which may be severe, including psychotic-like behavior. This abnormal thinking and behavior can consist of paranoid ideation, delusions, hallucinations, confusion, disorientation, aggressive behavior, agitation and delirium.
Dyskinesias: APOKYN may cause dyskinesia or exacerbate pre-existing dyskinesia. Intense Urges: Some people with PD have reported new or increased gambling urges, increased sexual urges, and other intense urges, while taking PD medicines, including APOKYN. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to specifically ask patients or their care partners about the development of new or increased gambling urges, sexual urges, uncontrolled spending or other urges while being treated with APOKYN. Physicians should consider dose reduction or stopping the medication if a patient develops such urges while taking APOKYN. Cardiac Events: Coronary Events—APOKYN reduces resting systolic and diastolic blood pressure and has the potential to exacerbate coronary (and cerebral) ischemia. Therefore, exercise caution when prescribing APOKYN for patients with known cardiovascular and cerebrovascular disease. QT Prolongation—Caution is recommended when administering APOKYN to patients with increased risk of QT prolongation, such as those with hypokalemia, hypomagnesemia, bradycardia, or a genetic predisposition, or who use other drugs that prolong the QT/QTc interval. Melanoma: Patients with Parkinson’s disease have a higher risk of developing melanoma than the general population. Patients should be monitored for melanomas frequently when using APOKYN. Adverse Events: The most common adverse events seen in controlled trials were yawning, drowsiness/somnolence, dyskinesias, dizziness/ postural hypotension, rhinorrhea, nausea and/or vomiting, hallucinations/ confusion and edema/swelling of extremities. Injection-site reactions, including bruising, granuloma, and pruritus, have been reported. To report SUSPECTED ADVERSE REACTIONS or product complaints, contact US WorldMeds at 1-877-727-6596 (1-877-7APOKYN). You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Please see booth representative for full Prescribing Information and Pen Instructions for Use/Patient Information. All trademarks are the property of their respective owners.
US WorldMeds, LLC is the exclusive licensee and distributor of APOKYN in the United States and Its territories. © 2015 Britannia Pharmaceuticals Limited. APOKYN is a registered trademark of Britannia Pharmaceuticals Limited. USWM-APO462-0115
WHAT WHAT ARE ARE YOUR YOUR PATIENTS PATIENTS WITH WITH PDPD PSYCHOSIS PSYCHOSIS HOLDING HOLDING BACK? BACK? Join ACADIA Join ACADIA Pharmaceuticals Pharmaceuticals Inc. for Inc. a virtual for a virtual realityreality experience experience that will that transform will transform how you how you see PD see psychosis. PD psychosis.
SeeSee what what they they seesee booth booth 309 309
For more For more information, information, visit visit PDpsychosis.com. PDpsychosis.com. Parkinson’s Parkinson’s disease (PD). disease (PD).
© ACADIA©Pharmaceuticals ACADIA Pharmaceuticals Inc. All rights Inc.reserved. All rights reserved. PDP-0016PDP-0016 06/15 06/15
Corporate Therapeutic Symposia The following company-based information sessions will provide delegates with non-CME educational opportunities to learn the latest in therapeutics.
SUNDAY, JUNE 14, 2015
MONDAY, JUNE 15, 2015
Lundbeck US
Teva Pharmaceutical
13:15-14:15 Location: Harbor B-C, 2nd Level, Harbor Tower Advances in the treatment of symptomatic Neurogenic Orthostatic Hypotension (nOH) Chair: Rajesh Pahwa Kansas City, KS, USA
14:00-15:00 Location: Seaport G-H, 2nd Level, Seaport Tower Designing Huntington’s disease trials to address unmet patient needs Chair: Karl Kieburtz Rochester, NY, USA
Orthostatic hypotension in the movement disorder patient
Horacio Kaufmann New York, NY, USA
Evaluating cardiovascular health in the patient with nOH - TBD
Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension
Stuart Isaacson Miami, FL, USA
Case study discussion
Daniel Claassen Nashville, TN, USA
MONDAY, JUNE 15, 2015 Britannia Pharmaceuticals, Ltd. and US WorldMeds 14:00-15:00 Location: Harbor D-F, 2nd Level, Harbor Tower Subcutaneous apomorphine for Parkinson’s disease motor fluctuations: Emerging treatment strategies
Corporate Therapeutic Symposia
APO-go® infusion in the treatment of motor fluctuations: Continuous Reliable “ON”
K. Ray Chaudhuri London, United Kingdom
126
Novel markers in Huntington’s disease
Bernhard Landwehrmeyer Ulm, Germany
Clinical scales used in interventional HD Trials
Tiago Mestre Ottawa, ON, Canada
TUESDAY, JUNE 16, 2015 Zambon 13:45-15:00 Location: Harbor D-F, 2nd Level, Harbor Tower Parkinson’s disease 2015: Advances in understanding disease pathways and progression Chairs: C. Warren Olanow New York, NY, USA Paolo Barone Napoli, Italy
Unmet needs in Parkinson’s disease: from pathophysiology to treatments
José Obeso Madrid, Spain
Apokyn® (apomorphine hydrochloride injection): Rapid & Reliable Turning “ON”
Stuart Isaacson Miami, FL, USA
Karl Kieburtz Rochester, NY, USA
Introduction to the fluctuating response of levodopa & the role of Apomorphine
Peter LeWitt Detroit, MI, USA
Unmet needs in Huntington’s disease
Dopamine and glutamate alterations in Parkinson’s disease: new insights
Stella Papa Atlanta, GA, USA
Moving forward in Parkinson’s disease: Advances in therapy for motor and non-motor complications
K. Ray Chaudhuri London, United Kingdom
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Corporate Therapeutic Symposia TUESDAY, JUNE 16, 2015
WEDNESDAY, JUNE 17, 2015
Ipsen
ACADIA Pharmaceuticals
14:00-15:00 Location: Seaport G-H, 2nd Level, Seaport Tower Management of patients with cervical dystonia: A step forward Chair: Joseph Jankovic Houston, TX, USA
13:30-14:30 Location: Seaport G-H, 2nd Level, Seaport Tower Beyond motor symptoms of Parkinson’s disease
Listening to patients perspectives
Janet Hieshetter Chicago, IL, USA
How could abobotulinum toxin A increase patient’s and physician’ satisfaction?
Mark Lew Los Angeles, CA, USA
Reshaping the toxins world for patients
Keith Foster Salisbury, United Kingdom
UCB 19:45-20:45 Location: Harbor D-F, 2nd Level, Harbor Tower The path of Parkinson’s disease patients in an evolving era Chair: William Ondo Houston, TX, USA
Is there a need for pharmacotherapy in newly diagnosed parkinson’s patients?
Larry Elmer Toledo, OH, USA
Managing parkinson’s disease patients in an electronic era with mobile devices
Kevin Biglan Rochester, NY, USA
Neuropsychiatric complications of Parkinson’s disease: focus on parkinson’s disease psychosis
David John Burn Newcastle upon Tyne, United Kingdom
Sleep disturbance in Parkinson’s disease
Alon Y. Avidan Los Angeles, CA, USA
Caregiver burden: Challenges in Parkinson’s disease psychosis
Jennifer Goldman Chicago, IL, USA
Medtronic 13:30-14:30 Location: Harbor D-F, 2nd Level, Harbor Tower Long-term outcomes & therapeutic optimization of DBS for Parkinson’s disease William J. Marks, Jr. San Francisco, CA, USA Jens Volkmann Wũrzburg, Germany
THURSDAY, JUNE 18, 2015 Cynapsus Therapeutics 13:30-14:30 Location Harbor D-F, 2nd Level, Harbor Tower Waiting to turn ON: The impact and importance of OFF episodes in Parkinson’s disease patients and the need for turning ON therapies Chair: C. Warren Olanow New York, NY, USA Stuart Isaacson Miami, FL, USA Robert Hauser Tampa, FL, USA Russell Katz USA 13:30-14:30 Location Seaport G-H, 2nd Level, Seaport Tower Evolving role of personalized strategies and patient-centered approaches in the management of Parkinson’s disease from clinical data to individualized care Michele Tagliati Los Angeles, CA, USA Mayela Rodriguez-Violante Mexico City, Mexico
127
Corporate Therapeutic Symposia
Med Learning Group
Science and Technology Pavillion Science and Technology Pavilion Location: Regatta, 4th Level, Harbor Tower Through the Science and Technology Pavilion, MDS’ industry partners provide delegates the opportunity to learn about the latest science in an interactive session. CME credit is not given for any activities in the Science and Technology Pavilion. All Congress participants are encouraged to visit the Pavilion. Lundbeck US Monday, June 15 10:00-17:00 The Lundbeck Medical Affairs Science and Technology Pavilion will showcase an overview of Symptomatic Neurogenic Orthostatic Hypotension (NOH) via interactive kiosk/media, and will be presented by key clinical experts/study investigators and Lundbeck Medical Affairs representatives.
128
AbbVie Wednesday, June 17 10:00-17:00 The Abbvie-sponsored Science and Technology Pavilion will provide an educational platform to learn more about Advanced Parkinson’s disease, Multidisciplinary Care and carbidopa and levodopa enteral suspension. In addition to information displays throughout the day, delegates have an opportunity to attend medical presentations by clinical experts involved in multidisciplinary care and Advanced Parkinson’s disease at 12:30 and 16:00.
INNOVATION DRIVES OUR SCIENCE. HUMANITY DRIVES OUR PURPOSE. To address healthcare challenges across the world, we unite a biotech spirit with the strength of a successful pharmaceutical business. The result is a biopharmaceutical company combining science, passion, and expertise to improve health and healthcare in new ways. Making a remarkable impact in people’s lives is more than our promise. It’s our purpose.
Please visit us at Booth #411 abbvie.com
Please join us! Advances in potential new therapies for Hyperkinetic Movement Disorders Sponsored by Auspex Pharmaceuticals Heavy hors d’oeuvres and cocktails will be served at 7:30pm
Event date and time: Tuesday, June 16, 2015, from 8pm to 9pm Location: Seaport GH, Manchester Grand Hyatt
PRESENTERS Joseph Jankovic, MD
Professor of Neurology Distinguished Chair in Movement Disorders Director, Parkinson’s Disease Center and Movement Disorders Clinic Department of Neurology Baylor College of Medicine
Hubert H. Fernandez, MD Professor of Medicine (Neurology) Cleveland Clinic Lerner College of Medicine Case Western Reserve University Co-Chair, Parkinson’s Study Group
David Stamler, MD
Chief Medical Officer, Auspex Pharmaceuticals
130
Restoring Movement with Ease
-
Cynapsus is proud to be a supporter of the 19th International Congress of Parkinson’s Disease and Movement Disorders. Cynapsus is a specialty pharmaceutical company developing a convenient and easy to use sublingual (oral mucosal) thin film strip which provides a rapid, reliable and sustained “ON” in Parkinson's disease patients suffering all types of “OFF” episodes. Cynapsus’ drug candidate, APL-130277, is an easy-toadminister, fast-acting reformulation of apomorphine, which is the only approved drug (in the United States, Europe, Japan and other countries) for the acute, intermittent treatment of “OFF” episodes in Parkinson's disease patients. Cynapsus is focused on completing the clinical, regulatory development and commercialization of APL-130277 such that it might provide patients, their care givers and neurologists a convenient and safe means of achieving a fast “ON”. TSX: CTH OTCQX: CYNAF
www.cynapsus.ca
Exhibitor Information EXHIBIT HALL
Location: Grand Hall, Lobby Level Please allow adequate time in your daily schedule to visit the Exhibit Hall. The exhibition is an integral component of your International Congress experience, offering you the opportunity to speak with representatives of companies providing services or marketing products directly related to Movement Disorders. Exhibit Hall hours are as follows: Monday, June 15 Tuesday, June 16 Wednesday, June 17 Thursday, June 18
9:00 – 18:00 9:00 – 18:00 9:00 – 18:00 9:00 – 16:00
EXHIBITOR REGISTRATION
Location: Palm Foyer, 2nd Level Exhibitors must register and pick up their badge at the Exhibitor Registration Desk. Exhibitor Registration Desk hours are as follows:
Exhibitor Information
Saturday, June 13: Sunday, June 14: Monday, June 15: Tuesday, June 16: Wednesday, June 17: Thursday, June 18:
132
16:00 – 20:00 7:00 – 20:00 7:00 – 18:00 7:00 – 18:00 7:00 – 18:00 7:00 – 16:00
EXHIBITOR BADGE POLICY
Admission to the Exhibit Hall will be by name badge only. Security guards will monitor Exhibit Hall entrances for proper identification. Exhibit stand personnel must show an official MDS exhibitor name badge in order to gain access to the Exhibit Hall during installation, show, or dismantlement hours. Exhibitor Personnel Badge (Yellow): Allows admittance to the Exhibit Hall only.
ENDORSEMENT DISCLAIMER
Products and services displayed in the Exhibit Hall or advertised in the program occur by contractual business arrangements between MDS and participating companies and organizations. These arrangements do not constitute nor imply an endorsement by MDS of these products and services.
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Exhibitor Information EXHIBIT AND POSTER HALL FLOOR PLAN
Exhibitor Information
133
Exhibitor Directory ABBVIE
1 North Waukegan Road North Chicago, IL 60064 USA Telephone: +1 800-255-5162 Website: www.abbvie.com Booth #: 411 AbbVie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.
ACADIA PHARMACEUTICALS
11085 Torreyana Road, Suite 100 San Diego, CA 92121 USA Telephone: +1 858-320-8655 Website: www.acadia-pharm.com Booth #: 309 ACADIA Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders.
ACORDA THERAPEUTICS, INC.
Exhibitor Information
420 Saw Mill River Road Ardsley, NY 10502 USA Telephone: +1 914-347-4300 Website: www.acorda.com
Booth #: 812 Acorda Therapeutics develops therapies that restore function and improve the lives of people with neurological disorders. Acorda markets threeFDAapproved therapies, includingAMPYRA®(dalfampridine) Extended Release Tablets, 10 mg. The Company has a pipeline of novel therapies that addresses a range of disorders, including post-stroke walking deficits, Parkinson’s disease, epilepsy and MS.
134
ALLERGAN, INC.
2525 Dupont Drive Irvine, CA 92612 USA Telephone: +1 714-246-4500 Fax: +1 714-246-4971 Website: www.allergan.com Booth #: 519 Allergan is a multi-specialty healthcare company established more than 60 years ago with a commitment to uncovering the best of science and helping people reach their life’s potential. With approximately 11,400 employees worldwide, we are committed to discovering new therapies to treat unmet medical needs in eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics and urology. APC55PQ14
AMERICAN PARKINSON DISEASE ASSOCIATION
135 Parkinson Avenue Staten Island, NY 10305 USA Telephone: +1 718-981-8001, ext 125 Fax: +1 718-981-4399 Website: www.apdaparkinson.org
Table #: 7 The American Parkinson Disease Association (APDA) was founded in 1961 to Ease the Burden – Find the Cure for Parkinson’s disease. APDA provides patient services and education serving more than 1 million American’s with Parkinson’s disease and their families and research opportunities for new scientists in the field of PD research as well as continued funding for established senior investigators.
AUSPEX PHARMACEUTICALS
3333 North Torrey Pines Court, Suite 400 La Jolla, CA 92037 USA Telephone: +1 858-558-2400 Fax: +1 858-558-2401 Website: www.auspexpharma.com Booth #: 707 Auspex is a late stage biopharmaceutical company dedicated to developing innovative medicines for movement disorders. Auspex’s lead product candidate SD-809 is in the final stages of development for the treatment of chorea associated with Huntington’s disease. Auspex is also evaluating SD-809 for the treatment of tardive dyskinesia and tics associated with Tourette syndrome.
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Exhibitor Directory BENIGN ESSENTIAL BLEPHAROSPASM RESEARCH FOUNDATION, INC.
P.O. Box 12468 Beaumont, TX 77726-2468 USA Telephone: +1 409-832-0788 Fax: +1 409-832-0890 Website: www.blepharospasm.org
Table #: 5 The purpose of BEBRF is to promote, develop and carry on the search for the cause and cure for Benign Essential Blepharospasm/Meige and other related disorders.
BOSTON SCIENTIFIC
25155 Rye Canyon Loop Valencia, CA 91355 USA Telephone: +1 661-949-4000 Website: www.vercise.com Booth #: 315 Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. As an innovation leader in Neuromodulation and implantable Deep Brain Stimulation Technology, Boston Scientific is committed to transforming lives through innovative medical solutions that improve the health of patients.
BRITANNIA PHARMACEUTICALS LTD.
200 Longwater Avenue Green Park, Reading RG2 6GP United Kingdom Telephone: +44 011 892 15900 Website: www.britannia-pharm.com www.apo-go.com
Booth #: 821 GAITRite is a truly portable pressure sensitive walkway with a quick 5 minute setup measuring temporal spatial parameters, providing easy identification of gait anomalies, comes in various lengths. Our new wider SURFACE System allows instrumentation of an entire room and is Wi-Fi based. All GAITRite Systems provide reporting publishing options.
FHC, INC.
1201 Main Street Bowdoin, ME 04287 USA Telephone: +1 207-666-8190 Fax: +1 207-666-8292 Website: www.fh-co.com Booth #: 621 Innovating through collaboration with the neuroscience community, FHC presents its latest and signature offerings: Distance Expert®– Neurophysiology for telemedical DBS-surgical assistance; neuroCase for onsite DBS case support; STarFix™ for patient-specific, “no capital” stereotaxy; WayPoint™ Navigator for planning and visualizing; and STar™ Drive for neurosurgical positioning (24/7 technical support available).
FULGENT DIAGNOSTICS
4978 Santa Anita Avenue, Suite 205 Temple City, CA 91780 USA Telephone: +1 626-350-0537 Fax: +1 626-454-1667 Booth #: 709 Fulgent Diagnostics provides a wide array of genetic testing ranging from 4,600+ single gene tests, 170+ preset panels, rearrangement testing, and All-in-One reflex test. Fulgent Diagnostics provides flexibility. We tailor our tests to your unique requirements at the most competitive pricing available compared to any CLIA lab in the industry.
135
Exhibitor Information
Booth #: 601 Britannia Pharmaceuticals Limited is a UK based pharmaceutical company specializing in niche innovative products for chronic and serious medical conditions, and in particular, the treatment of patients with Parkinson’s disease. The need for apomorphine as a treatment option for Parkinson’s disease has led to the development of APO-go and other associated brands around the globe, which are available in many countries through our Distribution or Licensing Partners.
CIR SYSTEMS/GAITRITE
376 Lafayette Road, Suite 202 PO Box 899 Sparta, NJ 07871 USA Telephone: +1 973-862-6151 Fax: +1 973-862-6451 Website: www.gaitrite.com
Exhibitor Directory GE HEALTHCARE
31047 Genstar Road Hayward, CA 94544 USA Telephone: +1 510-240-6042 Website: www.impaxpharma.com
Booth #: 811 GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.
Booth #: 815 Impax Pharmaceuticals™ is a branded product division of Impax Laboratories™, Inc. Impax Pharmaceuticals is focused on targeting significant unmet needs, with a primary focus on developing treatments for neurological disorders.
GLOBAL KINETICS CORPORATION
530 Collins Street, Level 6 Melbourne, VIC 3000 Australia Telephone: +61 3 9605 0034 Website: www.globalkineticscorporation.com Booth #: 617 GKC has developed the Parkinson’s KinetiGraph (PKG). The PKG provides an objective, ambulatory assessment of Parkinson’s patients during activities of daily living, via a simple wristwatch-like device worn continuously for 6-10 days. It reports their clinical state including scaled measures of bradykinesia & dyskinesia, fluctuation severity, a one-number fluctuation score, self-reported concordance and periods of daytime sleepiness.
GREAT LAKES NEUROTECHNOLOGIES
Exhibitor Information
IMPAX PHARMACEUTICALS
35c Campus Drive, 5th Floor Marlborough, MA 01752 USA Telephone: +1 508-683-2368 Website: www.gehealthcare.com
10055 Sweet Valley Drive Valley View, OH 44125 USA Telephone: +1 216-361-5410 Fax: +1 216-361-5420 Website: www.GLNeuroTech.com
Booth #: 711 Kinesia technology provides continuous Parkinson’s monitoring for in-clinic and home applications. Intelligent remote sensing technology increases sensitivity and reliability of outcome measures for pharmaceutical trials, DBS measurement, and patient care. Kinesia is validated in over 60 publications and is successfully used in pharmaceutical and medical device trials around the globe. 136
INSIGHTEC
Nachum Chet 5 Street Haifa 39120 Israel Telephone: +972 4 8131380 Website: www.insightec.com Booth #: 718 INSIGHTEC is the global leader in MR-guided Focused Ultrasound (MRgFUS) and developer of the ExAblate therapeutic platform. The first company to successfully focus ultrasound through the cranium, INSIGHTEC offers a noninvasive treatment option for the treatment of essential tremor, Parkinson’s tremor and neuropathic pain and has CE mark for these treatments. The ExAblate Neuro is presently an Investigational Device undergoing FDA clinical evaluation in the US. INSIGHTEC is actively pursuing research and development to expand the applications for its technology with a goal of becoming a non-invasive standard of care in medicine.
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Exhibitor Directory IPSEN
MEDTRONIC
65 Quai Georges Gorse Boulogne Billancourt 92100 France Telephone: +33 1 58 33 5000 Website: www.ipsen.com/en/
710 Medtronic Parkway Minneapolis, MN 55432-5604 USA Telephone: +1 763-514-4000 Website: www.professional.medtronic.com
Booth #: 511 Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2014. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Ipsen’s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2014, R&D expenditure totaled close to €187 million, representingabout 15% of Group sales. Ipsen also has a significant presence in primary care. The Group hasmore than4,500 employees worldwide.
Booth #: 501 At Medtronic, we’re committed to innovating for life by pushing the boundaries of medical technology and changing the way the world treats chronic disease. It’s the reason we’ve developed an unprecedented breadth and depth of innovative therapies over the past 60 years. This includes Medtronic Deep Brain Stimulation (DBS), with over 125,000 people worldwide having received our therapy.
INTERNATIONAL ESSENTIAL TREMOR FOUNDATION
P.O. Box 14005 Lenexa, KS 66285-4005 USA Telephone: +1 913-341-3880
Table #: 3 The International Essential Tremor Foundation (IETF) funds essential tremor research to find a treatment and cure for people with ET, increases awareness, and provides educational materials and tools for healthcare providers, the public, and those affected by ET.
LUNDBECK
Four Parkway North Deerfield, IL 60015 USA Telephone: +1 847-282-1000 Website: www.lundbeckus.com
Booth #: 719 Merz North America is a specialty healthcare company that develops and commercializes innovative treatment solutions in aesthetics, dermatology and neurology in the U.S. and Canada. Our ambition is to become a recognized leader in the treatment of movement disorders, and in aesthetics and dermatology.
MULTIPLE SYSTEM ATROPHY COALITION
9935-D Rea Road, #212 Charlotte, NC 28277 USA Telephone: +1 866-737-4999 Website: www.multiplesystematrophy.org
Table #: 2 The MSA Coalition is dedicated to supporting patients and educating healthcare professionals about Multiple System Atrophy. Educational pamphlets and DVDs available.
Exhibitor Information
Booth #: 806 Lundbeck, a global pharmaceutical company based in Copenhagen, Denmark, was founded in 1915. As one of the world’s leading companies specializing in brain disorders, Lundbeck’s key focus is to address disorders such as depression, anxiety, schizophrenia, epilepsy, and Huntington’s, Alzheimer’s and Parkinson’s disease.
MERZ NEUROSCIENCES A DIVISION OF MERZ N. AMERICA
6501 Six Forks Road Raleigh, NC 27615 USA Telephone: +1 919-582-8000 Fax: +1 919-615-4851 Website: www.merzusa.com
137
Exhibitor Directory NATIONAL SPASMODIC TORTICOLLIS ASSOCIATION
9920 Talbert Avenue Fountain Valley, CA 92708 USA Telephone: +1 714-378-9837 Website: www.torticollis.org
Table #: 8 The NSTA is dedicated to supporting Spasmodic Torticollis patients by providing information, answering questions, and providing hope and moral support. NSTA educates the public and the medical community about Spasmodic Torticollis, advocate for patients’ rights, and support research aimed at understanding, treating, and ultimately curing this painful and debilitating neurological disorder.
OXFORD UNIVERSITY PRESS
198 Madison Avenue New York, NY 10016 USA Telephone: +1 800-445-9714 Website: www.oup.com/us
Booth #: 720 OUP proudly announces the launch of OxfordMedicalOnline as well as “Cognitive Impairment and Dementia in Parkinson’s Disease,” the “Handbook of Neurological Therapy,” the “Video Protocols in Movement Disorders,” Klein’s “Movement Disorders,” the Oxford Textbook of Movement Disorders,” and “Hyperkinetic Movement Disorders” and other classics.
PARKINSON’S WELLNESS RECOVERY
Exhibitor Information
140 West Fort Lowell Road Tucson, AZ 85705 USA Telephone: +1 520-591-5346 Fax: +1 888-780-0154 Website: www.pwr4life.org
Table #: 1 PWR! is a 501(c)(3) nonprofit founded by Becky Farley PT, MS, PhD to develop and implement worldwide access to Parkinson disease-specific neuroplasticity-principled programming.PWR! subsidizes cutting edge Exercise4BrainChange®programs for people with PD in a Model Community Center (PWR!Gym) in Tucson, AZ; and trains therapists and fitness professionals worldwide.
138
PHOTOPHARMICS, INC.
6222 West 10480 North Highland, UT 84003 USA Telephone: +1 801-494-7804 Fax: +1 801-609-7055 Website: www.photopharmics.com Booth #: 713 PhotoPharmics, Inc. is conducting a DBPC clinical trial to establish the safety and efficacy of a non-invasive, specialized, ocular light therapy lamp for Parkinson’s disease.
PROTOKINETICS
60 Garlor Drive Havertown, PA 19083 USA Telephone: +1 610-449-4879 Fax: +1 610-853-2925 Website: www.protokinetics.com Booth #: 809 The ProtoKinetics Zeno Walkway and PKMAS program quickly and easily produces pressure, temporal and spatial parameters over a variety of testing protocols. The equipment offers easy output of objective measures during the evaluation and clinical research of individuals with central nervous system disorders, peripheral neuropathy, stroke, etc.
SPEECHVIVE
603 Wexford Drive Lafayette, IN 47905 USA Telephone: +1 612-723-7200 Website: www.speechvive.com Booth #: 715 SpeechVive is a behind the ear device which helps people with Parkinson’s disease speak more loudly and communicate more effectively. Clinical data over four years demonstrated SpeechVive to be effective in 90% of the people using the device.
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Exhibitor Directory ST. JUDE MEDICAL
THE PARKINSON’S ASSOCIATION
6300 Bee Cave Road Building 2 Suite 100 Austin, TX 78746 USA Telephone: +1 512-286-4050 Website: www.sjm.com
8555 Aero Drive, Suite 308 San Diego, CA 92123-1745 USA Telephone: +1 858-273-6763 Website: www.ParkinsonsAssociation.org
Booth #: 518 St. Jude Medical is dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases by creating cost-effective medical technologies that save and improve lives of patients around the world. For more information, please visit sjm.com.
Table #: 9 The Parkinson’s Association is a 501(c)3 non-profit that helps improve the quality of life for those living with Parkinson’s disease. We partner with the medical community and offer vital programs and services that ease the burden of Parkinson’s by supporting patients, their families and friends who see life change as the Parkinson’s disease progresses.
TEVA CNS
11100 Nall Avenue Overland Park, KS 66211 USA Telephone: +1 800-221-4026 Website: www.tevausa.com Booth #: 401 Teva CNS invites you to visit booth #401 in the MDS exhibit hall to discuss our dedication to supporting and improving the lives of individuals with neurological disorders.
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON’S RESEARCH
Grand Central Station P.O. Box 4777 New York, NY 10163 USA Telephone: +1 212-509-0995 Fax: +1 212-509-1107 Website: www.micaheljfox.org
P.O. Box 5013 Pleasanton, CA 94566-0513 USA Telephone: +1 510-681-6565 Fax: +1 925-369-0485 Website: www.tremoraction.org Table #: 6 Tremor Action Network, acronym TAN, is a 501(c)(3) public benefit organization dedicated to providing boutique services that include oneon-one support and guidance. TremorAction.org connects the bench to the Tremor patient. TAN videos in English and Español provide a better understanding of movement disorders.
UCB
Allée de la Recherche 60 Brussels 1070 Belgium Telephone: +32 2 559 9427 Website: www.ucb.com Booth #: 301 UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With about 9000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).
139
Exhibitor Information
Table #: 10 MJFF aims to accelerate Parkinson’s research toward improved therapies and a cure through an aggressively funded, highly targeted research program coupled with global collaboration of Parkinson’s community stakeholders. Connect with staff movement disorder specialists to discuss the latest research, funding opportunities and our new physician offerings.
TREMOR ACTION NETWORK
Exhibitor Directory US WORLDMEDS
4441 Springdale Road Louisville, KY 40241 USA Telephone: +1 502-815-8100 Website: www.usworldmeds.com Booth #: 701 US WorldMeds holds a fundamental belief that our science has the potential to improve patients’ lives. Our portfolio of products and development projects reflects our commitment to bring innovative therapies to patients with unmet medical needs. Please visit our US WorldMeds booth to learn more.
WORLD PARKINSON COALITION
1359 Broadway, Suite 1509 New York, NY 10018 USA Telephone: +1 212-923-4700 Fax: +1 212-923-4778 Website: www.worldpdcoalition.org Table #: 4 The 4th World Parkinson Congress will take place from September 20 – 23, 2016 in Portland, OR, USA. By bringing some of the world’s most respected movement disorder specialists, neuroscientists, nurses, rehab specialists together with people with Parkinson’s and care partners, WPC 2016 will provide a vibrant international forum to learn about the latest scientific discoveries, medical practices, and care initiatives for PD. Visit www. WPC2016.org for more information.
Exhibitor Information
ZAMBON SPA
Via Lillo del Duca 10 Bresso (Milan) 20091 Italy Telephone: +39 02 6652401 Website: www.zambongroup.com www.zambonpharma.com Booth #: 611 Zambon is a leading Italian pharmaceutical and fine-chemical multinational company. Zambon is well-established in 3 areas: respiratory, pain, woman care; it is also strongly committed in CNS area with Xadago® (safinamide) for PD. Zambon is headquartered in Milan and was established in 1906 in Vicenza. Zambon is present in 15 countries.
140
IF YOU’RE LOOKING FOR THE
Products may not be approved for all regions. Check with your St. Jude Medical representative for product availability in your country. DBS products are not approved for use in the U.S. Unless otherwise noted, ™ indicates that the name is a trademark of, or licensed to, St. Jude Medical or one of its subsidiaries. ST. JUDE MEDICAL and the nine-squares symbol are trademarks and service marks of St. Jude Medical, Inc. and its related companies. © 2015 St. Jude Medical, Inc. All Rights Reserved. SJM-MDS-0315-0001 | This content is for international use only.
IN DBS TECHNOLOGY,
VISIT THE ST. JUDE MEDICAL INTERNATIONAL BOOTH #518.
Education Grant Supporters MDS acknowledges the supporters of the following 2015 International Congress activities through unrestricted educational grants: Therapeutic Plenary Session 1101: Managing Parkinson’s disease: Past, present and future, supported by BIAL - Portela & Cª., S.A.
Skills Workshop 2412: DBS for non-parkinsonian movement disorders, supported by Medtronic
Plenary Session 5101: Emerging paradigms for functional surgery for movement disorders, supported by Medtronic
Therapeutic Plenary Session 1102: Treatment of dystonia, supported by Merz North America
Skills Workshop 3412: Practical issues in using neuroimaging in Movement Disorders: What, when, why, supported by GE Healthcare
Plenary Session 5102: Controversies in Movement Disorders, supported by Medtronic
Therapeutic Plenary Session 1103: Therapeutic options for mood, cognition and psychosis in Parkinson’s disease, supported by ACADIA Pharmaceuticals Plenary Session 2102: 25 years of Movement Disorders – Movement Disorders Grand Rounds, supported by GE Healthcare Parallel Session 2208: New technologies in evaluation of treatment of movement disorder patients, supported by UCB
144
Plenary Session 4102: Breaking news in movement disorders, supported by Boston Scientific Parallel Session 4206: Electrophysiological, morphological and molecular basis of levodopa-induced dyskinesias and their therapeutic implications, supported by Adamas Pharmaceuticals Skills Workshop 4412: Managing acute and chronic post-operative issues following DBS in Parkinson’s disease, supported by Medtronic
Plenary Session 5103: Blue Ribbon Highlights, supported by UCB 2015 MDS Video Challenge 2015 MDS Video Challenge, supported by Allergan Guided Poster Tour #9 Parkinson’s Disease: Clinical Trials, supported by UCB Guided Poster Tour #16 Parkinson’s disease: Neuropharmacology, supported by UCB
JUNE 14-18 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
2015
SAN DIEGO, CA, USA
Acknowledgements The International Congress Oversight Committee of the 19th International Congress of Parkinson’s Disease and Movement Disorders wishes to acknowledge and thank the following companies for their support: Platinum Level
Silver Level
Bronze Level
Above companies are confirmed as of April 24, 2015 145
Notes
146
Matthew Stern President, International Parkinson and Movement Disorder Society, 2013-2015
Victor Fung Chair, Congress Scientific Program Committee, 2013 - 2015
Irene Litvan Co-Chair, Congress Scientific Program Committee, 2015
has attended the International Parkinson and Movement Disorder Society’s 19th International Congress of Parkinson’s Disease and Movement Disorders on June 14-18, 2015 in San Diego, CA, USA
CERTIFIES THAT
Accurate Targeting. Precise Control. Analysis of Vantage Study
Mean UPDRS III scores meds OFF
40
37.4
62.6% Mean Improvement
30
15.0
20
in UPDRS III Scores (Meds OFF)1 at 6 months post implant vs. baseline.
13.5
10
N=40
N=40
N=38
Baseline
3 Months
6 Months
VERCISE ™ DEEP BRAIN STIMULATION SYSTEM 1. References: Timmerman L., Alesch, A., et.al. VANTAGE trial: A prospective, multi-center trial evaluating Deep Brain Stimulation with a new multiple-source, constant-current rechargeable system (Vercise™) in Parkinson’s disease. Movement Disorder Society, Poster June 2013. CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use. Results from clinical studies are not predictive of results in other studies. Results in other studies may vary. The Vercise™ Deep Brain Stimulation (DBS) System is indicated for use in unilateral or bilateral stimulation of the subthalamic nucleus (STN) or internal globus pallidus (GPi) for treatment of levodopa-responsive Parkinson’s disease which is not adequately controlled with medication and also for treatment of intractable primary and secondary dystonia, for persons 7 years of age or older. Thalamic stimulation using the Boston Scientific Vercise™ DBS System is indicated for the suppression of tremor not adequately controlled by medications in patients diagnosed with Essential Tremor Parkinson’s disease. All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. NM-299501-AA_MAR2015 ©2015 Boston Scientific Corporation or its affiliates. All rights reserved.
Choose Confidently. Choose Quality of Life.
Choose DBS Therapy.
Until there is a cure, we must help our patients live well with PD. Learn how DBS Therapy can play a role. Attend the Corporate Therapeutic Symposium:
Long Term Outcomes and Therapeutic Optimization of DBS for Parkinson’s Disease
Wednesday, June 17, 2015 1:30 p.m. – 2:30 p.m. Harbor DEF, Manchester Grand Hyatt Roy R. Medtronic DBS Therapy for Parkinson’s Disease Patient
IMPORTANT SAFETY INFORMATION: Risks of DBS therapy may include: surgical complications, infection, failure to deliver therapy as needed and/or worsening of some symptoms. For complete safety information about Medtronic DBS Therapy, call Medtronic toll-free at 1-800-328-0810 or visit medtronicdbs.com
UC201506088 EN
19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
SAN DIEGO, CA, USA JUNE 14-18, 2015
